Fusosome Compositions and Uses Thereof
Fusosomes with liver-specific regulatory elements address the challenge of delivering therapeutic transgenes to liver cells, ensuring stable expression and minimizing immune response, thus improving gene therapy efficacy.
Patent Information
- Application Number
- JP2021500638
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-15
- Filing Date
- 2019-07-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-07-09
AI Technical Summary
Delivering large biological factors to cells is challenging due to the plasma membrane barrier, and existing methods face difficulties in maintaining stable long-term expression of therapeutic transgenes while avoiding immune responses in non-target cells.
Fusosomes, comprising retroviral vectors with liver-specific regulatory elements and non-liver-specific regulatory elements, are designed to enhance target cell specificity and reduce immune response, ensuring stable expression of exogenous agents in liver cells while minimizing expression in non-liver cells.
The fusosomes achieve targeted and stable expression of therapeutic transgenes in liver cells, reducing immune activation and neutralizing antibody production, thereby enhancing the durability of gene therapy.
Smart Images

Figure 0007588578000213 
Figure 0007588578000214 
Figure 0007588578000215
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Application No. 62 / 695,537, filed July 9, 2018, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," U.S. Provisional Application No. 62 / 767,241, filed November 14, 2018, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," U.S. Provisional Application No. 62 / 848,284, filed May 15, 2019, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," U.S. Provisional Application No. 62 / 695,650, filed July 9, 2018, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," U.S. Provisional Application No. 62 / 695,650, filed November 14, 2018, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," U.S. Provisional Application No. This application claims priority from U.S. Provisional Application No. 62 / 767,261, filed May 15, 2019, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," and U.S. Provisional Application No. 62 / 848,305, filed May 15, 2019, entitled "FUSOSOME COMPOSITIONS AND USES THEREOF," the contents of which are incorporated by reference in their entireties.
[0002] INCORPORATION-BY-REFERENCE TO SEQUENCE LISTING This application has been submitted with an electronic Sequence Listing. The Sequence Listing is provided as a file named V2050-7024WO_SeqList.TXT, created on July 9, 2019, and is 2,549,164 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety. [Background technology]
[0003] Complex biological agents are promising therapeutic candidates for various diseases.However, because plasma membrane acts as a barrier between cells and extracellular space, it is difficult to deliver large biological factors into cells.In the art, there is a need for a new method for delivering complex biological agents into cells of a subject. Summary of the Invention [Means for solving the problem]
[0004] The present disclosure provides, at least in part, fusosome methods and compositions for in vivo delivery. In some embodiments, the fusosomes contain a combination of elements that promote specificity for target cells, such as one or more fusogens, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome compositions contain one or more modifications that reduce an immune response to the fusosomes.
[0005] Enumeration of Embodiments Provided herein are fusosomes containing retroviral vectors or particles, such as lentiviral vectors or particles, which, after introduction into cells in a subject, result in increased expression of a desired exogenous agent (e.g., a therapeutic transgene) in liver target cells relative to non-target cells. For example, in some cases, increased expression follows in vivo administration of the provided fusosomes (e.g., retroviral vectors or particles) to a subject, e.g., a human subject. In particular, one of the major challenges to successful gene therapy is the ability to maintain stable, long-term expression of a therapeutic transgene (e.g., an exogenous agent) from genetically engineered cells in vivo. Expression of a transgene in non-target cells, such as antigen-presenting cells (APCs), in some aspects results in activation of the adaptive immune response, leading to the generation of neutralizing antibodies against the transgene product by B cells and / or the elimination of transgene-producing cells by T cells. Thus, restricting transgene expression to target cells can substantially impact the durability of transgene expression by avoiding immune clearance. Furthermore, cell-type-specific transgene expression may be highly relevant to disease biology, such as restricting pro-apoptotic gene expression to targeted liver cells.
[0006] In particular, provided herein are fusosomes (e.g., retroviral vectors or particles) that contain expression of a nucleic acid sequence under the control of or regulated by a positive liver cell-specific regulatory element (e.g., a liver cell promoter) and / or a non-liver cell-specific regulatory element. In some embodiments, the non-liver cell-specific regulatory element is due to miRNA-mediated gene silencing, such as by a nucleic acid sequence complementary to an miRNA sequence in non-liver cells. In some embodiments, the provided fusosomes (e.g., retroviral vectors or particles) can specifically drive transgene (exogenous agent) expression in liver cells while limiting or restricting expression in non-target (non-liver) cells.
[0007] Among the embodiments provided are the following: 1. The following: a) a lipid bilayer containing a fusogen; and b) Below: (i) a payload gene encoding an exogenous agent, e.g., a payload gene encoding an exogenous agent of Table 5, optionally wherein the exogenous agent is set forth in any of SEQ ID NOs: 161-518, or a functional fragment or functional variant thereof comprising at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 161-518; and (ii) a nucleic acid comprising a positive liver cell-specific regulatory element (e.g., a liver cell-specific promoter) operably linked to a payload gene, wherein the positive liver cell-specific regulatory element increases expression of the payload gene in liver cells relative to otherwise similar fusosomes lacking the positive liver cell-specific regulatory element; Fusosomes containing
[0008] 2. The fusosome of embodiment 1, wherein the nucleic acid further comprises a non-liver cell-specific regulatory element (e.g., a non-liver cell-specific miRNA recognition sequence) operably linked to the payload gene, wherein the non-liver cell-specific regulatory element reduces expression of the payload gene in the non-liver cell relative to an otherwise similar fusosome lacking the non-liver cell-specific regulatory element.
[0009] 3. The following: a) a lipid bilayer containing a fusogen; and b) Below: (i) a payload gene encoding an exogenous agent, e.g., an exogenous agent of Table 5, optionally wherein the exogenous agent is set forth in any of SEQ ID NOs: 161-518, or a functional fragment or functional variant thereof comprising at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 161-518; and (ii) a nucleic acid comprising a promoter operably linked to a payload gene, wherein the promoter is selected from an Apoa2, Cyp3a4, LP1B, MIR122, hemopexin, SERPINA1, or HLP promoter, e.g., according to a sequence in Table 3, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, and optionally the promoter comprises a sequence set forth in any of SEQ ID NOs: 133-136 or 519-525, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto; Fusosomes containing
[0010] 4. The following: a) a lipid bilayer containing a fusogen; and b) Below: (i) a payload gene encoding an exogenous agent, e.g., a payload gene encoding an exogenous agent of Table 5, wherein optionally the exogenous agent is set forth in any of SEQ ID NOs: 161-518, or a functional fragment or functional variant thereof comprising at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 161-518; and (ii) a nucleic acid comprising a non-target cell-specific regulatory element (NTCSRE) (e.g., a non-target cell-specific miRNA recognition sequence) operably linked to a payload gene, wherein the NTCSRE reduces expression of the payload gene in the non-target cell or tissue compared to an otherwise similar fusosome lacking the NTCSRE; containing, fusosomes.
[0011] 5. The following: a) a lipid bilayer containing a fusogen; and b) Below: (i) a payload gene encoding an exogenous agent, e.g., a payload gene encoding an exogenous agent of Table 5, optionally wherein the exogenous agent is set forth in any of SEQ ID NOs: 161-518, or a functional fragment or functional variant thereof comprising at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 161-518; and (ii) a nucleic acid comprising a negative target cell-specific regulatory element (negative TCSSE) (e.g., a tissue-specific miRNA recognition sequence) operably linked to a payload gene, wherein the negative TCSSE reduces expression of the exogenous agent in a non-target cell or tissue compared to an otherwise similar nucleic acid lacking the negative TCSSE. containing, fusosomes.
[0012] 6. The fusosome of either embodiment 4 or 5, wherein the nucleic acid further comprises a positive liver cell-specific regulatory element (e.g., a liver cell-specific promoter) operably linked to the payload gene, wherein the positive liver cell-specific regulatory element increases expression of the payload gene in liver cells compared to otherwise similar fusosomes lacking the positive liver cell-specific regulatory element.
[0013] 7. The following: a) a lipid bilayer containing fusogens; b) a nucleic acid comprising a payload gene encoding an exogenous agent, for example, a payload gene encoding an exogenous agent of Table 5, optionally wherein the exogenous agent is set forth in any of SEQ ID NOs: 161-518 or a functional fragment or functional variant thereof comprising at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 161-518; and c) One or both of the following: (i) a first exogenous or overexpressed immunosuppressive protein on the lipid bilayer; or (ii) a first immunostimulatory protein that is absent or present at reduced levels (e.g., reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) compared to fusosomes produced from an otherwise similar, unmodified source cell; containing, fusosomes.
[0014] 8. The fusosome of any of the preceding embodiments, which is one or more of the following: i) fusosomes fuse with target cells at a higher rate, e.g., at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, than with non-target cells; ii) fusosomes fuse with target cells at a higher rate, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, than with other fusosomes; iii) the fusosomes fuse with the target cells at a rate such that the agent within the fusosomes is delivered to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the target cells after 24, 48, or 72 hours; iv) the fusosomes deliver nucleic acid, e.g., retroviral nucleic acid, to target cells at a higher rate, e.g., at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, than to non-target cells; v) the fusosome delivers a nucleic acid, e.g., a retroviral nucleic acid, to a target cell at a higher rate, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, than another fusosome; or vi) The fusosomes deliver nucleic acid, e.g., retroviral nucleic acid, to the target cells at a rate such that the agent in the fusosomes is delivered to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the target cells after 24, 48, or 72 hours.
[0015] 9. The fusosome of any of the preceding embodiments, wherein one or more (e.g., two or all three) of the following apply: the fusosome is a retroviral vector, the lipid bilayer is constituted by an envelope, e.g., a viral envelope, and the nucleic acid is a retroviral nucleic acid.
[0016] 10. The fusosome of any of the preceding embodiments, wherein the nucleic acid comprises one or more (e.g., all) of the following nucleic acid sequences: a 5' LTR (e.g., comprising a U5 domain and lacking a functional U3 domain), a Psi packaging element (Psi), a central polypurine tract (cPPT) promoter operably linked to a payload gene, a payload gene (optionally comprising an intron before the open reading frame), a polyA tail sequence, a WPRE, and a 3' LTR (e.g., lacking a U5 domain and a functional U3).
[0017] 11. The fusosome of any of the preceding embodiments, comprising one or more (e.g., all) of a polymerase (e.g., a reverse transcriptase, e.g., pol or a portion thereof), an integrase (e.g., pol or a portion thereof, e.g., a functional or non-functional variant), a matrix protein (e.g., gag or a portion thereof), a capsid protein (e.g., gag or a portion thereof), a nucleocapsid protein (e.g., gag or a portion thereof), and a protease (e.g., pro).
[0018] 12. The fusosome of embodiment 7, comprising (i) and (ii).
[0019] 13. The fusosome of any of embodiments 7 to 12, further comprising a second exogenous or overexpressed immunosuppressive protein on the lipid bilayer.
[0020] 14. The fusosomes of any of embodiments 7 to 13, comprising a second immunostimulatory protein that is absent or present at reduced levels, wherein the reduced level is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to fusosomes produced from otherwise similar unmodified source cells.
[0021] 15. The fusosome of any of embodiments 7-14, wherein the nucleic acid, e.g., retroviral vector, further comprises a positive liver cell-specific regulatory element (e.g., a liver cell-specific promoter) operably linked to the payload gene, and the positive liver cell-specific regulatory element increases expression of the payload gene in liver cells compared to otherwise similar fusosomes lacking the positive liver cell-specific regulatory element.
[0022] 16. The fusosome of any of embodiments 7-15, wherein the nucleic acid, e.g., retroviral nucleic acid, comprises a non-target cell-specific regulatory element (NTCSRE) (e.g., a non-target cell-specific miRNA recognition sequence) operably linked to the payload gene, and the NTCSRE reduces expression of the payload gene in the non-target cell or tissue compared to an otherwise similar fusosome lacking the NTCSRE.
[0023] 17. The fusosome of any of embodiments 7-15, wherein the nucleic acid, e.g., retroviral nucleic acid, comprises a negative target cell-specific regulatory element (negative TCSSE) (e.g., a tissue-specific miRNA recognition sequence) operably linked to the payload gene, and the negative TCSSE reduces expression of the exogenous agent in non-target cells or tissues compared to an otherwise similar nucleic acid, e.g., retroviral nucleic acid, lacking the negative TCSSE.
[0024] 18. The fusosome of any of embodiments 7-17, which, when administered to a subject (e.g., a human subject or a mouse), is one or more of the following: i) the fusosomes do not generate a detectable antibody response (e.g., after a single dose or multiple doses), or antibodies to the fusosomes are present at levels less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels, e.g., according to a FACS antibody detection assay, e.g., the assay of Example 13 or Example 14; ii) the fusosomes do not produce a detectable cellular immune response (e.g., a T cell response, an NK cell response, or a macrophage response), or a cellular immune response to the fusosomes is present at a level that is less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels, e.g., according to a PBMC lysis assay (e.g., the assay of Example 5), an NK cell lysis assay (e.g., the assay of Example 6), a CD8 killer T cell lysis assay (e.g., the assay of Example 7), or a macrophage phagocytosis assay (e.g., the assay of Example 8); iii) the fusosomes do not elicit a detectable innate immune response, e.g., complement activation (e.g., after a single dose or multiple doses), or the innate immune response to the fusosomes is present at a level less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels, e.g., according to a complement activation assay (e.g., the assay of Example 9); iv) less than 10%, 5%, 4%, 3%, 2%, or 1% of the fusosomes are inactivated by serum, e.g., according to a serum inactivation assay, e.g., the assay of Example 11 or Example 12; v) target cells that receive an exogenous agent from fusosomes do not develop a detectable antibody response (e.g., after a single dose or multiple doses), or antibodies to the target cells are present at levels less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels, e.g., according to a FACS antibody detection assay, e.g., the assay of Example 15; or vi) Target cells that receive an exogenous agent from fusosomes do not produce a detectable cellular immune response (e.g., a T cell response, an NK cell response, or a macrophage response), or the cellular response against the target cells is at a level that is less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels, e.g., according to a macrophage phagocytosis assay (e.g., the assay of Example 16), a PBMC lysis assay (e.g., the assay of Example 17), an NK cell lysis assay (e.g., the assay of Example 18), or a CD8 killer T cell lysis assay (e.g., the assay of Example 19).
[0025] 19. The fusosomes of embodiment 18, wherein the background level is a comparable level in the same subject before administration of the fusosomes.
[0026] 20. The fusosome of any of embodiments 7-19, wherein the immunosuppressive protein (e.g., the first immunosuppressive protein or the second immunosuppressive protein) is a complement regulatory protein or CD47.
[0027] 21. The fusosome of any of embodiments 7 to 20, wherein the immunostimulatory protein (e.g., the first immunostimulatory protein or the second immunostimulatory protein) is an MHC I (e.g., HLA-A, HLA-B, HLA-C, HLA-E, or HLA-G) or MHC II (e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR) protein.
[0028] 22. The payload gene encoding the exogenous agent is OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LMBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, BTD, The fusosome of any of the preceding embodiments, wherein the fusosome is selected from HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, or LDLR.
[0029] 23. The fusosome of any of the preceding embodiments, wherein the fusogen comprises VSV-G.
[0030] 24. The fusosome of embodiment 1, 2, 6, 15, 22, or 23, wherein the positive liver-specific regulatory element comprises a liver-specific promoter, a liver-specific enhancer, a liver-specific splice site, a liver-specific site that extends the half-life of RNA or protein, a liver-specific mRNA export-promoting site, a liver-specific translation-enhancing site, or a liver-specific post-translational modification site.
[0031] 25. The fusosome of embodiment 1, 2, 6, 15, or 22-24, wherein the positive liver-specific regulatory element comprises a hepatocyte-specific promoter.
[0032] 26. The fusosome of embodiment 25, wherein the hepatocyte-specific promoter comprises a motif of Table 3, and optionally, the promoter is set forth in any of SEQ ID NOs: 133-136 or 519-525, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 133-136 or 519-525.
[0033] 27. The fusosome of embodiment 25 or 26, wherein the positive liver-specific regulatory element comprises a promoter selected from enhanced transthyretin (ET), hAAT, Alb, Apoa2, Cyp3a4, LP1B, MIR122, hemopexin, SERPINA1, or HLP promoter.
[0034] 28. The fusosome of any of embodiments 4 to 6, or 16 to 21, wherein the negative TCSRE or NTCSRE comprises a non-target cell-specific miRNA recognition sequence, a non-target cell-specific protease recognition site, a non-target cell-specific ubiquitin ligase site, a non-target cell-specific transcriptional repression site, or a non-target cell-specific epigenetic repression site.
[0035] 29. The fusosome of any of embodiments 4 to 6, or 16 to 21, or 28, wherein the negative TCSRE or NTCSRE comprises a non-target cell-specific miRNA recognition sequence, a non-target cell-specific protease recognition site, a non-target cell-specific ubiquitin ligase site, a non-target cell-specific transcriptional repression site, or a non-target cell-specific epigenetic repression site.
[0036] 30. The fusosome of any of embodiments 4-6, 16-21, 28, or 29, wherein the negative TCSRE or NTCSRE comprises a non-liver cell-specific miRNA recognition sequence, a non-liver cell-specific protease recognition site, a non-liver cell-specific ubiquitin ligase site, a non-liver cell-specific transcriptional repression site, or a non-liver cell-specific epigenetic repression site.
[0037] 31. The fusosome of any of embodiments 4-6, 16-21, or 28-30, wherein the negative TCSRE or NTCSRE comprises a non-liver cell-specific miRNA recognition sequence bound by a miRNA of Table 4, e.g., by one or more (e.g., two or more) miR-142, mir-181a-2, mir-181b-1, mir-181c, mir-181a-1, mir-181b-2, mir-181d, miR-223, or miR-126.
[0038] 32. The fusosome of any of embodiments 28-31, wherein the negative TCSRE or NTCSRE is located or encoded within a transcribed region (e.g., a transcribed region encoding an exogenous agent), e.g., such that RNA produced by the transcribed region contains a miRNA recognition sequence within a UTR or coding region.
[0039] 33. The fusosome of any of the preceding embodiments, wherein the nucleic acid, e.g., retroviral nucleic acid, comprises one or more insulator sequences.
[0040] 34. The fusosome of embodiment 33, wherein the nucleic acid, e.g., a retroviral nucleic acid, comprises two insulator sequences, e.g., a first insulator sequence upstream of the payload gene and a second insulator sequence downstream of the payload gene, e.g., the first insulator sequence and the second insulator sequence comprise the same or different sequences.
[0041] 35. The fusosome of any of the preceding embodiments, which is not genotoxic or does not increase the rate of tumor formation in target cells.
[0042] 36. The fusosome of any of the preceding embodiments, wherein the nucleic acid, e.g., retroviral nucleic acid, is capable of being integrated into the genome of the target cell.
[0043] 37. The fusosome of embodiment 36, wherein the nucleic acid, such as a retroviral nucleic acid, is an integration-competent lentivirus or an integration-incompetent lentivirus.
[0044] 38. The fusosome of any of the preceding embodiments, wherein the target cell is selected from a hepatocyte, a liver sinusoidal endothelial cell, a cholangiocyte, a stellate cell, an antigen-presenting cell present in the liver (e.g., a Kupffer cell), an immune lymphocyte present in the liver (e.g., a T cell, a B cell, or a NK cell), or a portal tract fibroblast.
[0045] 39. The fusosome of any of embodiments 4-6 and 9-38, which is one or more of the following: i) less than 10%, 5%, 4%, 3%, 2%, or 1% of the exogenous agent detectably present in the subject is in non-target cells; ii) at least 90%, 95%, 96%, 97%, 98%, or 99% of the cells in the subject that detectably contain the exogenous agent are target cells (e.g., cells of a single cell type, e.g., T cells); iii) fewer than 1,000,000, 500,000, 200,000, 100,000, 50,000, 20,000, or 10,000 cells in the subject detectably contain the exogenous agent are non-target cells; iv) the average level of the exogenous agent in all target cells of the subject is at least 100-fold, 200-fold, 500-fold, or 1,000-fold higher than the average level of the exogenous agent in all non-target cells of the subject; or v) The exogenous agent is not detectable in non-target cells of the subject.
[0046] 40. The fusosome of any of the previous embodiments, wherein the nucleic acid, eg, retroviral nucleic acid, encodes a positive TCSRE and / or an NTCSRE or a negative TCSRE.
[0047] 41. The fusosome of any of the previous embodiments, wherein the nucleic acid, e.g., retroviral nucleic acid, comprises a positive TCSRE and / or the complement of an NTCSRE or a negative TCSRE.
[0048] 42. The fusosome of any of embodiments 40 or 41, wherein the positive TCSSE comprises a liver-specific promoter that is at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 250%, 300%, 400%, 500%, 750%, 1000% or more active in liver cells (e.g., hepatocytes) than in non-target cells.
[0049] 43. The fusosome of any of embodiments 40 to 42, wherein the negative TCSRE or NTCSRE comprises an miRNA recognition sequence that reduces gene expression by at least 10%, 25%, 50%, 75%, or 100% in hematopoietic cells compared to hepatocytes.
[0050] 44. The fusosome of any of the preceding embodiments, which does not deliver nucleic acid, e.g., retroviral nucleic acid, to a non-target cell, e.g., an antigen-presenting cell, an MHC class II+ cell, a professional antigen-presenting cell, an atypical antigen-presenting cell, a macrophage, a dendritic cell, a myeloid dendritic cell, a plasmacytoid dendritic cell, a CD11c+ cell, a CD11b+ cell, a splenocyte, a B cell, a hepatocyte, an endothelial cell, or a non-cancerous cell.
[0051] 45. The fusosomes of any of the preceding embodiments, wherein, e.g., using quantitative PCR, e.g., using the assay of Example 1, less than 10%, 5%, 2.5%, 1%, 0.5%, 0.1%, 0.01%, 0.001%, 0.0001%, 0.00001%, or 0.000001% of the non-target cell type (e.g., one or more of antigen-presenting cells, MHC class II+ cells, professional antigen-presenting cells, atypical antigen-presenting cells, macrophages, dendritic cells, myeloid dendritic cells, plasmacytoid dendritic cells, CD11c+ cells, CD11b+ cells, splenocytes, B cells, hepatocytes, endothelial cells, or non-cancerous cells) comprise nucleic acid, e.g., retroviral nucleic acid.
[0052] 46. The fusosome of any of the preceding embodiments, wherein the target cell comprises 0.00001-10, .0001-10, .001-10, .01-10, .1-10, .5-5, 1-4, 1-3, or 1-2 copies of a nucleic acid, e.g., a retroviral nucleic acid, or portion thereof, per host genome, e.g., wherein the copy number of the nucleic acid, e.g., the retroviral nucleic acid, is assessed following administration in vivo.
[0053] 47. 10%, 5%, 2.5%, 1%, 0.5%, 0.1%, or 0.01% of non-target cells (e.g., antigen-presenting cells, MHC class II+ cells, professional antigen-presenting cells, atypical antigen-presenting cells, macrophages, dendritic cells, myeloid dendritic cells, plasmacytoid dendritic cells, CD11c+ cells, CD11b+ cells, splenocytes, B cells, hepatocytes, endothelial cells, or non-cancerous cells) contain an exogenous agent; or The exogenous agent (e.g., a protein) is not detectably present in non-target cells, such as antigen-presenting cells, MHC class II+ cells, professional antigen-presenting cells, atypical antigen-presenting cells, macrophages, dendritic cells, myeloid dendritic cells, plasmacytoid dendritic cells, CD11c+ cells, CD11b+ cells, splenocytes, B cells, hepatocytes, endothelial cells, or non-cancerous cells; The fusosome of any of the preceding embodiments.
[0054] 48. The fusosome of any of the preceding embodiments, wherein the fusosome delivers a nucleic acid, e.g., a retroviral nucleic acid, to a target cell, e.g., a T cell, a CD3+ T cell, a CD4+ T cell, a CD8+ T cell, a hepatocyte, a hematopoietic stem cell, a CD34+ hematopoietic stem cell, a CD105+ hematopoietic stem cell, a CD117+ hematopoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2 / Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, an NKG2D+ natural killer cell, an SLC1A3+ stem cell, an SLC7A10+ adipocyte, or a CD30+ lung epithelial cell.
[0055] 49. For example, using quantitative PCR, e.g., using the assay of Example 3, at least 0.00001%, 0.0001%, 0.001%, 0.001%, 0.01%, 0.1%, 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of target cells (e.g., T cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, hepatocytes, hematopoietic stem cells, CD34+ hematopoietic stem cells, CD105+ hematopoietic stem cells, CD117+
[0023] The fusosome of any of the preceding embodiments, wherein one or more of the following cells comprise a nucleic acid, e.g., a retroviral nucleic acid: a hematopoietic stem cell, a CD105+ endothelial cell, a B cell, a CD20+ B cell, a CD19+ B cell, a cancer cell, a CD133+ cancer cell, an EpCAM+ cancer cell, a CD19+ cancer cell, a Her2 / Neu+ cancer cell, a GluA2+ neuron, a GluA4+ neuron, an NKG2D+ natural killer cell, an SLC1A3+ stem cell, an SLC7A10+ adipocyte, or a CD30+ lung epithelial cell.
[0056] 50. At least 0.00001%, 0.0001%, 0.001%, 0.001%, 0.01%, 0.1%, 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or is 90% of target cells (e.g., T cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, hepatocytes, hematopoietic stem cells, CD34+ hematopoietic stem cells, CD105+ hematopoietic stem cells, CD117+ hematopoietic stem cells, CD105 + endothelial cell, B cell, CD20+ B cell, CD19+ B cell, cancer cell, CD133+ cancer cell, EpCAM+ cancer cell, CD19+ cancer cell, Her2 / Neu+ cancer cell, GluA2+ neuron, GluA4+ neuron, NKG2D+ natural killer cell, SLC1A3+ stem cell, SLC7A10+ adipocyte, or CD30+ lung epithelial cell) comprises an exogenous agent.
[0057] 51. The fusosome of any of the preceding embodiments, wherein upon administration, the ratio of target cells comprising nucleic acid, e.g., retroviral nucleic acid, to non-target cells comprising nucleic acid, e.g., retroviral nucleic acid, is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by quantitative PCR assay, e.g., using the assays of Examples 1 and 3.
[0058] 52. The fusosome of any of the preceding embodiments, wherein the ratio of the average copy number of nucleic acid, e.g., retroviral nucleic acid or portion thereof, in target cells to the average copy number of nucleic acid, e.g., retroviral nucleic acid or portion thereof, in non-target cells is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by quantitative PCR assay, e.g., using the assays of Examples 1 and 3.
[0059] 53. The fusosome of any of the preceding embodiments, wherein the ratio of the median copy number of the nucleic acid, e.g., retroviral nucleic acid or portion thereof, in target cells to the median copy number of the nucleic acid, e.g., retroviral nucleic acid or portion thereof, in non-target cells is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by quantitative PCR assay, e.g., using the assays of Examples 1 and 3.
[0060] 54. The fusosome of any of the preceding embodiments, wherein the ratio of target cells containing the exogenous RNA agent to non-target cells containing the exogenous RNA agent is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by reverse transcription quantitative PCR assay.
[0061] 55. The fusosomes of any of the preceding embodiments, wherein the ratio of average exogenous RNA agent levels in target cells to average exogenous RNA agent levels in non-target cells is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, by reverse transcription quantitative PCR assay.
[0062] 56. The fusosomes of any of the preceding embodiments, wherein the ratio of median exogenous RNA agent levels in target cells to median average exogenous RNA agent levels in non-target cells is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, by reverse transcription quantitative PCR assay.
[0063] 57. The fusosome of any of the preceding embodiments, wherein the ratio of target cells comprising the exogenous protein agent to non-target cells comprising the exogenous protein agent is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by FACS assay, e.g., using the assays of Examples 2 and 4.
[0064] 58. The fusosomes of any of the preceding embodiments, wherein the ratio of the average exogenous protein agent level in target cells to the average exogenous protein agent level in non-target cells is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by FACS assay, e.g., using the assays of Examples 2 and 4.
[0065] 59. The fusosome of any of the preceding embodiments, wherein the ratio of median exogenous protein agent level in target cells to median exogenous protein agent level in non-target cells is at least 1.5, 2, 3, 4, 5, 10, 25, 50, 100, 500, 1000, 5000, 10,000, e.g., by FACS assay, e.g., using the assays of Examples 2 and 4.
[0066] 60. Below: i) exogenous or overexpressed immunosuppressive proteins on the lipid bilayer, e.g., envelope; and (ii) immunostimulatory proteins that are absent or present at reduced levels (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduced) compared to fusosomes produced from an otherwise similar, unmodified source cell.
[0023] The fusosome of any of the preceding embodiments, comprising one or both of:
[0067] 61. The following: i) a first exogenous or overexpressed immunosuppressive protein on a lipid bilayer, e.g., an envelope, and a second exogenous or overexpressed immunosuppressive protein on a lipid bilayer, e.g., an envelope; ii) a first exogenous or overexpressed immunosuppressive protein on the lipid bilayer, e.g., envelope, and a second immunostimulatory protein that is absent or present at reduced levels (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduced) compared to fusosomes produced from an otherwise similar, unmodified source cell; or iii) a first immunostimulatory protein that is absent or present at reduced levels (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduced) relative to fusosomes produced from an otherwise similar, unmodified source cell, and a second immunostimulatory protein that is absent or present at reduced levels (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduced) relative to fusosomes produced from an otherwise similar, unmodified source cell;
[0023] The fusosome of any of the preceding embodiments, comprising one or more of:
[0068] 62. The fusosomes of any of the preceding embodiments, wherein the fusosomes circulate for at least 0.5, 1, 2, 3, 4, 6, 12, 18, 24, 36, or 48 hours after administration to a subject.
[0069] 63. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 30 minutes after administration.
[0070] 64. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation one hour after administration.
[0071] 65. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 2 hours after administration.
[0072] 66. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 4 hours after administration.
[0073] 67. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 8 hours after administration.
[0074] 68. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 12 hours after administration.
[0075] 69. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 18 hours after administration.
[0076] 70. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 24 hours after administration.
[0077] 71. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 36 hours after administration.
[0078] 72. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are in circulation 48 hours after administration.
[0079] 73. The fusosome of any of the preceding embodiments, which has reduced immunogenicity as measured by a reduced humoral response following one or more administrations of the fusosome to a suitable animal model, e.g., an animal model described herein, compared to a reference fusosome, e.g., an unmodified fusosome that is otherwise similar to the fusosome.
[0080] 74. The fusosome of embodiment 73, wherein the reduced humoral response is measured in a serum sample by anti-cellular antibody titers, e.g., anti-retroviral antibody titers, e.g., by ELISA.
[0081] 75. The fusosomes of any of the preceding embodiments, wherein serum samples from animals administered the fusosomes have a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in anti-fusosome antibody titers compared to serum samples from subjects administered unmodified cells.
[0082] 76. The fusosomes of any of the preceding embodiments, wherein a serum sample from a subject administered the fusosomes has an increased anti-cellular antibody titer, e.g., an increase of 1%, 2%, 5%, 10%, 20%, 30%, or 40% from baseline, e.g., where baseline refers to a serum sample from the same subject prior to administration of the fusosomes.
[0083] 77. The subject receiving fusosomes or a pharmaceutical composition containing fusosomes has, is known to have, or will be tested for pre-existing antibodies (e.g., IgG or IgM) reactive with fusosomes; the subject receiving the fusosomes does not have detectable levels of pre-existing antibodies reactive with the fusosomes; The subject receiving the fusosomes or a pharmaceutical composition comprising the fusosomes has, is known to have, or is tested for antibodies (e.g., IgG or IgM) reactive with the fusosomes; A subject who has been administered fusosomes or a pharmaceutical composition comprising fusosomes (e.g., at least one, two, three, four, five, or more times) does not have detectable levels of antibodies reactive with fusosomes; or the level of antibody does not increase by more than 1%, 2%, 5%, 10%, 20%, or 50% between two time points, the first time point being before the first administration of fusosomes and the second time point being after one or more administrations of fusosomes; The fusosome of any of the preceding embodiments.
[0084] 78. The fusosomes of any of the previous embodiments, wherein the fusosomes are produced by the method of Example 5, 6, or 7, for example, from cells transfected with HLA-G or HLA-E cDNA.
[0085] 79. The fusosomes of any of the preceding embodiments, wherein fusosomes generated from NMC-HLA-G cells exhibit a reduced rate of lysis, e.g., PBMC-mediated lysis, NK cell-mediated lysis, and / or CD8+ T cell-mediated lysis, at a particular time point compared to fusosomes generated from NMC or NMC-empty vector.
[0086] 80. The fusosome of any of the preceding embodiments, wherein the modified fusosome avoids phagocytosis by macrophages.
[0087] 81. The fusosomes of any of the preceding embodiments, wherein the fusosomes are produced by the method of Example 8, e.g., from cells transfected with CD47 cDNA.
[0088] 82. The fusosome of any of the preceding embodiments, wherein the phagocytic index is reduced when macrophages are incubated with a retroviral vector derived from NMC-CD47 compared to a vector derived from NMC or an NMC empty vector.
[0089] 83. The fusosome of any of the preceding embodiments, having a reduction in macrophage phagocytosis, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to a reference fusosome, e.g., an unmodified fusosome that is otherwise similar to the fusosome, wherein the reduction in macrophage phagocytosis is determined by assaying an in vitro phagocytic index, e.g., as described in Example 8.
[0090] 84. The fusosome of any of the preceding embodiments, wherein the fusosome composition, when incubated with macrophages in an in vitro assay of macrophage phagocytosis, has a phagocytic index of 0, 1, 10, 100, or more, e.g., as measured by the assay of Example 8.
[0091] 85. The fusosome of any of the preceding embodiments, which has been modified to have reduced complement activity compared to unmodified fusosomes.
[0092] 86. The fusosomes of any of the preceding embodiments, produced by the method of Example 9, e.g., from cells transfected with a cDNA encoding a complement regulatory protein, e.g., DAF.
[0093] The fusosomes of any of the preceding embodiments, wherein the dose of fusosomes at which 87,200 pg / ml of C3a is present is greater for modified fusosomes (e.g., HEK293-DAF) incubated with the corresponding mouse serum (e.g., HEK-293 DAF mouse serum) than for reference fusosomes (e.g., HEK293 retroviral vector) incubated with the corresponding mouse serum (e.g., HEK293 mouse serum).
[0094] The fusosomes of any of the preceding embodiments, wherein the dose of fusosomes at which 88,200 pg / ml of C3a is present is greater in modified fusosomes (e.g., HEK293-DAF) incubated with naive mouse serum than in reference fusosomes (e.g., HEK293 retroviral vector) incubated with naive mouse serum.
[0095] 89. The fusosomes of any of the preceding embodiments, wherein the fusosomes are resistant to complement-mediated inactivation in patient serum 30 minutes after administration according to the assay of Example 9.
[0096] 90. The fusosomes of any of the preceding embodiments, wherein at least 0.001%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the fusosomes are resistant to complement-mediated inactivation.
[0097] 91. The fusosome of any of embodiments 86-90, wherein the complement regulatory protein comprises one or more of: a protein that binds to decay-accelerating factor (DAF, CD55), e.g., factor H (FH)-like protein-1 (FHL-1), e.g., C4b-binding protein (C4BP), e.g., complement receptor 1 (CD35), e.g., membrane cofactor protein (MCP, CD46), e.g., protectin (CD59), e.g., a protein that inhibits classical and alternative complement pathway CD / C5 convertase enzymes, e.g., a protein that regulates MAC assembly.
[0098] 92. The fusosome of any of the preceding embodiments, e.g., produced by the method of Example 10 from cells transfected with DNA encoding shRNA targeting MHC class I, and wherein the retroviral vector derived from, e.g., NMC-shMHC class I, results in reduced expression of MHC class I compared to NMC and NMC vector controls.
[0099] 93. The fusosomes of any of the preceding embodiments, wherein the measure of immunogenicity for the fusosomes is serum inactivation, e.g., serum inactivation measured as described in Example 11, e.g., as described herein.
[0100] 94. The fusosomes of any of the preceding embodiments, wherein the percentage of cells receiving the exogenous agent does not differ between fusosome samples incubated with serum from fusosome-naive mice and heat-inactivated serum.
[0101] 95. The fusosomes of any of the embodiments, wherein the percentage of cells receiving the exogenous agent does not differ between fusosome samples incubated with serum from fusosome-naive mice and serum-free control incubations.
[0102] 96. The fusosomes of any of the preceding embodiments, wherein the percentage of cells receiving the exogenous agent is less in fusosome samples incubated with positive control serum than in fusosome samples incubated with serum from fusosome-naive mice.
[0103] 97. The fusosomes of any of the preceding embodiments, wherein the modified fusosomes, e.g., those modified by the methods described herein, have reduced serum inactivation (e.g., reduced compared to administration of unmodified fusosomes) following multiple (e.g., more than one, e.g., two or more) administrations of the modified fusosomes.
[0104] 98. The fusosomes of any of the preceding embodiments, wherein the fusosomes described herein are not inactivated by serum after multiple administrations.
[0105] 99. The fusosomes of any of the preceding embodiments, wherein the measure of the immunogenicity of the fusosomes is, e.g., serum inactivation after multiple doses, e.g., serum inactivation after multiple doses measured as described herein, e.g., as described in Example 12.
[0106] 100. The fusosomes of any of the preceding embodiments, wherein the percentage of cells receiving the exogenous agent does not differ between fusosome samples incubated with serum from mice treated with modified (e.g., HEK293-HLA-G) fusosomes and heat-inactivated serum.
[0107] 101. The fusosomes of any of the preceding embodiments, wherein the percentage of cells receiving the exogenous agent does not differ between fusosome samples incubated with serum and heat-inactivated serum from mice treated 1, 2, 3, 5, or 10 times with modified (e.g., HEK293-HLA-G) fusosomes.
[0108] 102. The fusosomes of any of the preceding embodiments, wherein the percentage of cells receiving the exogenous agent does not differ between fusosome samples incubated with serum from vehicle-treated mice and from mice treated with modified (e.g., HEK293-HLA-G) fusosomes.
[0109] 103. The fusosomes of any of the preceding embodiments, wherein the percentage of cells receiving the exogenous agent is less in fusosomes derived from reference cells (e.g., HEK293) than in modified (e.g., HEK293-HLA-G) fusosomes.
[0110] 104. The fusosomes of any of the preceding embodiments, wherein the measure of immunogenicity to the fusosomes is a macrophage response.
[0111] 105. The fusosomes of any of the preceding embodiments, wherein the subject receiving the fusosomes described herein has a pre-existing antibody that binds to and recognizes the fusosomes, measured as described herein, e.g., as described in Example 13.
[0112] 106. The fusosomes of any of the preceding embodiments, wherein serum from fusosome-naive mice shows more signal (e.g., fluorescence) than a negative control, e.g., serum from mice depleted of IgM and IgG, indicating, e.g., that immunogenicity has occurred.
[0113] 107. The fusosomes of any of the preceding embodiments, wherein serum from fusosome-naive mice shows a similar signal (e.g., fluorescence) compared to a negative control, indicating, for example, that no detectable immunogenicity occurred.
[0114] 108. The fusosome of any of the preceding embodiments, wherein the fusosome is a modified fusosome, e.g., modified by a method described herein, and wherein the humoral response after multiple (e.g., more than one, e.g., two or more) administrations of the modified fusosome is reduced (e.g., reduced compared to administration of unmodified fusosomes), e.g., as described in Example 14, e.g., as measured as described herein.
[0115] 109. The fusosomes of any of the previous embodiments, wherein the fusosomes are produced by the method of Example 5, 6, 7, or 14, for example, from cells transfected with HLA-G or HLA-E cDNA.
[0116] 110. The fusosome of any of the preceding embodiments, wherein the humoral response is assessed by determining the value of the level of anti-fusosome antibodies (e.g., IgM, IgG1, and / or IgG2 antibodies).
[0117] 111. The fusosomes of any of the preceding embodiments, wherein the modified (e.g., NMC-HLA-G) fusosomes have reduced anti-viral IgM or IgG1 / 2 antibody titers (e.g., as measured by fluorescence intensity by FACS) following injection compared to a control, e.g., NMC fusosomes or NMC-empty fusosomes.
[0118] 112. The fusosome of any of the preceding embodiments, wherein the recipient cell is not targeted by an antibody response or the antibody response is below a reference level, e.g., when measured as described herein, e.g., as described in Example 15.
[0119] 113. The fusosomes of any of the preceding embodiments, wherein the signal (e.g., mean fluorescence intensity) is similar in recipient cells from fusosome-treated mice and PBS-treated mice.
[0120] 114. The fusosome of any of the preceding embodiments, wherein the measure of immunogenicity of the recipient cells is a macrophage response.
[0121] 115. The fusosomes of any of the preceding embodiments, wherein the recipient cells are not targeted by macrophages, or are targeted at below reference levels.
[0122] 116. The fusosomes of any of the preceding embodiments, wherein the phagocytic index, measured as described herein, e.g., as described in Example 16, is similar in recipient cells from fusosome-treated mice and PBS-treated mice.
[0123] 117. The fusosome of any of the preceding embodiments, wherein the measure of recipient cell immunogenicity is a PBMC response.
[0124] 118. The fusosome of any of the preceding embodiments, wherein the recipient cells do not induce a PBMC response.
[0125] 119. The fusosomes of any of the preceding embodiments, wherein the percentage of CD3+ / CMG+ cells is similar in recipient cells derived from fusosome-treated mice and PBS-treated mice, e.g., when measured as described herein, e.g., as described in Example 17.
[0126] 120. The fusosome of any of the preceding embodiments, wherein the measure of immunogenicity of the recipient cells is a natural killer cell response.
[0127] 121. The fusosome of any of the preceding embodiments, wherein the recipient cells do not induce a natural killer cell response, or e.g., induce a natural killer cell response that is lower than a reference value.
[0128] 122. The fusosomes of any of the preceding embodiments, wherein the percentage of CD3+ / CMG+ cells is similar in recipient cells derived from fusosome-treated mice and PBS-treated mice, e.g., when measured as described herein, e.g., as described in Example 18.
[0129] 123. The fusosome of any of the preceding embodiments, wherein the measure of immunogenicity of the recipient cells is a CD8+ T cell response.
[0130] 124. The fusosome of any of the preceding embodiments, wherein the recipient cells do not induce a CD8+ T cell response, or e.g., induce a CD8+ T cell response that is lower than a reference value.
[0131] 125. The fusosomes of any of the preceding embodiments, wherein the percentage of CD3+ / CMG+ cells is similar in recipient cells derived from fusosome-treated mice and PBS-treated mice, e.g., when measured as described herein, e.g., as described in Example 19.
[0132] 126. The fusosome of any of the preceding embodiments, wherein the fusogen is a retargeted fusogen.
[0133] 127. The fusosome of any of the preceding embodiments, comprising a nucleic acid, e.g., a retroviral nucleic acid, encoding one or both of (i) a positive target cell-specific regulatory element operably linked to a nucleic acid encoding an exogenous agent, or (ii) a non-control cell-specific regulatory element or a negative TCSSE operably linked to a nucleic acid encoding an exogenous agent.
[0134] 128. A pharmaceutical composition comprising the fusosomes of any of the preceding embodiments and a pharmaceutically acceptable carrier, diluent, or excipient.
[0135] 129. A method for delivering an exogenous agent to a subject (e.g., a human subject), comprising administering to the subject a fusosome of any of embodiments 1-127 or a pharmaceutical composition of claim 128, thereby delivering the exogenous agent to the subject.
[0136] 130. A method for modulating a function in a subject (e.g., a human subject), a target tissue (e.g., a liver), or a target cell (e.g., a liver cell, e.g., a hepatocyte), comprising contacting, e.g., administering to, the subject, the target tissue, or the target cell a fusosome of any of embodiments 1 to 127, or a pharmaceutical composition of embodiment 128.
[0137] 131. The method of embodiment 130, wherein the target tissue or target cell is present in a subject.
[0138] 132. A method for treating a genetic defect in a subject (e.g., a human subject), comprising administering to the subject a fusosome of any of embodiments 1 to 127, or a pharmaceutical composition of embodiment 128.
[0139] 133. The method of embodiment 132, wherein the gene deficiency is a gene deficiency in Table 5.
[0140] 134. The method of embodiment 132 or 133, wherein the genetic defect is a genetic defect that can be treated by a payload gene encoding an exogenous agent.
[0141] 135. The fusosome of any of embodiments 1-127 or the pharmaceutical composition of embodiment 128 for use in treating a subject (e.g., a human subject) having a genetic defect.
[0142] 136. Use of fusosomes of any of embodiments 1 to 127 or the pharmaceutical composition of embodiment 128 for the manufacture of an agent for use in treating a subject (e.g., a human subject) having a genetic defect.
[0143] 137. The fusosome or pharmaceutical composition for use of embodiment 135, or the use of embodiment 136, wherein the fusosome comprises a payload gene encoding an exogenous agent for treating a genetic defect.
[0144] 138. The following: a) providing a cell containing nucleic acid, e.g., retroviral nucleic acid, and a fusogen; b) culturing the cells under conditions that allow the production of fusosomes; and c) isolating, enriching, or purifying fusosomes from the cells, thereby producing fusosomes; A method for producing fusosomes according to any one of embodiments 1 to 127, comprising:
[0145] Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
[0146] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences mentioned herein, for example, in any table, are incorporated by reference. Unless otherwise specified, sequence accession numbers specified herein, including in the tables herein, refer to database entries current as of May 15, 2018. When a gene or protein references multiple sequence accession numbers, all sequence variants are included. Additionally, the materials, methods, and examples are merely illustrative and not intended to be limiting. In certain embodiments, for example, the following are provided: (Item 1) below: a) a lipid bilayer containing a fusogen, and b) Below: (i) a payload gene encoding an exogenous agent; and (ii) a nucleic acid comprising a positive liver cell-specific regulatory element operably linked to the payload gene, wherein the positive liver cell-specific regulatory element increases expression of the payload gene in liver cells compared to an otherwise similar fusosome lacking the positive liver cell-specific regulatory element. (Item 2) 2. The fusosome of item 1, wherein the nucleic acid further comprises a non-target cell-specific regulatory element (NTCSRE) operably linked to a payload gene, the NTCSRE reducing expression of the payload gene in non-liver cells compared to otherwise similar fusosomes lacking the NTCSRE. (Item 3) below: a) a lipid bilayer containing a fusogen; and b) Below: (i) a payload gene encoding an exogenous agent; and (ii) a nucleic acid comprising a promoter operably linked to the payload gene, wherein the promoter is selected from an Apoa2, Cyp3a4, LP1B, MIR122, hemopexin, SERPINA1, or HLP promoter. (Item 4) below: a) a lipid bilayer containing a fusogen; and b) Below: (i) a payload gene encoding an exogenous agent; and (ii) a nucleic acid comprising a non-target cell-specific regulatory element (NTCSRE) operably linked to a payload gene, wherein: A fusosome, wherein the NTCSRE is a non-liver cell-specific miRNA recognition sequence, a non-liver cell-specific protease recognition site, a non-liver cell-specific ubiquitin ligase site, a non-liver cell-specific transcriptional repression site, or a non-liver cell-specific epigenetic repression site, and the NTCSRE reduces expression of a payload gene in a non-liver cell or tissue compared to an otherwise similar fusosome lacking the NTCSRE. (Item 5) 5. The fusosome of item 4, wherein the nucleic acid further comprises a positive liver cell-specific regulatory element operably linked to the payload gene, the positive liver cell-specific regulatory element increasing expression of the payload gene in liver cells compared to otherwise similar fusosomes lacking the positive liver cell-specific regulatory element. (Item 6) below: (i) a first exogenous or overexpressed immunosuppressive protein on a lipid bilayer, or (ii) a first immunostimulatory protein that is absent or present at a reduced level, optionally wherein the reduced level is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduced compared to fusosomes produced from an otherwise similar unmodified source cell. (Item 7) 7. The fusosome according to any one of items 1 to 6, wherein the payload gene is a gene for treating a genetic defect. (Item 8) A fusosome, a) a lipid bilayer containing a fusogen; b) a nucleic acid comprising a payload gene encoding an exogenous agent for treating said genetic defect; and c) One or both of the following: (i) a first exogenous or overexpressed immunosuppressive protein on the lipid bilayer; or (ii) a first immunostimulatory protein that is absent or present at a reduced level (e.g., reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) compared to fusosomes produced from an otherwise similar unmodified source cell. (Item 9) 9. The fusosome according to any one of items 6 to 8, comprising (i) and (ii). (Item 10) 10. The fusosome according to any one of items 6 to 9, comprising (i) and further comprising a second exogenous or overexpressed immunosuppressive protein on the lipid bilayer. (Item 11) 11. The fusosomes according to any one of items 6 to 10, comprising (ii) and further comprising a second immunostimulatory protein that is absent or present at reduced levels, optionally wherein the reduced levels are at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduced compared to fusosomes produced from an otherwise similar unmodified source cell. (Item 12) 12. The fusosome according to any one of Items 8 to 11, wherein the nucleic acid further comprises a positive liver cell-specific regulatory element operably linked to the payload gene, wherein the positive liver cell-specific regulatory element increases expression of the payload gene in liver cells compared to otherwise similar fusosomes lacking the positive liver cell-specific regulatory element. (Item 13) 13. The fusosome according to any one of items 8 to 12, wherein the nucleic acid further comprises a non-target cell-specific regulatory element (NTCSRE) operably linked to a payload gene, the NTCSRE reducing expression of the payload gene in non-liver cells or tissues compared to otherwise similar fusosomes lacking the NTCSRE. (Item 14) When administered to a subject: i) the fusosomes do not produce a detectable antibody response or antibodies to the fusosomes are present at levels less than 10%, 5%, 4%, 3%, 2%, or greater than 1% above background levels; ii) the fusosomes do not elicit a detectable cellular immune response, or the cellular immune response to the fusosomes is present at levels less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels; iii) the fusosomes do not elicit a detectable innate immune response, or the innate immune response to the fusosomes is present at levels less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels. iv) less than 10%, 5%, 4%, 3%, 2%, or 1% of the fusosomes are inactivated by serum; v) target cells that receive the exogenous agent from the fusosomes do not develop a detectable antibody response, or antibodies to the target cells are present at levels less than 10%, 5%, 4%, 3%, 2%, or greater than 1% of background levels; or vi) The fusosome according to any one of items 6 to 13, wherein the target cells that received the exogenous agent from the fusosome do not develop a detectable cellular immune response, or the cellular response against the target cells is present at a level that is less than 10%, 5%, 4%, 3%, 2%, or more than 1% of background levels. (Item 15) 15. The fusosomes of item 14, wherein the background level is the corresponding level in the same subject before administration of the fusosomes. (Item 16) 16. The fusosome according to any one of items 6 to 15, wherein the immunosuppressive protein is a complement regulatory protein or CD47. (Item 17) 17. The fusosome according to any one of items 6 to 16, wherein the immunostimulatory protein is an MHC I or MHC II protein. (Item 18) The payload gene is OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, PAL, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LNBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, BTD, HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, LDLR, ACAD8, ACADSB, ACAT1, ACSF3, ASPA, AUH, DNAJC19, ETHE1, FBP1, FTCD, GSS, HIBCH, IDH2, L2HGDH, MLYCD, OPA3, OPLAH, OXCT1, POLG, PPM1K, SERAC1, SLC25A1, SUCLA2, SUCLG1, TAZ, AGK, CLPB, TMEM70, ALDH18A1, OAT, CA5A, GLUD1, GLUL, UMPS, SLC22A5, CPT1A, HADHA, HADH, SLC52A1, SLC52A2, SLC52A3, HADHB, GYS2, PYGL, SLC2A2, ALG1, ALG2, ALG3, ALG6, ALG8, ALG9, ALG11, ALG12, ALG13, ATP6V0A2, B3GLCT, CHST14, COG1, COG2, COG4, COG5, COG6, COG7, COG8, DOLK, DHDDS, DPAGT1, DPM1, DPM2, DPM3, G6PC3, GFPT1, GMPPA, GMPPB, MAGT1, MAN1B1, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PGM3, RFT1, SEC23B, SLC35A1,SLC35A2、SLC35C1、SSR4、SRD5A3、TMEM165、TRIP11、TUSC3、ALG14、B4GALT1、DDOST、NUS1、RPN2、SEC23A、SLC35A3、ST3GAL3、STT3A、STT3B、AGA、ARSA、A RSB、ASAH1、ATP13A2、CLN3、CLN5、CLN6、CLN8、CTNS、CTSA、CTSD、CTSF、CTSK、DNAJC5、FUCA1、GAA、GALC、GALNS、GLA、GLB1、GM2A、GNPTAB、GNPTG、GNS、GR N、GUSB、HEXA、HEXB、HGSNAT、HYAL1、IDS、IDUA、KCTD7、LAMP2、MAN2B1、MANB A、MCOLN1、MFSD8、NAGA、NAGLU、NEU1NPC1、NPC2、SGSH、PPT1、PSAP、SLC17A5 、SMPD1、SUMF1、TPP1、AHCY、GNMT、MAT1A、GCH1、PCBD1、PTS、QDPR、SPR、DNAJC12、ALDH4A1、PRODH、HPD、GBA、HGD、AMN、CD320、CUBN、GIF、TCN1、TCN2、PRE PL、PHGDH、PSAT1、PSPH、AMT,GCSH、GLDC、LIAS、NFU1、SLC6A9、SLC2A1、ATP7 A、AP1S1、CP、SLC33A1、PEX7、PHYH、AGPS、GNPAT、ABCD1、ACOX1、PEX1、PEX2、 PEX3、PEX5、PEX6、PEX10、PEX12、PEX13、PEX14、PEX16、PEX19、PEX26、AMACR 、ADA、ADSL、AMPD1、GPHN、MOCOS、MOCS1、PNP、XDH、SUOX、OGDH、SLC25A19、DH TKD1、SLC13A5、FH、DLAT、MPC1、PDHA1、PDHB、PDHX、PDP1、ABCC2、SLCO1B1、S LCO1B3、HFE2、ADAMTS13、PYGM、COL1A2、TNFRSF11B、TSC1、TSC2、DHCR7、PGK 1、VLDLR、KYNU、F5、C3、COL4A1、CFH、SLC12A2、GK、SFTPC、CRTAP、P3H1、COL7 A1、PKLR、TALDO1、TF、EPCAM、VHL、GC、SERPINA1、ABCC6、F8、F9、ApoB、PCSK9、18. The fusosome according to any one of items 1 to 17, wherein the fusosome is selected from LDLRAP1, ABCG5, ABCG8, LCAT, SPINK5, and GNE. (Item 19) 19. The fusosome according to any one of Items 1 to 18, wherein the payload gene encodes an exogenous agent comprising a sequence set forth in any one of SEQ ID NOs: 161 to 518, or a functional fragment thereof, or a functional variant thereof comprising an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 161 to 518. (Item 20) 19. The fusosome according to any one of items 1 to 19, which is one or more of the following: i) the fusosomes fuse with liver cells at a higher rate than with non-liver cells, and optionally the higher rate is at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold; ii) the fusosomes fuse with liver cells at a higher rate than with other fusosomes, and optionally the higher rate is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold; iii) the fusosomes fuse with liver cells at a rate such that the exogenous agent within the fusosomes is delivered to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the liver cells after 24, 48, or 72 hours; iv) the fusosomes deliver the nucleic acid to a higher percentage of liver cells than to non-liver cells, and optionally the higher percentage is at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold; v) the fusosomes deliver a higher percentage of the nucleic acid to liver cells than other fusosomes, and optionally the higher percentage is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold; or vi) the fusosomes deliver nucleic acid to liver cells at a rate such that the agent in the fusosomes is delivered to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the target cells after 24, 48, or 72 hours. (Item 21) The payload gene encoding the exogenous agent is selected from the group consisting of OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LMBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, BTD, H 21. The fusosome according to any one of items 1 to 20, wherein the fusosome is selected from LCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, or LDLR. (Item 22) 22. The fusosome according to any one of items 1 to 21, wherein the fusogen is a viral envelope protein. (Item 23) 23. The fusosome according to any one of items 1 to 22, wherein the fusogen comprises VSV-G. (Item 24) 22. The fusosome according to any one of items 1 to 21, wherein the fusogen comprises a sequence selected from Nipah virus F and G proteins, measles virus F and H proteins, Tupaia paramyxovirus F and H proteins, paramyxovirus F and G proteins or F and H proteins or F and HN proteins, Hendra virus F and G proteins, Henipavirus F and G proteins, Morbillivirus F and H proteins, Respirovirus F and HN proteins, Sendai virus F and HN proteins, Rubulavirus F and HN proteins, or Avulavirus F and HN proteins, or derivatives thereof, or any combination thereof. (Item 25) 25. The fusosome according to any one of items 1 to 21 and 24, wherein the fusogen comprises a domain of at least 100 amino acids in length having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a wild-type paramyxovirus fusogen, and optionally the wild-type paramyxovirus fusogen is set forth in any one of SEQ ID NOs: 1 to 132. (Item 26) 26. The fusosome of item 25, wherein the wild-type paramyxovirus is a Nipah virus, and optionally, the Nipah virus is a Henipavirus. (Item 27) 27. The fusosome according to any one of items 1 to 26, wherein the fusogen is retargeted for delivery to liver cells. (Item 28) 28. The fusosome according to items 1, 2, 5, 6, 7 and 14 to 27, wherein the positive liver-specific regulatory element comprises a liver-specific promoter, a liver-specific enhancer, a liver-specific splice site, a liver-specific site that extends the half-life of RNA or protein, a liver-specific mRNA export-promoting site, a liver-specific translation-enhancing site, or a liver-specific post-translational modification site. (Item 29) 29. The fusosome of item 28, wherein the positive liver-specific regulatory element comprises a hepatocyte-specific promoter. (Item 30) 30. The fusosome of item 28 or 29, wherein the positive liver-specific regulatory element comprises a promoter selected from enhanced transthyretin (ET), Alb, Apoa2, Cyp3a4, LP1B, MIR122, hemopexin, SERPINA1, or HLP promoter. (Item 31) Item 31. The fusosome according to Item 3 or 30, wherein the promoter has a sequence set forth in any one of SEQ ID NOs: 133 to 136 or 519 to 525, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. (Item 32) 30. The fusosome of claim 28 or 29, wherein the positive liver-specific regulatory element comprises the ApoE.HCR-hAAT promoter, and optionally the promoter comprises the sequence set forth in SEQ ID NO: 133 or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO: 133. (Item 33) 33. The fusosome according to any one of Items 2, 6, 7, and 15 to 32, wherein the NTCSRE comprises a non-liver cell-specific miRNA recognition sequence, a non-liver cell-specific protease recognition site, a non-liver cell-specific ubiquitin ligase site, a non-liver cell-specific transcriptional repression site, or a non-liver cell-specific epigenetic repression site. (Item 34) 34. The fusosome of item 33, wherein the NTCSRE comprises a non-liver cell-specific miRNA recognition sequence, and the miRNA recognition sequence can be bound by one or more of miR-142, mir-181a-2, mir-181b-1, mir-181c, mir-181a-1, mir-181b-2, mir-181d, miR-223, or miR-126. (Item 35) 35. The fusosome of claim 33 or 34, wherein the NTCSRE is located or encoded within a transcribed region encoding an exogenous agent, and optionally, the RNA produced by the transcribed region comprises an miRNA recognition sequence within a UTR or coding region. (Item 36) 36. The fusosome according to any one of items 1 to 35, wherein the nucleic acid comprises one or more insulator sequences. (Item 37) 37. The fusosome of item 36, wherein the nucleic acid comprises two insulator sequences, optionally comprising a first insulator sequence upstream of the payload gene and a second insulator sequence downstream of the payload gene, and optionally wherein the first insulator sequence and the second insulator sequence comprise the same or different sequences. (Item 38) 38. The fusosome according to any one of items 1 to 37, wherein the fusosome is a retroviral vector particle. (Item 39) 39. The fusosome according to any one of items 1 to 38, wherein the nucleic acid is capable of being integrated into the genome of a liver cell. (Item 40) 40. The fusosome according to any one of items 1 to 39, wherein the liver cells are selected from hepatocytes, liver sinusoidal endothelial cells, bile duct cells, stellate cells, antigen-presenting cells present in the liver, immune lymphocytes present in the liver, and portal tract fibroblasts. (Item 41) 41. A pharmaceutical composition comprising the fusosome according to any one of items 1 to 40 and a pharmaceutically acceptable carrier, diluent, or excipient. (Item 42) A method for delivering an exogenous agent to a subject, comprising administering to the subject the fusosome according to any one of Items 1 to 40 or the pharmaceutical composition according to Item 41, thereby delivering the exogenous agent to the subject. (Item 43) 41. A method for regulating liver or liver cell function in a subject, the method comprising contacting the liver or liver cells of the subject with the fusosome according to any one of Items 1 to 40 or the pharmaceutical composition according to Item 41. (Item 44) 44. The method of claim 43, wherein the target tissue or target cell is present in the subject. (Item 45) 45. The method of claim 43 or 44, wherein the contacting is carried out by administering the fusosomes to the subject. (Item 46) A method for treating a gene defect in a subject, the method comprising administering to the subject the fusosome according to any one of Items 1 to 40 or the pharmaceutical composition according to Item 41. (Item 47) 47. The method of claim 46, wherein the genetic defect is a genetic defect that can be treated by a payload gene encoding the exogenous agent. (Item 48) 48. The method according to any one of items 42 to 47, wherein the subject is a human subject. (Item 49) 42. The fusosome according to any one of items 1 to 40 or the pharmaceutical composition according to item 41 for use in treating a subject having a gene defect. (Item 50) 42. Use of a fusosome according to any one of items 1 to 40 or a pharmaceutical composition according to item 41 for the manufacture of a medicament for use in treating a subject having a genetic defect. (Item 51) 51. The fusosome or pharmaceutical composition for use according to item 49, or the use according to item 50, wherein the fusosome comprises a payload gene encoding an exogenous agent for treating a genetic defect. (Item 52) below: a) providing a cell containing the nucleic acid and the fusogen; b) culturing the cells under conditions that allow the production of fusosomes; and c) A method for preparing fusosomes according to any one of items 1 to 40, comprising isolating, concentrating, or purifying fusosomes from the cells, thereby preparing fusosomes.
[0147] The following detailed description of the invention will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the invention, there are described herein specific embodiments that are illustrated in the specification, it being understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. [Brief explanation of the drawings]
[0148] [Figure 1] Figure 1 quantifies the staining of fusosomes with F-actin dyes. [Figure 2] FIG. 2 is a graph showing the ability of fusosomes and parental cells to polymerize actin over a period of 3, 5, and 24 hours. [Figure 3] FIG. 3 is a table showing size distribution statistics of fusosomes and parent cells as determined by NTA and microscopy. [Figure 4] FIG. 4 is a table showing the average size and volume of fusosomes and parent cells. [Figure 5] FIG. 5 is a series of graphs showing the soluble:insoluble ratios observed for fusosome or cell preparations. [Figure 6] FIG. 6 is a series of graphs showing MvH(CD8)+F fusosome fusion to target or non-target cells, and the absolute amount of target fusion. [Figure 7] FIG. 7 shows the mean fluorescence intensity of 2-NBDG in VSV-G fusosomes. [Figure 8] FIG. 8 shows esterase activity in the cytosol of VSV-G fusosomes. [Figure 9A] Figures 9A-9B are a series of images showing Cre recombinase delivery by fusosomes, as detected by bioluminescence imaging in mice. (A) Ventral images and luminescence signal overlays of exposed livers and spleens from IV fusosome-treated mice (1x and 3x concentrations). The bottom shows luminescence signal only. (B) Total flux signal of fusosome-targeted spleens and livers; γ-scale is a log10 scale. Mice treated with 3x the fusosome treatment concentration showed significantly greater signal in the spleen than background 72 hours after treatment (p=0.0004). [Figure 9B] Figures 9A-9B are a series of images showing Cre recombinase delivery by fusosomes, as detected by bioluminescence imaging in mice. (A) Ventral images and luminescence signal overlays of exposed livers and spleens from IV fusosome-treated mice (1x and 3x concentrations). The bottom shows luminescence signal only. (B) Total flux signal of fusosome-targeted spleens and livers; γ-scale is a log10 scale. Mice treated with 3x the fusosome treatment concentration showed significantly greater signal in the spleen than background 72 hours after treatment (p=0.0004). [Figure 10A] Figures 10A-10B are a series of images showing Cre recombinase delivery to mouse liver and spleen by fusosomes, as detected by bioluminescence imaging. (A) From left to right: Dorsal images and luminescence signal overlays of excised liver, heart, lung, kidney, small intestine, pancreas, and spleen, collected and imaged within 5 minutes of euthanasia. The bottom shows luminescence signal only. (B) Total flux signal of fusosome-targeted spleen and liver, as well as other tissues; γ-scale is a log10 scale. Mice treated with a 3x higher concentration of fusosomes showed significantly greater signal in the spleen compared to the tissue with the lowest signal (heart) (p<0.0001). [Figure 10B] Figures 10A-10B are a series of images showing Cre recombinase delivery to mouse liver and spleen by fusosomes, as detected by bioluminescence imaging. (A) From left to right: Dorsal images and luminescence signal overlays of excised liver, heart, lung, kidney, small intestine, pancreas, and spleen, collected and imaged within 5 minutes of euthanasia. The bottom shows luminescence signal only. (B) Total flux signal of fusosome-targeted spleen and liver, as well as other tissues; γ-scale is a log10 scale. Mice treated with a 3x higher concentration of fusosomes showed significantly greater signal in the spleen compared to the tissue with the lowest signal (heart) (p<0.0001). [Figure 11] FIG. 11 is a table showing delivery of Cre cargo by NivG+F fusosomes via a non-endocytic pathway. [Figure 12] FIG. 12 is a graph showing the GAPDH:total protein ratio measured by bicinchoninic acid assay in fusosomes and parental cells. [Figure 13] FIG. 13 is a graph showing the lipid:protein ratio measured by the bicinchoninic acid assay in fusosomes and parental cells. [Figure 14] FIG. 14 is a graph showing the protein:DNA ratio measured by the bicinchoninic acid assay in fusosomes and parental cells. [Figure 15] FIG. 15 is a graph showing the lipid:DNA ratio measured by the bicinchoninic acid assay in fusosomes and parental cells. [Figure 16] FIG. 16 is a graph showing the protein levels of the exosomal marker CD63 in exosomes and fusosomes. [Figure 17] FIG. 17 is a graph showing the intensity of the calnexin signal detected in fusosomes and parental cells. [Figure 18] FIG. 18 is a graph showing the lipid:DNA ratios determined for fusosomes and parental cells. [Figure 19A]19A-19B are a series of graphs showing the proportion of lipid species as a percentage of total lipid in parental cells, exosomes, and fusosomes. [Figure 19B] 19A-19B are a series of graphs showing the proportion of lipid species as a percentage of total lipid in parental cells, exosomes, and fusosomes. [Figure 20] FIG. 20 is a series of graphs showing the protein content of parental cells, exosomes, and fusosomes with respect to proteins associated with specific compartments, as indicated. [Figure 21] FIG. 21 is a series of graphs showing the levels of ARRDC1 (left panel) or TSG101 (right panel) as a percentage of the total protein content in parental cells, exosomes, and fusosomes. [Figure 22A] Figures 22A-22C show results for cell lines, including the targeted human hepatoma cell line (HepG2) and non-targeted (non-hepatic) cell lines, transduced with lentiviruses (LVs) encoding nucleic acid constructs containing a positive TCSRE or NTCSRE. Figure 22A shows GFP expression in the human hepatoma cell line (HepG2), human embryonic kidney cell line (293LX), human T cell line of hematopoietic origin (Molt4.8), and mouse brain-derived endothelial cell line (bEND.3) transduced with LVs generated under the control of the PGK promoter using miRT sequences (hPGK-eGFP+miRT) or without miRT sequences (hPGK-eGFP). Figure 22B shows GFP expression in HepG2 and 293LX cells transduced with LVs generated under the control of the PGK promoter (hPGK-eGFP) or LVs containing miRT sequences and GFP under the control of the hepatocyte-specific promoter ApoE (hApoE-eGFP+miRT). Figure 22C shows quantification of phenylalanine (Phe) in the supernatants of HepG2 and 293LX cells transduced with LV containing the transgene phenylalanine ammonia-lyase (PAL) under the control of the SFFV promoter (SFFV-PAL) or LV containing the mirT sequence and under the control of the hApoE promoter (hApoE-PAL+miRT). [Figure 22B]Figures 22A-22C show results for cell lines, including the targeted human hepatoma cell line (HepG2) and non-targeted (non-hepatic) cell lines, transduced with lentiviruses (LVs) encoding nucleic acid constructs containing a positive TCSRE or NTCSRE. Figure 22A shows GFP expression in the human hepatoma cell line (HepG2), human embryonic kidney cell line (293LX), human T cell line of hematopoietic origin (Molt4.8), and mouse brain-derived endothelial cell line (bEND.3) transduced with LVs generated under the control of the PGK promoter using miRT sequences (hPGK-eGFP+miRT) or without miRT sequences (hPGK-eGFP). Figure 22B shows GFP expression in HepG2 and 293LX cells transduced with LVs generated under the control of the PGK promoter (hPGK-eGFP) or LVs containing miRT sequences and GFP under the control of the hepatocyte-specific promoter ApoE (hApoE-eGFP+miRT). Figure 22C shows quantification of phenylalanine (Phe) in the supernatants of HepG2 and 293LX cells transduced with LV containing the transgene phenylalanine ammonia-lyase (PAL) under the control of the SFFV promoter (SFFV-PAL) or LV containing the mirT sequence and under the control of the hApoE promoter (hApoE-PAL+miRT). [Figure 22C]Figures 22A-22C show results for cell lines, including the targeted human hepatoma cell line (HepG2) and non-targeted (non-hepatic) cell lines, transduced with lentiviruses (LVs) encoding nucleic acid constructs containing a positive TCSRE or NTCSRE. Figure 22A shows GFP expression in the human hepatoma cell line (HepG2), human embryonic kidney cell line (293LX), human T cell line of hematopoietic origin (Molt4.8), and mouse brain-derived endothelial cell line (bEND.3) transduced with LVs generated under the control of the PGK promoter using miRT sequences (hPGK-eGFP+miRT) or without miRT sequences (hPGK-eGFP). Figure 22B shows GFP expression in HepG2 and 293LX cells transduced with LVs generated under the control of the PGK promoter (hPGK-eGFP) or LVs containing miRT sequences and GFP under the control of the hepatocyte-specific promoter ApoE (hApoE-eGFP+miRT). Figure 22C shows quantification of phenylalanine (Phe) in the supernatants of HepG2 and 293LX cells transduced with LV containing the transgene phenylalanine ammonia-lyase (PAL) under the control of the SFFV promoter (SFFV-PAL) or LV containing the mirT sequence and under the control of the hApoE promoter (hApoE-PAL+miRT). DETAILED DESCRIPTION OF THE INVENTION
[0149] The present disclosure provides, at least in part, fusosome methods and compositions for in vivo delivery. In some embodiments, the fusosomes contain a combination of elements that promote specificity for target cells, such as one or more retargeted fusogens, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome compositions contain one or more modifications that reduce an immune response to the fusosomes.
[0150] definition Terms used in the claims and specification are defined as set forth below unless otherwise specified.
[0151] As used herein, "detectably present," when used in the context of an exogenous agent being detectably present, means that the exogenous agent itself is detectably present. For example, if the exogenous agent is a protein, the exogenous protein agent can be detectably present regardless of whether the nucleic acid encoding it is detectably present.
[0152] As used herein, "fusosome" refers to an amphipathic lipid bilayer surrounding a lumen or cavity and a fusogen that interacts with the amphipathic lipid bilayer. In embodiments, fusosomes contain nucleic acid. In some embodiments, fusosomes are membrane-enclosed preparations. In some embodiments, fusosomes are derived from a source cell.
[0153] As used herein, a "fusosome composition" refers to a composition comprising one or more fusosomes.
[0154] As used herein, "fusogen" refers to an agent or molecule that creates an interaction between two membrane-bound lumens. In embodiments, a fusogen promotes membrane fusion. In other embodiments, a fusogen creates a connection, e.g., a pore, between two lumens (e.g., the lumen of a retroviral vector and the cytoplasm of a target cell). In some embodiments, a fusogen comprises a complex of two or more proteins, e.g., neither protein has solely fusogenic activity. In some embodiments, a fusogen comprises a targeting domain.
[0155] As used herein, "insulator sequence" refers to a nucleotide sequence that blocks an enhancer or prevents heterochromatin spreading. Insulator sequences can be wild-type or mutant.
[0156] As used herein, the term "effective amount" refers to that amount of a pharmaceutical composition sufficient to significantly and positively modify the symptoms and / or condition being treated (e.g., provide a positive clinical response). The effective amount of active ingredient for use in a pharmaceutical composition will vary depending on the particular condition being treated, the severity of the condition, the duration of treatment, the nature of any concurrent therapy, the particular active ingredient(s) used, the particular pharmaceutically acceptable excipients and / or carriers employed, and similar factors according to the knowledge and expertise of the attending physician.
[0157] As used herein, an "exogenous agent" with respect to a virus, VLP, or fusosome refers to an agent that is not contained in or encoded by the corresponding wild-type virus or fusogen produced from a corresponding wild-type source cell. In some embodiments, the exogenous agent is not naturally occurring, such as a protein or nucleic acid having a sequence that is altered (e.g., by insertion, deletion, or substitution) compared to a naturally occurring protein. In some embodiments, the exogenous agent is not naturally occurring in the source cell. In some embodiments, the exogenous agent is naturally present in the source cell but is exogenous to the virus. In some embodiments, the exogenous agent is not naturally occurring in the recipient cell. In some embodiments, the exogenous agent is naturally present in the recipient cell, but not at a desired level or for a desired time. In some embodiments, the exogenous agent comprises RNA or a protein.
[0158] As used herein, the term "pharmaceutically acceptable" refers to excipients, compositions and / or dosage forms that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0159] As used herein, "promoter" refers to a cis-regulatory DNA sequence that drives transcription of a gene when operably linked to the gene coding sequence. A promoter may contain transcription factor binding sites. In some embodiments, a promoter functions in cooperation with one or more enhancers distal to the gene.
[0160] As used herein, a "positive target cell-specific regulatory element" (or positive TCSRE) refers to a nucleic acid sequence that increases the level of an exogenous agent in a target cell compared to a non-target cell, wherein a nucleic acid encoding the exogenous agent is operably linked to the positive TCSRE. In some embodiments, the positive TCSRE is a functional nucleic acid sequence, e.g., the positive TCSRE can comprise a promoter or enhancer. In some embodiments, the positive TCSRE encodes a functional RNA sequence, e.g., the positive TCSRE can encode a splice site that promotes correct splicing of RNA in the target cell. In some embodiments, the positive TCSRE encodes a functional protein sequence, or the positive TCSRE can encode a protein sequence that promotes correct post-translational modification of a protein. In some embodiments, the positive TCSRE reduces the level or activity of a down-regulator or inhibitor of the exogenous agent. In some embodiments, the target cell is a liver cell, and the positive target cell-specific regulatory element is a liver cell-specific regulatory element.
[0161] As used herein, a "negative target cell-specific regulatory element" (or negative TCSSE) refers to a nucleic acid sequence that reduces the level of an exogenous agent in a non-target cell compared to a target cell, wherein a nucleic acid encoding the exogenous agent is operably linked to the negative TCSSE. In some embodiments, the negative TCSSE is a functional nucleic acid sequence, e.g., an miRNA recognition site, that causes degradation or inhibition of a retroviral nucleic acid in the non-target cell. In some embodiments, the nucleic acid sequence encodes a functional RNA sequence, e.g., the nucleic acid encodes an miRNA sequence present in an mRNA encoding the exogenous protein agent, such that the mRNA is degraded or inhibited in the non-target cell. In some embodiments, the negative TCSSE increases the level or activity of a down-regulator or inhibitor of the exogenous agent. In some embodiments, the non-target cell is a non-liver cell.
[0162] As used herein, a "non-target cell-specific regulatory element" (or NTCSRE) refers to a nucleic acid sequence that reduces the level of an exogenous agent in a non-target cell compared to a target cell, wherein a nucleic acid encoding the exogenous agent is operably linked to the NTCSRE. In some embodiments, the NTCSRE is a functional nucleic acid sequence, e.g., an miRNA recognition site, that causes degradation or inhibition of a retroviral nucleic acid in the non-target cell. In some embodiments, the nucleic acid sequence encodes a functional RNA sequence, e.g., the nucleic acid encodes an miRNA sequence present in an mRNA encoding an exogenous protein agent, such that the mRNA is degraded or inhibited in the non-target cell. In some embodiments, the NTCSRE increases the level or activity of a down-regulator or inhibitor of the exogenous agent. In some embodiments, the non-target cell is a non-liver cell, and the non-target cell-specific regulatory element is a non-liver cell-specific regulatory element. The terms "negative TCSRE" and "NTCSRE" are used interchangeably herein.
[0163] As used herein, "non-liver cell-specific regulatory element" refers to a non-target cell-specific regulatory element (NTCSRE), where the target cell is a liver cell. Thus, a non-liver cell-specific regulatory element refers to a nucleic acid sequence that reduces the level of an exogenous agent in a non-liver cell (e.g., an immune cell) or tissue compared to a liver cell, where the nucleic acid encoding the exogenous agent is operably linked to the non-liver cell-specific regulatory element.
[0164] As used herein, a "retargeted fusogen" refers to a fusogen that includes a targeting moiety with a sequence that is not part of the naturally occurring form of the fusogen. In embodiments, the fusogen includes a different targeting moiety compared to the targeting moiety of the naturally occurring form of the fusogen. In embodiments, the naturally occurring form of the fusogen lacks a targeting domain, and the retargeted fusogen includes a targeting moiety that is not present in the naturally occurring form of the fusogen. In embodiments, the fusogen is modified to include a targeting moiety. In embodiments, the fusogen includes one or more sequence changes outside of the targeting moiety, e.g., in the transmembrane domain, the fusogenically active domain, or the cytoplasmic domain, compared to the naturally occurring form of the fusogen.
[0165] As used herein, "retroviral nucleic acid" refers to a nucleic acid that comprises at least the minimum sequence requirements for packaging into a retrovirus or retroviral vector, alone or in combination with a helper cell, helper virus, or helper plasmid. In some embodiments, the retroviral nucleic acid further comprises or encodes an exogenous agent, a positive target cell-specific regulatory element, a non-target cell-specific regulatory element, or a negative TCSSE. In some embodiments, the retroviral nucleic acid comprises one or more of a 5' LTR (e.g., to facilitate integration), a U3 (e.g., to activate viral genome RNA transcription), an R (e.g., a Tat binding region), a U5, a 3' LTR (e.g., to facilitate integration), a packaging site (e.g., psi (Ψ)), or an RRE (e.g., to bind Rev and promote nuclear export). Retroviral nucleic acid can comprise RNA (e.g., when part of a virion) or DNA (e.g., when introduced into a source cell or after reverse transcription in a recipient cell). In some embodiments, the retroviral nucleic acid is packaged using a helper cell, a helper virus, or a helper plasmid containing one or more (eg, all) of gag, pol, and env.
[0166] As used herein, "target cell" refers to a cell type to which it is desired that a fusosome (e.g., a lentiviral vector) deliver an exogenous agent. In embodiments, the target cell is a particular tissue type or class of cell, e.g., an immune effector cell, e.g., a T cell. In some embodiments, the target cell is a diseased cell, e.g., a cancer cell. In some embodiments, a fusogen, e.g., a retargeted fusogen (alone or in combination with a positive TCSRE, NTCSRE, negative TCSRE, or any combination thereof), directs preferential delivery of the exogenous agent to the target cell relative to non-target cells.
[0167] As used herein, "non-target cells" refers to cell types to which it is not desirable for a lentiviral vector to deliver an exogenous agent. In some embodiments, non-target cells are cells of a particular tissue type or class. In some embodiments, non-target cells are non-disease cells, e.g., non-cancerous cells. In some embodiments, a fusogen, e.g., a retargeted fusogen (alone or in combination with a positive TCSRE, NTCSRE, negative TCSRE, or any combination thereof), leads to lower delivery of an exogenous agent to non-target cells compared to target cells.
[0168] As used herein, the terms "treat", "treating", or "treatment" refer to ameliorating a disease or disorder, e.g., the underlying cause of the disorder or at least one of its clinical symptoms, e.g., delaying, preventing, or reducing the onset of the disease or disorder.
[0169] As used herein, "cell biological material" refers to a portion of a cell, including the lumen and cell membrane, or a cell with partial or complete nuclear inactivation. In some embodiments, the cell biological material includes one or more of cytoskeletal components, organelles, and ribosomes. In embodiments, the cell biological material is an enucleated cell, a microvesicle, or a cell ghost.
[0170] Fusosomes, e.g., cell-derived fusosomes Fusosomes can take various forms. For example, in some embodiments, the fusosomes described herein are derived from source cells. Fusosomes can be or include, for example, extracellular vesicles, microvesicles, nanovesicles, exosomes, apoptotic bodies (derived from apoptotic cells), microparticles (e.g., derived from platelets), ectosomes (e.g., derived from neutrophils and monocytes in serum), prostatosomes (obtained from prostate cancer cells), cardiosomes (obtained from cardiac cells), or any combination thereof. In some embodiments, fusosomes are naturally released from source cells, and in some embodiments, the source cells are treated to enhance fusosome formation. In some embodiments, fusosomes are about 10-10,000 nm in diameter, e.g., about 30-100 nm in diameter. In some embodiments, fusosomes comprise one or more synthetic lipids.
[0171] In some embodiments, the fusosome is or comprises a virus, e.g., a retrovirus, e.g., a lentivirus. According to one embodiment of the present invention, the fusosome comprising a lipid bilayer comprises a retroviral vector comprising an envelope. For example, in some embodiments, the amphipathic lipid bilayer of the fusosome is or comprises a viral envelope. The viral envelope can comprise a fusogen, e.g., a fusogen endogenous to the virus or a pseudotyped fusogen. In some embodiments, the lumen or cavity of the fusosome comprises viral nucleic acid, e.g., retroviral nucleic acid, e.g., lentiviral nucleic acid. The viral nucleic acid can be a viral genome. In some embodiments, the fusosome further comprises, e.g., in its cavity or lumen, one or more viral nonstructural proteins.
[0172] Fusosomes can have a variety of properties that facilitate delivery of a payload, such as encoding a desired transgene or exogenous agent, to a target cell. For example, in some embodiments, the fusosome and source cell together contain sufficient nucleic acid(s) to create a particle capable of fusing with a target cell. In embodiments, these nucleic acid(s) encode a protein having one or more (e.g., all) of the following activities: gag polyprotein activity, polymerase activity, integrase activity, protease activity, and fusogenic activity.
[0173] Fusosomes can also comprise various structures that facilitate delivery of a payload to a target cell. For example, in some embodiments, fusosomes (e.g., viruses, e.g., retroviruses, e.g., lentiviruses) comprise one or more (e.g., all) of the following proteins: gag polyprotein, polymerase (e.g., pol), integrase (e.g., functional or non-functional variants), protease, and fusogen. In some embodiments, fusosomes further comprise rev. In some embodiments, one or more of the aforementioned proteins are encoded by the retroviral genome, and in some embodiments, one or more of the aforementioned proteins are provided in trans, e.g., by a helper cell, helper virus, or helper plasmid. In some embodiments, the fusosomal nucleic acid (e.g., retroviral nucleic acid) comprises one or more (e.g., all) of the following nucleic acid sequences: a 5' LTR (e.g., comprising a U5 and lacking a functional U3 domain), a Psi packaging element (Psi), a central polypurine tract (cPPT) promoter operably linked to a payload gene, a payload gene (optionally comprising an intron before the open reading frame), a polyA tail sequence, a WPRE, and a 3' LTR (e.g., lacking a U5 and a functional U3). In some embodiments, the fusosomal nucleic acid (e.g., retroviral nucleic acid) further comprises one or more insulator sequences. In some embodiments, the fusosomal nucleic acid (e.g., retroviral nucleic acid) further comprises one or more miRNA recognition sites. In some embodiments, the one or more miRNA recognition sites are located downstream of the polyA tail sequence, e.g., between the polyA tail sequence and the WPRE.
[0174] In some embodiments, the fusosomes provided herein are administered to a subject, e.g., a mammal, e.g., a human. In such embodiments, the subject is at risk for, has symptoms of, can be diagnosed with, or can be identified as having a particular disease or condition (e.g., a disease or condition described herein). In one embodiment, the subject has a genetic defect, such as those listed in Table 5. In some embodiments, the fusosomes comprise a nucleic acid sequence encoding an exogenous agent for treating a disease or condition, such as for treating a genetic defect.
[0175] Lentiviral components and helper cells In some embodiments, the retroviral nucleic acid comprises one or more (e.g., all) of the following: a 5' promoter (e.g., to control expression of the entire packaged RNA), a 5' LTR (e.g., a U5 containing an R (including a polyadenylation tail signal) and / or a primer activation signal), a primer binding site, a psi packaging signal, an RRE element for nuclear export, a promoter immediately upstream of the transgene to control expression of the transgene, the transgene (or other exogenous agent element), a polypurine tract, and a 3' LTR (e.g., containing a mutated U3, R, and U5). In some embodiments, the retroviral nucleic acid further comprises one or more of a cPPT, a WPRE, and / or an insulator sequence.
[0176] Retroviruses typically replicate by converting their genomic RNA into a linear, double-stranded DNA copy by reverse transcription, followed by covalent integration of the genomic DNA into the host genome. Exemplary retroviruses suitable for use in certain embodiments include, but are not limited to, Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, murine stem cell virus (MSCV), and Rous sarcoma virus (RSV), and lentiviruses.
[0177] In some embodiments, the retrovirus is a gamma retrovirus. In some embodiments, the retrovirus is an epsilon retrovirus. In some embodiments, the retrovirus is an alpha retrovirus. In some embodiments, the retrovirus is a beta retrovirus. In some embodiments, the retrovirus is a delta retrovirus. In some embodiments, the retrovirus is a lentivirus. In some embodiments, the retrovirus is a spumaretrovirus. In some embodiments, the retrovirus is an endogenous retrovirus.
[0178] Exemplary lentiviruses include, but are not limited to, HIV (human immunodeficiency virus; including HIV types 1 and 2); visna-maedi virus (VMV); caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV). In some embodiments, an HIV-based vector backbone (i.e., HIV cis-acting sequence elements) is used.
[0179] In some embodiments, a vector herein is a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule. The transferred nucleic acid is generally linked, e.g., inserted, into the vector nucleic acid molecule. The vector may contain a sequence that directs autonomous replication within a cell, or may contain a sequence sufficient to allow it to integrate into host cell DNA. Useful vectors include plasmids (e.g., DNA plasmids or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. Useful viral vectors include replication-defective retroviruses and lentiviruses.
[0180] Viral vectors, for example, can include nucleic acid molecules (e.g., transfer plasmids) that typically contain virally derived nucleic acid elements that facilitate the transfer of the nucleic acid molecule or its integration into a cell's genome or a viral particle that mediates nucleic acid transfer. Viral particles typically contain various viral components, and sometimes host cell components, in addition to the nucleic acid(s). Viral vectors can include, for example, viruses or viral particles that can transfer nucleic acids into cells or transfer the transferred nucleic acid (e.g., as naked DNA). Viral vectors and transfer plasmids can include structural and / or functional genetic elements that are primarily derived from viruses. Retroviral vectors can include viral vectors or plasmids that contain structural and functional genetic elements, or portions thereof, that are primarily derived from retroviruses. Lentiviral vectors can include viral vectors or plasmids that contain structural and functional genetic elements, or portions thereof, that are primarily derived from lentiviruses, including LTRs.
[0181] In embodiments, a lentiviral vector (e.g., a lentiviral expression vector) may comprise a lentiviral transfer plasmid (e.g., as naked DNA) or an infectious lentiviral particle. With respect to elements such as cloning sites, promoters, regulatory elements, heterologous nucleic acids, etc., it should be understood that the sequences of these elements can be present in the form of RNA in a lentiviral particle or in the form of DNA in a DNA plasmid.
[0182] In some vectors described herein, at least a portion of one or more protein coding regions that contribute to or are essential for replication may be absent compared to the corresponding wild-type virus, resulting in a viral vector that is replication-defective. In some embodiments, the vector is capable of transducing target non-dividing host cells and / or integrating its genome into the host genome.
[0183] The structure of wild-type retroviral genomes often includes a 5' long terminal repeat (LTR) and a 3' long terminal repeat (LTR), between which or within which are located a packaging signal that enables genome packaging, a primer binding site, an integration site that allows integration into the host cell genome, and the gag, pol, and env genes that encode packaging components that promote viral particle assembly. More complex retroviruses contain additional features, such as the HIV rev and RRE sequences, which enable efficient export of integrated proviral RNA transcripts from the nucleus to the cytoplasm of infected target cells. In proviruses, viral genes are flanked on both ends by regions called long terminal repeats (LTRs). LTRs are involved in proviral integration and transcription. LTRs also function as enhancer-promoter sequences, allowing them to control viral gene expression. Retroviral RNA encapsidation is mediated by the psi sequence located at the 5' end of the viral genome.
[0184] The LTRs themselves are usually similar (e.g., identical) sequences that can be divided into three elements called U3, R, and U5. U3 is derived from a sequence unique to the 3' end of the RNA. R is derived from a sequence repeated at both ends of the RNA, and U5 is derived from a sequence unique to the 5' end of the RNA. The sizes of the three elements vary greatly among retroviruses.
[0185] In viral genomes, the transcription initiation site is usually at the boundary between U3 and R of one LTR, and the poly(a) addition (termination) site is at the boundary between R and U5 of the other LTR. U3 contains most of the transcriptional control elements of the provirus, including a promoter and multiple enhancer sequences that respond to cellular and, in some cases, viral transcriptional activator proteins. Some retroviruses contain one or more of the following genes that encode proteins involved in regulating gene expression: tot, rev, tax, and rex.
[0186] Regarding the structural genes gag, pol, and env themselves, gag encodes the internal structural proteins of the virus. The gag protein is proteolytically processed into the mature proteins MA (matrix), CA (capsid), and NC (nucleocapsid). The pol gene encodes the DNA polymerase, associated RNase H, and reverse transcriptase (RT) including integrase (IN), which mediate genome replication. The env gene encodes the surface (SU) glycoprotein and transmembrane (TM) protein of the virion, which form a complex that interacts specifically with cellular receptor proteins. This interaction facilitates infection, for example, by fusion of the viral and cellular membranes.
[0187] In replication-defective retroviral vector genomes, the pol and env regions may be absent or non-functional. The R regions at both ends of the RNA are usually repetitive sequences. U5 and U3 represent unique sequences at the 5' and 3' ends of the RNA genome, respectively.
[0188] Retroviruses may also contain additional genes encoding proteins other than gag, pol, and env. Examples of additional genes include one or more of vif, vpr, vpx, vpu, tat, rev, and nef (in HIV). EIAV contains an additional gene, S2 (among others). Proteins encoded by additional genes perform various functions, some of which may overlap with functions provided by cellular proteins. For example, in EIAV, tat functions as a transcriptional activator of the viral long terminal repeat (LTR) (Derse and Newbold 1993 Virology 194:530-6; Maury et al. 1994 Virology 200:632-42). tat binds to a stable stem-loop RNA secondary structure called TAR. Rev regulates and coordinates viral gene expression via the Rev response element (RRE) (Martarano et al. 1994 J. Virol. 68:3102-11). The mechanisms of action of these two proteins are thought to be largely similar to those of similar primate viruses. In addition, an EIAV protein, Ttm, has been identified, encoded by the first exon of tat spliced into the env coding sequence at the start of the transmembrane protein.
[0189] In addition to protease, reverse transcriptase, and integrase, non-primate lentiviruses contain a fourth pol gene product that encodes a dUTPase, which may play a role in the ability of these lentiviruses to infect certain non-dividing or slowly dividing cell types.
[0190] In embodiments, a recombinant lentiviral vector (RLV) is a vector that carries sufficient retroviral genetic information to allow packaging of an RNA genome into viral particles capable of infecting target cells in the presence of packaging components. Infection of a target cell can involve reverse transcription and integration into the target cell genome. RLVs typically carry non-viral coding sequences delivered to the target cell by the vector. In embodiments, RLVs are incapable of independent replication to produce infectious retroviral particles within the target cell. RLVs typically lack functional gag-pol and / or env genes and / or other genes involved in replication. Vectors can be configured as split-intron vectors, for example, as described in PCT Patent Application WO 99 / 15683, which is incorporated herein by reference in its entirety.
[0191] In some embodiments, lentiviral vectors comprise a minimal viral genome, e.g., viral vectors that have been engineered to remove non-essential elements and retain essential elements to provide the functions necessary to infect, transduce, and deliver a nucleotide sequence of interest to a target host cell, e.g., as described in WO 98 / 17815, which is incorporated herein by reference in its entirety.
[0192] A minimal lentiviral genome may comprise, for example, (5')R-U5-one or more first nucleotide sequences-U3-R(3'). However, the plasmid vector used to produce the lentiviral genome in the source cell may also comprise transcriptional regulatory control sequences operably linked to the lentiviral genome to direct transcription of the genome in the source cell. These regulatory sequences may include native sequences associated with the transcribed retroviral sequence, e.g., the 5'U3 region, or may include another viral promoter, e.g., a heterologous promoter such as the CMV promoter. Some lentiviral genomes contain additional sequences to promote efficient virus production. For example, in the case of HIV, rev and RRE sequences may be included. Alternatively or in combination, codon optimization can be used; for example, the gene encoding the exogenous agent may be codon-optimized, as described, for example, in WO 01 / 79518, which is incorporated herein by reference in its entirety. Alternative sequences that perform similar or identical functions to the rev / RRE system may also be used. For example, a functional analog of the rev / RRE system is found in the Mason-Pfizer monkey virus. This is known as a CTE, which contains an RRE-type sequence in its genome that is thought to interact with factors in infected cells. The cellular factors can be thought of as rev analogs. Therefore, the CTE can be used as a substitute for the rev / RRE system. In addition, the Rex protein of HTLV-I can functionally replace the Rev protein of HIV-I. Rev and Rex have effects similar to those of IRE-BP.
[0193] In some embodiments, the retroviral nucleic acid (e.g., lentiviral nucleic acid, e.g., primate or non-primate lentiviral nucleic acid) (1) comprises a deleted gag gene, where the deletion in gag removes one or more nucleotides downstream of about 350 or 354 nucleotides of the gag coding sequence; (2) has one or more accessory genes not present in the retroviral nucleic acid; (3) lacks the tat gene but includes a leader sequence between the end of the 5' LTR and the ATG of gag; or (4) is a combination of (1), (2), and (3). In one embodiment, the lentiviral vector comprises all of features (1), (2), and (3). This strategy is described in further detail in International Publication WO 99 / 32646, which is incorporated herein by reference in its entirety.
[0194] In some embodiments, the primate lentiviral minimal system does not require any of the HIV / SIV additional genes vif, vpr, vpx, vpu, tat, rev, and nef for either vector production or transduction of dividing and non-dividing cells, hi some embodiments, the EIAV minimal vector system does not require S2 for either vector production or transduction of dividing and non-dividing cells.
[0195] Deletion of additional genes may allow vectors to be created without genes associated with lentiviral (e.g., HIV) infection disease. Tat, in particular, has been associated with disease. Second, deletion of additional genes allows the vector to package more heterologous DNA. Third, genes with unknown functions, such as S2, can be omitted to reduce the risk of undesired effects. Examples of minimal lentiviral vectors are disclosed in WO 99 / 32646 and WO 98 / 17815.
[0196] In some embodiments, the retroviral nucleic acid lacks at least tat and S2 (if an EIAV vector system), and possibly also vif, vpr, vpx, vpu, and nef. In some embodiments, the retroviral nucleic acid also lacks rev, RRE, or both.
[0197] In some embodiments, the retroviral nucleic acid comprises vpx. The Vpx polypeptide binds to and induces the degradation of the SAMHD1 restriction factor, degrading free dNTPs in the cytoplasm. Thus, when Vpx degrades SAMHD1 and reverse transcription activity increases, the concentration of free dNTPs in the cytoplasm increases, promoting reverse transcription of the retroviral genome and integration into the target cell genome.
[0198] Different cells use specific codons differently. This codon bias corresponds to the bias in the relative abundance of specific tRNAs in cell types. By changing the codons in the sequence so that they are adjusted to match the relative abundance of the corresponding tRNAs, it is possible to increase expression. Similarly, by intentionally selecting codons whose corresponding tRNAs are known to be rare in a particular cell type, it is possible to decrease expression. Thus, additional translational control is available. Further description of codon optimization can be found, for example, in International Publication No. 99 / 41397, the entire contents of which are incorporated herein by reference.
[0199] Many viruses, including HIV and other lentiviruses, use a number of rare codons, and by changing these to correspond to commonly used mammalian codons, expression of the packaging components in mammalian producer cells can be increased.
[0200] Codon optimization has many other advantages. Due to these sequence changes, nucleotide sequences encoding packaging components may have reduced or eliminated RNA instability sequences (INS). At the same time, the amino acid sequences coding for the packaging components are maintained so that the viral components encoded by the sequences remain the same, or at least similar enough so that the functionality of the packaging components is not impaired. In some embodiments, codon optimization also overcomes the Rev / RRE requirement for export, making the optimized sequences Rev-independent. In some embodiments, codon optimization also reduces homologous recombination between different constructs within a vector system (e.g., between overlapping regions in the gag-pol and env open reading frames). In some embodiments, codon optimization results in increased viral titer and / or improved safety.
[0201] In some embodiments, only the codons associated with the INS are codon optimized, while in other embodiments, the entire sequence is codon optimized except for the sequence containing the gag-pol frameshift site.
[0202] The gag-pol gene contains two overlapping reading frames encoding the gag-pol proteins. Expression of both proteins depends on a frameshift during translation. This frameshift occurs as a result of ribosome "slippage" during translation. This slippage is thought to be caused, at least in part, by secondary structures in the RNA that stall the ribosome. Such secondary structures are present downstream of the frameshift site in the gag-pol gene. In HIV, the overlapping region extends from nucleotide 1222 downstream of the start of gag (nucleotide 1 is the A of the gag ATG) to the end of gag (nt 1503). As a result, the 281-bp fragment spanning the frameshift site and the overlapping region of the two reading frames is preferably not codon-optimized. In some embodiments, retaining this fragment may allow for more efficient expression of the gag-pol proteins. In EIAV, the start of the overlap is at nt 1262 (nucleotide 1 is the A of the gag ATG). The end of the overlap is at nt 1461. To ensure that the frameshift site and gag-pol overlap are maintained, the wild-type sequence can be retained from nt 1156 to 1465.
[0203] For example, derivations from optimal codon usage can be made to accommodate convenient restriction sites and conservative amino acid changes can be introduced into the gag-pol protein.
[0204] In some embodiments, codon optimization is based on codons with low codon usage in mammalian systems. The third, and sometimes the second and third, bases may be changed.
[0205] It will be appreciated that the degraded nature of the genetic code allows one of skill in the art to achieve numerous gag-pol sequences. Additionally, many retroviral variants have been described that can be used as starting points for generating codon-optimized gag-pol sequences. Lentiviral genomes can vary considerably. For example, HIV-I has many still-functioning quasi-species. This is also true for EIAV. These variants can be used to enhance specific parts of the transduction process. Examples of HIV-I variants can be found in the HIV database maintained by Los Alamos National Laboratory. Details of EIAV clones can be found in the NCBI database maintained by the National Institutes of Health.
[0206] The strategy of codon-optimized gag-pol sequences can be used in connection with retroviruses such as EIAV, FIV, BIV, CAEV, VMR, SIV, HIV-I, and HIV-2. Additionally, this method can be used to increase expression of genes from HTLV-I, HTLV-2, HFV, HSRV, and human endogenous retroviruses (HERVs), MLV, and other retroviruses.
[0207] As described above, the packaging components of a retroviral vector can include the expression products of the gag, pol, and env genes. Furthermore, packaging can utilize a short sequence of four stem-loops followed by partial sequences from gag and env as a packaging signal. Thus, a deleted gag sequence can be included in the retroviral vector genome (in addition to the complete gag sequence in the packaging construct). In embodiments, a retroviral vector contains a packaging signal that includes 255-360 nucleotides of gag in a vector that still retains the env sequence, or approximately 40 nucleotides of gag in a specific combination of gag and env deletions that are splice donor mutations. In some embodiments, a retroviral vector contains a gag sequence that contains one or more deletions, for example, a gag sequence that includes approximately 360 nucleotides from the N-terminus.
[0208] The retroviral vector, helper cell, helper virus, or helper plasmid can include retroviral structural and accessory proteins, such as gag, pol, env, tat, rev, vif, vpr, vpu, vpx, or nef proteins, or other retroviral proteins. In some embodiments, the retroviral proteins are derived from the same retrovirus. In some embodiments, the retroviral proteins are derived from more than one retrovirus, e.g., two, three, four, or more retroviruses.
[0209] The gag and pol coding sequences are generally organized as the Gag-Pol precursor of native lentiviruses. The gag sequence encodes the 55 kD Gag precursor protein, also called p55. p55 is cleaved by virally encoded protease 4 (the product of the pol gene) during maturation into four smaller proteins called MA (matrix [p17]), CA (capsid [p24]), NC (nucleocapsid [p9]), and p6. The pol precursor protein is cleaved from Gag by the virally encoded protease and further digested to separate the protease (p10), RT (p50), RNase H (p15), and integrase (p31) activities.
[0210] Native Gag-Pol sequences can be utilized in helper vectors (e.g., helper plasmids or helper viruses) or can be modified. These modifications include chimeric Gag-Pols, in which the Gag and Pol sequences are derived from different viruses (e.g., different species, subspecies, strains, clades, etc.) and / or the sequences have been modified to improve transcription and / or translation and / or reduce recombination.
[0211] In various examples, the retroviral nucleic acid comprises a polynucleotide encoding a 150-250 (e.g., 168) nucleotide portion of the gag protein that (i) contains a mutated INS1 inhibitory sequence that reduces restriction of RNA nuclear export compared to wild-type INS1, (ii) contains a two nucleotide insertion that results in a frameshift and premature termination, and / or (iii) does not contain the INS2, INS3, and INS4 inhibitory sequences of gag.
[0212] In some embodiments, the vectors described herein are hybrid vectors that contain both retroviral (e.g., lentiviral) and non-lentiviral sequences. In some embodiments, the hybrid vectors contain retroviral, e.g., lentiviral, sequences for reverse transcription, replication, integration, and / or packaging.
[0213] According to certain embodiments, most or all of the viral vector backbone sequences are derived from a lentivirus, e.g., HIV-1. However, it should be understood that many different sources of retroviral and / or lentiviral sequences can be used, and that combined and numerous substitutions and changes in a particular lentiviral sequence can be accommodated without impairing the transfer vector's ability to perform the functions described herein. Various lentiviral vectors are described in Naldini et al. (1996a, 1996b, and 1998), Zufferey et al. (1997), Dull et al., 1998, U.S. Patent No. 6,013,516, and U.S. Patent No. 5,994,136, many of which can be adapted to produce retroviral nucleic acid.
[0214] Long terminal repeats (LTRs) are typically found at both ends of a provirus. LTRs typically contain domains located at the ends of retroviral nucleic acids that, in the context of the natural sequence, are direct repeats and include the U3, R, and U5 regions. LTRs generally promote retroviral gene expression (e.g., promotion, initiation, and polyadenylation of gene transcripts) and viral replication. LTRs can contain multiple regulatory signals, including transcriptional control elements, polyadenylation signals, and sequences for viral genome replication and integration. Viral LTRs are typically divided into three regions, designated U3, R, and U5. The U3 region typically contains enhancer and promoter elements. The U5 region is typically located between the primer binding site and the R region and can contain a polyadenylation sequence. R (repeat) regions can flank the U3 and U5 regions. LTRs are typically composed of U3, R, and U5 regions and can appear at both the 5' and 3' ends of the viral genome. In some embodiments, adjacent to the 5'LTR are sequences for reverse transcription of the genome (tRNA primer binding site) and efficient packaging of viral RNA into particles (Psi site).
[0215] The packaging signal can include sequences located within the retroviral genome that mediate insertion of viral RNA into the viral capsid or particle. See, for example, Clever et al., 1995. J. of Virology, Vol. 69, No. 4; pp. 2101-2109. Some retroviral vectors use a minimal packaging signal (psi [Ψ] sequence) for encapsidation of the viral genome.
[0216] In various embodiments, the retroviral nucleic acid comprises a modified 5'LTR and / or 3'LTR. Either or both of the LTRs may contain one or more modifications, including, but not limited to, one or more deletions, insertions, or substitutions. Modifications of the 3'LTR are often made to improve the safety of lentiviral or retroviral systems by rendering the virus replication-defective (e.g., a virus that is unable to fully and efficiently replicate so that infectious virions are not produced (e.g., progeny of a replication-defective lentivirus)).
[0217] In some embodiments, the vector is a self-inactivating (SIN) vector, e.g., a replication-deficient vector, e.g., a retroviral or lentiviral vector, in which the right (3') LTR enhancer-promoter region, known as the U3 region, has been modified (e.g., by deletion or substitution) to prevent viral transcription beyond the first round of viral replication. This is because the right (3') LTR U3 region can be used as a template for the left (5') LTR U3 region during viral replication, and the absence of the U3 enhancer-promoter inhibits viral replication. In embodiments, the 3' LTR is modified such that the U5 region has been removed, altered, or replaced, e.g., with an exogenous poly(A) sequence. The 3' LTR, the 5' LTR, or both the 3' and 5' LTRs can be modified LTRs.
[0218] In some embodiments, the U3 region of the 5'LTR is replaced with a heterologous promoter to drive transcription of the viral genome during viral particle production. Examples of heterologous promoters that can be used include, for example, the viral simian virus 40 (SV40) (e.g., early or late), cytomegalovirus (CMV) (e.g., immediate early), Moloney murine leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoters. In some embodiments, the promoter can drive high levels of transcription in a Tat-independent manner. In certain embodiments, heterologous promoters have the additional advantage of controlling how the viral genome is transcribed. For example, heterologous promoters can be inducible so that transcription of all or part of the viral genome occurs only in the presence of an inducer. Inducers include, but are not limited to, one or more compounds under which the host cells are cultured, or physiological conditions such as temperature or pH.
[0219] In some embodiments, the viral vector contains a TAR (transactivation response) element, located, for example, in the R region of the lentiviral (e.g., HIV) LTR. This element interacts with the lentiviral transactivator (tat) gene element to enhance viral replication. However, this element is not required, for example, in embodiments in which the U3 region of the 5' LTR is replaced by a heterologous promoter.
[0220] The R region, e.g., the region within a retroviral LTR that begins at the start of the capping group (i.e., the start of transcription) and ends just before the start of the polyA tract, can be flanked by the U3 and U5 regions. The R region plays a role during reverse transcription in the transfer of nascent DNA from one end of the genome to the other.
[0221] Retroviral nucleic acids can also contain FLAP elements, e.g., nucleic acids whose sequences include the central polypurine takeaway and central termination sequence (cPPT and CTS) of a retrovirus, e.g., HIV-1 or HIV-2. Suitable FLAP elements are described in U.S. Patent No. 6,682,907 and Zennou, et al., 2000, Cell, 101:173, which are incorporated herein by reference in their entireties. During HIV-1 reverse transcription, central initiation of plus-strand DNA at the central polypurine takeaway (cPPT) and central termination at the central termination sequence (CTS) can lead to the formation of a triple-stranded DNA structure, i.e., a central DNA flap. In some embodiments, the retroviral or lentiviral vector backbone contains one or more FLAP elements upstream or downstream of a gene encoding an exogenous agent. For example, in some embodiments, a transfer plasmid contains a FLAP element, e.g., a FLAP element derived from or isolated from HIV-1.
[0222] In embodiments, the retroviral or lentiviral nucleic acid comprises one or more export elements, such as cis-acting post-transcriptional regulatory elements that regulate the transport of RNA transcripts from the nucleus to the cytoplasm of the cell. Examples of RNA export elements include, but are not limited to, the human immunodeficiency virus (HIV) rev response element (RRE) (see, e.g., Cullen et al., 1991. J. Virol. 65:1053; and Cullen et al., 1991. Cell 58:423) and the hepatitis B virus post-transcriptional regulatory element (HPRE), which are incorporated herein by reference in their entireties. Generally, RNA export elements are located within the 3'UTR of a gene and can be inserted in one or more copies.
[0223] In some embodiments, expression of heterologous sequences in viral vectors is increased by incorporating one or more of, for example, a posttranscriptional regulatory element, a polyadenylation site, and a transcription termination signal into the vector. Various posttranscriptional regulatory elements can increase expression of heterologous nucleic acids in proteins, such as the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE; Zufferey et al., 1999, J. Virol., 73:2886); the posttranscriptional regulatory element present in hepatitis B virus (HPRE) (Huang et al., Mol. Cell. Biol., 5:3864), and the like (Liu et al., 1995, Genes Dev., 9:1766), each of which is incorporated herein by reference in its entirety. In some embodiments, the retroviral nucleic acids described herein include a posttranscriptional regulatory element such as a WPRE or HPRE.
[0224] In some embodiments, the retroviral nucleic acids described herein lack or do not include post-transcriptional regulatory elements such as a WPRE or HPRE.
[0225] Elements directing the termination and polyadenylation of heterologous nucleic acid transcripts can be included, for example, to increase expression of exogenous agents. Transcription termination signals may be found downstream of the polyadenylation signal. In some embodiments, the vector contains a polyadenylation sequence 3' to the polynucleotide encoding the exogenous agent. A polyA site can contain a DNA sequence that directs both the termination and polyadenylation of the nascent RNA transcript by RNA polymerase II. The polyadenylation sequence promotes mRNA stability and contributes to improved translation efficiency by adding a polyA tail to the 3' end of the coding sequence. Examples of polyA signals that can be used in retroviral nucleic acids include AATAAA, ATTAAA, AGTAAA, bovine growth hormone polyA sequence (BGHpA), rabbit β-globin polyA sequence (rβgpA), or another suitable heterologous or endogenous polyA sequence.
[0226] In some embodiments, the retroviral or lentiviral vector further comprises one or more insulator sequences, eg, an insulator sequence described herein.
[0227] In various embodiments, the vector comprises a promoter operably linked to a polynucleotide encoding an exogenous agent. The vector may have one or more LTRs, where any LTR comprises one or more modifications, such as one or more nucleotide substitutions, additions, or deletions. The vector may also comprise one or more accessory elements to enhance transduction efficiency (e.g., cPPT / FLAP), viral packaging (e.g., Psi (Ψ) packaging signal, RRE), and / or other elements to increase exogenous gene expression (e.g., poly(A) sequence), and may optionally include a WPRE or HPRE.
[0228] In some embodiments, the lentiviral nucleic acid comprises one or more of the following, all of which are present, e.g., 5' to 3': a promoter (e.g., CMV), an R sequence (e.g., including TAR), a U5 sequence (e.g., for integration), a PBS sequence (e.g., for reverse transcription), a DIS sequence (e.g., for genome dimerization), a psi packaging signal, a partial gag sequence, an RRE sequence (e.g., for nuclear export), a cPPT sequence (e.g., for nuclear import), a promoter driving expression of an exogenous agent, a gene encoding the exogenous agent, a WPRE sequence (e.g., for efficient transgene expression), a PPT sequence (e.g., for reverse transcription), an R sequence (e.g., for polyadenylation and termination), and a U5 signal (e.g., for integration).
[0229] Vectors engineered to remove splice sites Some lentiviral vectors have strong splicing and polyadenylation signals that can be integrated within active genes, leading to the formation of aberrant and sometimes truncated transcripts.
[0230] The mechanism of proto-oncogene activation may involve the generation of chimeric transcripts resulting from the interaction of promoter elements or splice sites contained in the genome of the insertional mutagen with the cellular transcription unit targeted for integration (Gabriel et al. 2009. Nat Med 15:1431-1436; Bokhoven, et al. J Virol 83:283-29). Chimeric fusion transcripts containing vector sequences and cellular mRNAs can be generated by read-through transcription that initiates from the vector sequences and proceeds to adjacent cellular genes, or vice versa.
[0231] In some embodiments, the lentiviral nucleic acids described herein comprise a lentiviral backbone in which at least two of the splice sites have been removed, e.g., to improve the safety profile of the lentiviral vector. The types and methods for identifying such splice sites are described in WO2012156839A2, which is incorporated by reference in its entirety.
[0232] Retrovirus production methods Large-scale production of viral particles is often useful to achieve a desired viral titer. Viral particles can be produced by transfecting transfer vectors into packaging cell lines containing viral structural and / or accessory genes, such as the gag, pol, env, tat, rev, vif, vpr, vpu, vpx, or nef genes, or other retroviral genes.
[0233] In embodiments, the packaging vector is an expression vector or viral vector that lacks a packaging signal and contains a polynucleotide encoding one, two, three, four, or more viral structural and / or accessory genes. Typically, packaging vectors are contained in packaging cells and introduced into cells via transfection, transduction, or infection. Retroviral, e.g., lentiviral, transfer vectors can be introduced into packaging cell lines via transfection, transduction, or infection to generate source cells or cell lines. Packaging vectors can be introduced into human cells or cell lines by standard methods, including, for example, calcium phosphate transfection, lipofection, or electroporation. In some embodiments, the packaging vector is introduced into cells with a primary selectable marker, such as neomycin, hygromycin, puromycin, blastocidin, zeocin, thymidine kinase, DHFR, Gln synthetase, or ADA, followed by selection in the presence of the appropriate drug to isolate clones. The selectable marker gene can be physically linked to the encoding gene by the packaging vector, for example, by an IRES or a self-cleaving viral peptide.
[0234] Packaging cell lines include cell lines that do not contain a packaging signal but stably or transiently express viral structural proteins and replicase (e.g., gag, pol, and env) that are capable of packaging viral particles. Any suitable cell line, e.g., mammalian cells, e.g., human cells, can be used. Suitable cell lines that can be used include, for example, CHO cells, BHK cells, MDCK cells, C3H 10T1 / 2 cells, FLY cells, Psi-2 cells, BOSC 23 cells, PA317 cells, WEHI cells, COS cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, W138 cells, MRC5 cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, and 211A cells. In embodiments, the packaging cells are 293 cells, 293T cells, or A549 cells.
[0235] Source cell lines include packaging cell lines and cell lines capable of producing recombinant retroviral particles containing transfer vector constructs containing packaging signals. Methods for preparing virus stock solutions are described, for example, by Y. Soneoka et al. (1995) Nucl. Acids Res. 23:628-633 and NRL Landau et al. (1992) J. Virol. 66:5110-5113, which are incorporated herein by reference. Infectious virus particles can be collected from packaging cells, for example, by cell lysis or collection of cell culture supernatant. If necessary, the collected virus particles can be concentrated or purified.
[0236] Plasmid and cell line packaging In some embodiments, the source cell contains one or more plasmids encoding viral structural proteins and replication enzymes (e.g., gag, pol, and env) capable of packaging viral particles. In some embodiments, the sequences encoding at least two of the gag, pol, and env precursors are on the same plasmid. In some embodiments, the sequences encoding the gag, pol, and env precursors are on different plasmids. In some embodiments, the sequences encoding the gag, pol, and env precursors have the same expression signal, e.g., promoter. In some embodiments, the sequences encoding the gag, pol, and env precursors have different expression signals, e.g., different promoters. In some embodiments, expression of the gag, pol, and env precursors is inducible. In some embodiments, the plasmids encoding the viral structural proteins and replication enzymes are transfected simultaneously or at different times. In some embodiments, the plasmids encoding the viral structural proteins and replication enzymes are transfected simultaneously or at different times from the packaging vector.
[0237] In some embodiments, the source cell line comprises one or more stably integrated viral structural genes. In some embodiments, expression of the stably integrated viral structural genes is inducible.
[0238] In some embodiments, expression of viral structural genes is regulated at the transcriptional level. In some embodiments, expression of viral structural genes is regulated at the translational level. In some embodiments, expression of viral structural genes is regulated at the post-translational level.
[0239] In some embodiments, expression of viral structural genes is regulated by a tetracycline (Tet)-dependent system, in which the Tet-regulated transcriptional repressor (Tet-R) binds to DNA sequences contained in the promoter and represses transcription through steric hindrance (Yao et al., 1998; Jones et al., 2005). Addition of doxycycline (dox) releases Tet-R, allowing transcription. Several other suitable transcriptionally regulated promoters, transcription factors, and small molecule inducers are suitable for regulating transcription of viral structural genes.
[0240] In some embodiments, the third generation lentiviral components, human immunodeficiency virus type 1 (HIV) Rev, Gag / Pol, and envelope under the control of a Tet-regulated promoter and linked to an antibiotic resistance cassette, are separately integrated into the source cell genome. In some embodiments, the source cell has only one copy each of Rev, Gag / Pol, and envelope proteins integrated into its genome.
[0241] In some embodiments, a nucleic acid encoding an exogenous agent (e.g., a retroviral nucleic acid encoding an exogenous agent) is also integrated into the source cell genome. In some embodiments, the nucleic acid encoding the exogenous agent is maintained episomally. In some embodiments, the nucleic acid encoding the exogenous agent is transfected into a source cell that has Rev, Gag / Pol, and envelope proteins stably integrated into the genome. See, e.g., Milani et al. EMBO Molecular Medicine, 2017, incorporated herein by reference in its entirety.
[0242] In some embodiments, the retroviral nucleic acid described herein is incapable of undergoing reverse transcription. Such nucleic acids, in embodiments, are capable of transiently expressing an exogenous agent. The retrovirus or VLP may comprise a disabled reverse transcriptase protein or may not comprise a reverse transcriptase protein. In embodiments, the retroviral nucleic acid comprises a disabled primer binding site (PBS) and / or att site. In embodiments, one or more viral accessory genes, including rev, tat, vif, nef, vpr, vpu, vpx, and S2, or functional equivalents thereof, are disabled or absent from the retroviral nucleic acid. In embodiments, one or more accessory genes selected from S2, rev, and tat are disabled or absent from the retroviral nucleic acid.
[0243] Strategies for packaging retroviral nucleic acids Typically, modern retroviral vector systems consist of (1) a viral genome with cis-acting vector sequences for transcription, reverse transcription, integration, translation, and packaging of viral RNA into viral particles, and (2) a producer cell line expressing the trans-acting retroviral gene sequences (e.g., gag, pol, and env) necessary for the production of viral particles. Complete separation of the cis- and trans-acting vector sequences ensures that the virus cannot sustain replication for more than one cycle of infection. The generation of live virus can be avoided by several strategies, for example, by minimizing overlap between the cis- and trans-acting sequences to avoid recombination.
[0244] Viral vector particles lacking or containing sequences lacking viral RNA may be the result of removing or excluding viral RNA from the sequence. In one embodiment, this can be achieved by using the endogenous packaging signal binding site on gag. Alternatively, the endogenous packaging signal binding site is on pol. In this embodiment, the delivered RNA will contain the cognate packaging signal. In another embodiment, a heterologous binding domain (heterologous to gag) located on the delivered RNA and a cognate binding site located on gag or pol can be used to ensure packaging of the delivered RNA. The heterologous sequence may be non-viral or viral, in which case it may be derived from a different virus. Vector particles can be used to deliver therapeutic RNA, in which case functional integrase and / or reverse transcriptase are not required. These vector particles can also be used to deliver therapeutic genes of interest, in which case pol is typically included.
[0245] In one embodiment, gag-pol is modified, and the packaging signal is replaced with the corresponding packaging signal.In this embodiment, the particle can package RNA with the new packaging signal.The advantage of this approach is that it can package RNA sequences that lack viral sequences, such as RNAi.
[0246] Another approach is to rely on the overexpression of the RNA to be packaged. In one embodiment, the RNA to be packaged is overexpressed in the absence of RNA containing a packaging signal. This can result in significant levels of therapeutic RNA being packaged, which is sufficient to transduce cells and produce biological effects.
[0247] In some embodiments, the polynucleotide comprises a nucleotide sequence encoding a viral gag protein or a retroviral gag and pol protein, wherein the gag protein or pol protein comprises a heterologous RNA-binding domain that can recognize a corresponding sequence in an RNA sequence and facilitate packaging of the RNA sequence into a viral vector particle.
[0248] In some embodiments, the heterologous RNA binding domain comprises an RNA binding domain derived from a bacteriophage coat protein, a Rev protein, a protein of the U1 small nuclear ribonucleoprotein particle, a Nova protein, a TFl 11A protein, a TISl protein, a trp RNA-binding decay protein (TRAP), or a pseudouridine synthase.
[0249] In some embodiments, the methods herein include detecting or confirming the absence of a replication-competent retrovirus. The methods may include assessing the RNA level of one or more target genes, such as viral genes, e.g., structural genes or packaging genes, whose gene products are expressed in certain cells infected with a replication-competent retrovirus, such as a gammaretrovirus or lentivirus, but which are not present in the viral vector used to transduce the cells with the heterologous nucleic acid and which are not present and / or expressed, or would not be expected to be present and / or expressed, in cells that do not contain a replication-competent retrovirus. A replication-competent retrovirus may be determined to be present when the RNA level of one or more target genes is higher than a reference value, which can be measured directly or indirectly, for example, from a positive control sample containing the target genes. For a detailed disclosure, see WO2018023094A1.
[0250] Repression of genes encoding exogenous agents in source cells Proteins (over)expressed in source cells may have an indirect or direct effect on the assembly and / or infectivity of vector virions. Incorporation of exogenous agents into vector virions may also affect downstream processing of the vector particle.
[0251] In some embodiments, a tissue-specific promoter is used to restrict expression of the exogenous agent in the source cells. In some embodiments, a heterologous translational control system is used in eukaryotic cell culture to repress translation of the exogenous agent in the source cells. More specifically, the retroviral nucleic acid can contain a binding site operably linked to a gene encoding the exogenous agent, where the binding site can interact with an RNA-binding protein such that translation of the exogenous agent is repressed or prevented in the source cells.
[0252] In some embodiments, the RNA-binding protein is a tryptophan RNA-binding attenuation protein (TRAP), e.g., a bacterial tryptophan RNA-binding attenuation protein. The use of an RNA-binding protein (e.g., a bacterial trp operon regulator protein, tryptophan RNA-binding attenuation protein, TRAP) and the RNA target to which it binds represses or prevents translation of a transgene in a source cell. This system is referred to as the Transgene Repression In vector Production cell system, or TRIP system.
[0253] In embodiments, the placement of a binding site for an RNA-binding protein (e.g., a TRAP binding sequence, tbs) upstream of the NOI translation start codon allows for specific repression of translation of mRNA derived from an internal expression cassette without adversely affecting vector RNA production or stability. The number of nucleotides between the tbs and the translation start codon of the gene encoding the exogenous agent can vary from 0 to 12 nucleotides. The tbs can be placed downstream of an internal ribosome entry site (IRES) to repress translation of the gene encoding the exogenous agent in a multicistronic mRNA.
[0254] Kill switch system and amplification In some embodiments, polynucleotides or cells harboring genes encoding exogenous agents utilize suicide genes, e.g., inducible suicide genes, to reduce the risk of direct toxicity and / or uncontrolled proliferation. In certain aspects, the suicide genes are not immunogenic to host cells harboring the exogenous agent. Examples of suicide genes include caspase-9, caspase-8, or cytosine deaminase. Caspase-9 can be activated using specific chemical inducers of dimerization (CIDs).
[0255] In certain embodiments, the vector comprises a gene segment that renders target cells, e.g., immune effector cells, e.g., T cells, susceptible to negative selection in vivo. For example, transduced cells may be eliminated as a result of changes in an individual's in vivo conditions. A negatively selectable phenotype may result from the insertion of a gene that confers sensitivity to an administered agent, e.g., a compound. Negatively selectable genes are known in the art and include, among others: the herpes simplex virus type I thymidine kinase (HSV-I TK) gene, which confers sensitivity to ganciclovir (Wigler et al., Cell 11:223, 1977); the cellular hypoxanthine phosphoribosyltransferase (HPRT) gene, the cellular adenine phosphoribosyltransferase (APRT) gene, and bacterial cytosine deaminase (Mullen et al., Proc. Natl. Acad. Sci. USA 89:33 (1992)).
[0256] In some embodiments, the transduced cells, e.g., immune effector cells such as T cells, comprise a polynucleotide that further comprises a positive marker that allows for the selection of cells with a negatively selectable phenotype in vitro. A positive selection marker can be a gene that, when introduced into a target cell, expresses a dominant phenotype that allows for the positive selection of cells carrying the gene. Genes of this type include, among others, the hygromycin-B phosphotransferase gene (hph), which confers resistance to hygromycin B, the Tn5-derived aminoglycoside phosphotransferase gene (neo or aph), which encodes resistance to the antibiotic G418, dihydrofolate reductase (DHFR), the adenosine deaminase gene (ADA), and multidrug resistance (MDR) genes.
[0257] In some embodiments, the positive selectable marker and negative selectable element are linked such that loss of the negative selectable element necessarily results in loss of the positive selectable marker. For example, positive and negative selectable markers can be fused so that loss of one results in loss of the other. An example of a fusion polynucleotide whose expression product is a polypeptide that confers both the desired positive and negative selection functions is the hygromycin phosphotransferase thymidine kinase fusion gene (HyTK). Expression of this gene produces a polypeptide that confers hygromycin B resistance for positive selection in vitro and ganciclovir sensitivity for negative selection in vivo. See Lupton SD, et al., Mol. and Cell. Biology 1 1:3374-3378, 1991. Furthermore, in embodiments, the polynucleotide encoding the chimeric receptor is present in a retroviral vector, e.g., the HyTK retroviral vector described in Lupton SD, et al., (1991), supra, that contains a fusion gene, particularly a fusion gene that confers hygromycin B resistance for in vitro positive selection and ganciclovir sensitivity for in vivo negative selection. See also publications PCT U591 / 08442 and PCT / U594 / 05601, which describe the use of bifunctional selectable fusion genes derived from the fusion of a dominant positive selectable marker and a negative selectable marker.
[0258] Suitable positive selectable markers are derived from genes selected from the group consisting of hph, nco, and gpt, and suitable negative selectable markers may be derived from genes selected from the group consisting of cytosine deaminase, HSV-I TK, VZV TK, HPRT, APRT, and gpt. Other suitable markers are bifunctional selectable fusion genes in which the positive selectable marker is derived from hph or neo and the negative selectable marker is derived from a cytosine deaminase or TK gene, or selectable marker.
[0259] Strategies for modulating lentiviral integration Retroviral and lentiviral nucleic acids have been disclosed in which key proteins / sequences are missing or disabled to prevent the retroviral or lentiviral genome from integrating into the target cell genome. For example, the highly conserved DDE motif of retroviral integrase (Engelman and Craigie (1992) J. Virol. 66:6361-6369; Johnson et al. (1986) Proc. Natl. Acad. Sci. USA 83:7648-7652; Khan et al. (1991) Nucleic Acids Res. 19:851-860) allows the production of integration-deficient retroviral nucleic acids.
[0260] For example, in some embodiments, a retroviral nucleic acid herein comprises a lentiviral integrase containing a mutation that renders the integrase unable to catalyze the integration of the viral genome into the cellular genome. In some embodiments, the mutation is a Type I mutation that directly affects integration, or a Type II mutation that induces a pleiotropic defect that affects virion morphogenesis and / or reverse transcription. An illustrative, non-limiting example of a Type I mutation is a mutation that affects any of three residues involved in the catalytic core domain of integrase: DX 39-58 DX 35 E (residues D64, D116, and E152 of HIV-1 integrase). In certain embodiments, the mutation that renders the integrase unable to catalyze the integration of the viral genome into the cellular genome is a substitution of one or more amino acid residues in the DDE motif of the catalytic core domain of integrase, preferably a substitution of the first aspartic acid residue of the DEE motif with an asparagine residue. In some embodiments, the retroviral vector does not comprise an integrase protein.
[0261] In some embodiments, the retrovirus integrates into an active transcription unit. In some embodiments, the retrovirus does not integrate near the transcription start site, the 5' end of a gene, or a DNAse 1 cleavage site. In some embodiments, retroviral integration does not activate proto-oncogenes or inactivate tumor suppressor genes. In some embodiments, the retrovirus is not genotoxic. In some embodiments, the lentivirus integrates into an intron.
[0262] In some embodiments, the retroviral nucleic acid integrates into the genome of the target cell at a specific copy number. The average copy number can be determined from a single cell, a population of cells, or an individual cell colony. Exemplary methods for determining copy number include polymerase chain reaction (PCR) and flow cytometry.
[0263] In some embodiments, the DNA encoding the exogenous agent is genomically integrated. In some embodiments, the DNA encoding the exogenous agent is episomally maintained. In some embodiments, the ratio of exogenous agent integrated into episomal DNA encoding the exogenous agent is at least 0.01, 0.1, 0.5, 1.0, 2, 5, 10, 100.
[0264] In some embodiments, the DNA encoding the exogenous agent is linear. In some embodiments, the DNA encoding the exogenous agent is circular. In some embodiments, the ratio of linear copies to circular copies of the DNA encoding the exogenous agent is at least 0.01, 0.1, 0.5, 1.0, 2, 5, 10, or 100.
[0265] In embodiments, the DNA encoding the exogenous agent is circular and comprises one LTR. In some embodiments, the DNA encoding the exogenous agent is circular and comprises two LTRs. In some embodiments, the ratio of circular, single-LTR DNA encoding the exogenous agent to circular, two-LTR DNA encoding the exogenous agent is at least 0.1, 0.5, 1.0, 2, 5, 10, 20, 50, or 100.
[0266] Episomal virus maintenance In poorly integrated retroviruses, circular cDNA by-products of reverse transcription (e.g., 1-LTR and 2-LTR) can accumulate in the cell nucleus without integrating into the host genome (Yanez-Munoz RJ et al., Nat. Med. 2006, 12:348-353). These intermediates are then ligated at the same frequency (e.g., 10 ) as other exogenous DNA. 3 ~10 5 / cell) and can integrate into cellular DNA.
[0267] In some embodiments, episomal retroviral nucleic acids are non-replicating. Episomal viral DNA can be modified to be maintained in replicating cells by including a eukaryotic origin of replication and a scaffold / matrix attachment region (S / MAR) for association with the nuclear matrix.
[0268] Thus, in some embodiments, the retroviral nucleic acids described herein comprise a eukaryotic origin of replication or a variant thereof. Examples of eukaryotic origins of replication of interest are the origin of replication of the β-globin gene described by Aladjem et al. (Science, 1995, 270:815-819), the consensus sequence derived from an autonomously replicating sequence associated with an alpha-satellite sequence previously isolated from monkey CV-1 cells and human skin fibroblasts as described by Price et al. Journal of Biological Chemistry, 2003, 278(22):19649-59, and the origin of replication of the human c-myc promoter region described by McWinney and Leffak (McWinney C. and Leffak M., Nucleic Acid Research 1990, 18(5):1233-42). In embodiments, the variants substantially retain the ability to initiate replication in eukaryotes. The ability of a particular sequence to initiate replication can be determined by any suitable method, for example, by autonomous replication assays based on bromodeoxyuridine incorporation and density shifts (Araujo, F.D. et al., supra; Frappier, L. et al.).
[0269] In some embodiments, the retroviral nucleic acid comprises a scaffold / matrix attachment region (S / MAR) or a variant thereof, e.g., a non-consensus-like AT-rich DNA element several hundred base pairs in length, which organizes the nuclear DNA of eukaryotic genomes into chromatin domains by periodic attachment to the protein scaffold or matrix of the cell nucleus. They are typically found in non-coding regions such as flanking regions, chromatin boundary regions, and introns. An example of an S / MAR region is the human IFN-γ gene (hIFN-γ ) described by Bode et al. (Bode J. et al., Science, 1992, 255:195-7). large), the 1.8 kbp S / MAR of the human IFN-γ gene, the 0.7 Kbp minimal S / MAR region of the human IFN-γ gene described by Ramezani (Ramezani A. et al., Blood 2003, 101:4717-24). short), Mesner LD et al., Proc Natl Acad Sci USA, 2003, 100:3281-86 (the 0.2 Kbp minimal region of the S / MAR of the human dehydrofolate reductase gene (hDHFR). In embodiments, functionally equivalent variants of S / MARs are sequences selected based on a set of six rules that, together or individually, have been suggested to contribute to S / MAR function (Kramer et al. (1996) Genomics 33, 305; Singh et al. (1997) Nucl. Acids Res 25, 1419). These rules were merged into the MAR-Wiz computer program, freely available at genomecluster.secs.oakland.edu / MAR-Wiz. In embodiments, variants substantially maintain the same function of the S / MAR from which they are derived, in particular the ability to specifically bind to the nuclear matrix. Those skilled in the art can determine whether a particular variant can specifically bind to the nuclear matrix by, for example, an in vitro or in vivo MAR assay as described in Mesner et al. (Mesner LD et al., supra). In some embodiments, a particular sequence is an S / MAR variant if it exhibits a tendency for DNA strand separation. This property can be determined using specific programs based on the methods of equilibrium statistical mechanics. The stress-induced duplex destabilization (SIDD) analysis method, as defined by Bode et al. (2005) J. Mol. Biol. 358, 597, "calculates the extent to which an imposed level of superhelical stress reduces the free energy required to open the duplex at each position along the DNA sequence. The results are displayed as a SIDD profile, where sites of strong destabilization appear as deep minima." The SIDD algorithm and mathematical foundations (Bi and Benham (2004) Bioinformatics 20, 1477) and analysis of SIDD profiles can be performed using the freely available internet resource at WebSIDD (www.genomecenter.ucdavis.edu / benham).Thus, in some embodiments, a polynucleotide is considered a variant of an S / MAR sequence if it exhibits a similar SIDD profile as the S / MAR.
[0270] Fusogens and Pseudotyping The fusosomes (eg, retroviral vectors) described herein can comprise a fusogen, eg, an endogenous fusogen or a pseudotyped fusogen.
[0271] In some embodiments, the fusogen comprises a protein (e.g., a glycoprotein), a lipid, or a small molecule. The fusogen can be, for example, a mammalian fusogen or a viral fusogen. In some embodiments, the fusogen comprises a protein fusogen, e.g., a mammalian protein or a homolog of a mammalian protein (e.g., 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity), a non-mammalian protein such as a viral protein or a homolog of a viral protein (e.g., 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity), a naturally occurring protein or a derivative of a naturally occurring protein, a synthetic protein, a fragment thereof, a variant thereof, a protein fusion, one or more fusogens or fragments, and any combination thereof. In some embodiments, the viral fusogen is a class I viral membrane fusion protein, a class II viral membrane protein, a class III viral membrane fusion protein, a viral membrane glycoprotein, or other viral fusion protein, or a homolog thereof, a fragment thereof, a variant thereof, or a protein fusion comprising one or more proteins or fragments thereof.
[0272] Fusogens, including viral envelope proteins (env), generally determine the range of host cells that can be infected and transformed by fusosomes. For lentiviruses such as HIV-1, HIV-2, SIV, FIV, and EIV, native env proteins include gp41 and gp120. In some embodiments, the viral env proteins expressed by the source cells described herein are encoded on a vector separate from the viral gag and pol genes, as previously described.
[0273] Examples of env genes from retroviruses that can be used include, but are not limited to, MLV envelope, 10A1 envelope, BAEV, FeLV-B, RD114, SSAV, Ebola, Sendai, FPV (fowl plague virus), and influenza virus envelope. Similarly, RNA viruses (e.g., Picornaviridae, Calciviridae, Astroviridae, Togaviridae, Flaviviridae, Coronaviridae, Paramyxoviridae, Rhabdoviridae, Filoviridae, Orthomyxoviridae, Bunyaviridae, Arenaviridae, etc.) can be used. In addition to RNA virus families such as Arenaviridae and Reoviridae, genes encoding envelopes derived from DNA viruses (Hepadnaviridae, Circoviridae, Parvoviridae, Papovaviridae, Adenoviridae, Herpesviridae, Poxyiridae, and Iridoviridae) can be used. Representative examples include FeLV, VEE, HFVW, WDSV, SFV, rabies, ALV, BIV, BLV, EBV, CAEV, SNV, ChTLV, STLV, MPMV, SMRV, RAV, FuSV, MH2, AEV, AMV, CT10, and EIAV.
[0274] In some embodiments, envelope proteins for display on fusosomes include, but are not limited to, any of the following sources: influenza A, such as H1N1, H1N2, H3N2, and H5N1 (avian influenza), influenza B, influenza C virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, rotavirus, any virus of the Norwalk virus group, enteric adenovirus, parvovirus, dengue virus, lyssaviruses, such as monkeypox, mononegavirus, and rabies virus, Lagos bat virus, Mokola virus, Duvenhage virus, European bat virus 1 and 2, Australian bat virus, ephemerovirus, vesiculovirus, vesicular stomatitis virus (VSV), herpesviruses, such as herpes simplex virus 1 and 2, and varicella zoster. cytomegalovirus, Epstein-Barr virus (EBV), human herpesvirus (HHV), human herpesvirus types 6 and 8, human immunodeficiency virus (HIV), papillomavirus, murine gammaherpesvirus, arenaviruses such as Argentine hemorrhagic fever virus, Bunyaviridae such as Bolivian hemorrhagic fever virus, Sabia-associated hemorrhagic fever virus, Venezuelan hemorrhagic fever virus, Lassa fever virus, Machupo virus, lymphocytic choriomeningitis virus (LCMV), and Crimean-Congo hemorrhagic fever virus, Filoviridae (filoviruses) including hantaviruses, viruses causing hemorrhagic renal syndrome, Rift Valley fever virus, Ebola hemorrhagic fever, and Marburg hemorrhagic fever, Flaviviridae including Kyasanur Forest disease virus, Paramyxoviridae such as Omsk hemorrhagic fever virus, viruses causing tick-borne encephalitis, Hendra virus, and Nipah virus, Variola Alphaviruses such as variola major and variola minor (smallpox), Venezuelan equine encephalitis virus, Eastern equine encephalitis virus, Western equine encephalitis virus, SARS-associated coronavirus (SARS-CoV), West Nile virus, any encephalitis-causing virus.
[0275] In some embodiments, the source cells described herein produce fusosomes pseudotyped with VSV-G glycoprotein, eg, recombinant retroviruses, eg, lentiviruses.
[0276] Fusosomes or pseudotyped viruses generally have one or more modifications in their envelope proteins, for example, the envelope protein is replaced with the envelope protein from another virus.For example, HIV can be pseudotyped with the fusion protein from a rhabdovirus, such as the vesicular stomatitis virus G protein (VSV-G) envelope protein, and HIV envelope protein (encoded by env gene) usually targets the virus to CD4+ presenting cells, allowing HIV to infect a wider range of cells.In some embodiments, lentivirus envelope protein is pseudotyped with VSV-G.In one embodiment, source cells produce recombinant retroviruses, such as lentiviruses, pseudotyped with VSV-G envelope glycoprotein.
[0277] Furthermore, fusogens or viral envelope proteins can be modified or engineered to contain polypeptide sequences that enable the transduction vector to target and infect host cells outside its normal range, or more specifically, restrict transduction to a cell or tissue type. For example, fusogens or envelope proteins can be linked in-frame to targeting sequences such as receptor ligands, antibodies (using recombinant antibody-type molecules such as antigen-binding portions of antibodies or single-chain antibodies), and polypeptide moieties or modifications thereof that, when displayed on the transduction vector coat, facilitate direct delivery of virion particles to the desired target cells (e.g., when glycosylation sites are present in the targeting sequence). Furthermore, envelope proteins can further contain sequences that modulate cellular function. Modulating cellular function with transduction vectors can increase or decrease the transduction efficiency of specific cell types in a mixed cell population. For example, stem cells can be more specifically transduced with envelope sequences containing ligands or binding partners that specifically bind to stem cells but not other cell types found in blood or bone marrow. Non-limiting examples include stem cell factor (SCF) and Flt-3 ligand. Other examples include, for example, antibodies (e.g., cell type-specific single chain antibodies) and essentially any antigen (including receptor) that binds to tissues such as lung, liver, pancreas, heart, endothelial, smooth, breast, prostate, epithelial, vascular cancers, etc.
[0278] Exemplary Fusogens In some embodiments, the fusosomes comprise one or more fusogens, eg, to promote fusion of the fusosome to a membrane, eg, a cell membrane.
[0279] In some embodiments, fusosomes contain one or more fusogens on their envelopes to target specific cell or tissue types. Fusogens include, but are not limited to, protein-based, lipid-based, and chemical-based fusogens. In some embodiments, fusosomes contain a first fusogen that is a protein fusogen and a second fusogen that is a lipid fusogen or a chemical fusogen. The fusogens may bind to fusogen-binding partners on the surface of target cells. In some embodiments, fusosomes containing the fusogens will integrate their membranes into the lipid bilayer of the target cells.
[0280] In some embodiments, one or more fusogens described herein may be contained in a fusosome.
[0281] Protein fusogens In some embodiments, the fusogen comprises a protein fusogen, e.g., a mammalian protein or a homolog of a mammalian protein (e.g., 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity), a non-mammalian protein such as a viral protein or a homolog of a viral protein (e.g., 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity), a naturally occurring protein or a derivative of a naturally occurring protein, a synthetic protein, a fragment thereof, a variant thereof, a protein fusion, one or more fusogens or fragments, and any combination thereof.
[0282] In some embodiments, the fusogen causes mixing between lipids in the fusosome and lipids within the target cell, hi some embodiments, the fusogen causes the formation of one or more pores between the interior of the fusosome and the cytosol of the target cell.
[0283] Mammalian proteins In some embodiments, the fusogen may comprise a mammalian protein, see Table 1A. Examples of mammalian fusogens include, but are not limited to, SNARE family proteins such as vSNAREs and tSNAREs, syncytin proteins such as Syncytin-1 ((DOI:10.1128 / JVI.76.13.6442-6452.2002) and Syncytin-2, myomaker (biorxiv.org / content / early / 2017 / 04 / 02 / 123158,doi.org / 10.1101 / 123158,doi:10.1096 / fj.201600945R,d oi:10.1038 / nature12343), myomixer (www.nature.com / nature / journal / v499 / n7458 / full / nature12343.html,doi:10.1038 / nature12343), myomerger (science.sciencemag.org / content / early / 2017 / 04 / 05 / science.aam9361,DOI:10.1126 / science.aam9361), FGFRL1 (fibroblast proliferation factor receptor-like 1), Minion (doi.org / 10.1101 / 122697), isoforms of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (e.g., as disclosed in U.S. Pat. No. 6,099,857A), gap junction proteins such as connexin 43, connexin 40, connexin 45, connexin 32, or connexin 37 (e.g., U.S. Patent Application Publication No. 2007 / 0224176), Hap2, any protein capable of inducing syncytium formation between heterologous cells (see Table 2 ), any protein with fusogenic properties (see Table 3), homologs thereof, fragments thereof, variants thereof, and protein fusions comprising one or more proteins or fragments thereof. In some embodiments, the fusogen is encoded by a human endogenous retroviral element (hERV) found in the human genome. Additional exemplary fusogens are disclosed in U.S. Pat. No. 6,099,857 A and U.S. Patent Application Publication No. 2007 / 0224176, the entire contents of which are incorporated herein by reference.
[0284] [Table 1A] [Table 1B] [Table 1C-1] [Table 1C-2] In some embodiments, fusosomes comprise curvature-generating proteins, such as epsin 1, dynamin, or proteins containing a BAR domain (see, e.g., Kozlovet et al., CurrOp StrucBio 2015, Zimmerberg et al. Nat Rev 2006, Richard et al., Biochem J 2011).
[0285] Non-mammalian proteins viral proteins In some embodiments, the fusogen can comprise a non-mammalian protein, e.g., a viral protein. In some embodiments, the viral fusogen is a class I viral membrane fusion protein, a class II viral membrane protein, a class III viral membrane fusion protein, a viral membrane glycoprotein, or other viral fusion protein, or a homolog thereof, a fragment thereof, a variant thereof, or a protein fusion comprising one or more proteins or fragments thereof.
[0286] In some embodiments, class I viral membrane fusion proteins include, but are not limited to, baculovirus F proteins, e.g., F proteins of the genus Nuclear Polyhedrosis Virus (NPV), e.g., Spodoptera exigua MNPV (SeMNPV) F protein and Lymantria dispar MNPV (LdMNPV), and paramyxovirus F proteins.
[0287] In some embodiments, class II viral membrane proteins include, but are not limited to, tick-borne encephalitis virus E (TBEV E), Semliki Forest virus E1 / E2.
[0288] In some embodiments, class III viral membrane fusion proteins include, but are not limited to, rhabdovirus G (e.g., vesicular gastritis virus (VSV-G) fusion protein G), herpesvirus glycoprotein B (e.g., Herpes Simplex virus 1 (HSV-1) gB)), Epstein-Barr virus glycoprotein B (EBV gB), Thogotovirus G, baculovirus gp64 (e.g., Autographa California multiple (AcMNPV) gp64), and Borna disease virus (BDV) glycoprotein (BDV G).
[0289] Examples of other viral fusogens, such as membrane glycoproteins and viral fusion proteins, include, but are not limited to, viral syncytial proteins such as influenza hemagglutinin (HA) or variants, or fusion proteins thereof; human immunodeficiency virus type 1 envelope protein (HIV-1 ENV), gp120 derived from HIV binding LFA-1 to form lymphocyte syncytia, HIV gp41, HIV gp160, or transactivator of transcription (TAT) of HIV; viral glycoprotein VSV-G, a viral glycoprotein from vesicular stomatitis virus of the Rhabdoviridae family; glycoproteins gB and gH-gL of varicella-zoster virus (VZV); murine leukemia virus (MLV)-10A1; gibbon ape leukemia virus glycoprotein (GaLV); G-type glycoproteins of rabies, Mokola, vesicular stomatitis, and togavirus; murine hepatitis virus JHM surface spike protein; porcine respiratory coronavirus spike and membrane glycoproteins; avian infectious bronchitis spike glycoprotein and its precursor; bovine enteric coronavirus spike protein; measles virus F and H, HN or G genes; canine distemper virus, Newcastle disease virus, human parainfluenza virus 3, simian virus 41, Sendai virus and human respiratory syncytial virus; gH of human herpesvirus 1 and varicella-zoster virus, along with the chaperone protein gL; human, bovine and cercopithecoid herpesvirus gB; envelope glycoproteins of Friend murine leukemia virus and Mason-Pfizer monkey virus; mumps virus hemagglutinin neuraminidase and glyoproteins F1 and F2; membrane glycoprotein from Venezuelan equine encephalomyelitis; paramyxovirus F protein; SIV gp160 protein; Ebola virus G protein; or Sendai virus fusion protein, or homologs thereof, fragments thereof, variants thereof, and protein fusions comprising one or more proteins or fragments thereof.
[0290] Non-mammalian fusogens include viral fusogens, their homologs, fragments, and fusion proteins comprising one or more proteins or fragments thereof. Viral fusogens include class I fusogens, class II fusogens, class III fusogens, and class IV fusogens. In embodiments, class I fusogens, such as human immunodeficiency virus (HIV) gp41, have a characteristic post-fusion conformation with a characteristic trimer of α-helical hairpins with a central coiled-coil structure. Class I viral fusion proteins include proteins with a central post-fusion six-helix bundle. Class I viral fusion proteins include influenza HA, parainfluenza F, HIV Env, Ebola GP, orthomyxovirus hemagglutinin, paramyxovirus F proteins (e.g., measles (Katoh et al. BMC Biotechnology 2010, 10:37)), retrovirus ENV proteins, and filovirus and coronavirus fusogens. In embodiments, class II viral fusogens, such as dengue E glycoprotein, have the structural characteristics of a beta sheet that refolds to form an elongated ectodomain resulting in a trimer of hairpins. In embodiments, class II viral fusogens lack a central coiled-coil. Class II viral fusogens are found in alphaviruses (e.g., E1 protein) and flaviviruses (e.g., E glycoprotein). Class II viral fusogens include fusogens from Semliki Forest virus, Sinbis virus, rubella virus, and dengue virus. In embodiments, class III viral fusogens, such as vesicular stomatitis virus G glycoprotein, combine structural features found in classes I and II. In embodiments, class III viral fusogens contain an alpha helix (e.g., the protein folds back to form a six-helix bundle, similar to class I viral fusogens) and a beta sheet with an amphipathic fusion peptide at its terminus, reminiscent of class II viral fusogens. Class III viral fusogens are found in rhabdoviruses and herpesviruses.In embodiments, the Class IV viral fusogen is a fusion-associated small transmembrane (FAST) protein encoded by non-enveloped reovirus (doi:10.1038 / sj.emboj.7600767, Nesbitt, Rae L., "Targeted Intracellular Therapeutic Delivery Using Liposomes Formulated with Multifunctional FAST proteins" (2012). Electronic Thesis and Dissertation Repository. Paper 388). In embodiments, the Class IV viral fusogen is small enough that it does not form hairpins (doi:10.1146 / annurev-cellbio-101512-122422, doi:10.1016 / j.devcel.2007.12.008).
[0291] Protein fusogens or viral envelope proteins can be retargeted by mutating amino acid residues in the fusogen protein or the targeting protein (e.g., hemagglutinin protein). In some embodiments, the fusogen is randomly mutated. In some embodiments, the fusogen is rationally mutated. In some embodiments, the fusogen is subjected to directed evolution. In some embodiments, the fusogen is truncated and only a subset of the peptides is used in the retroviral vector or VLP. For example, amino acid residues in the measles hemagglutinin protein can be mutated to change the protein's binding properties and redirect fusion (doi:10.1038 / nbt942, Molecular Therapy vol.16 no.8, 1427-1436 Aug.2008, doi:10.1038 / nbt1060, DOI:10.1128 / JVI.76.7.3558-3563.2002, DOI:10.1128 / JVI.75.17.8016-8020.2001, doi:10.1073pnas.0604993103).
[0292] In some embodiments, a protein fusogen or viral envelope protein is retargeted by i) mutating amino acids in the native fusogen protein sequence or viral envelope protein sequence, and / or ii) engineering the fusogen protein or viral envelope protein to include a polypeptide sequence that enables the fusogen or viral envelope protein to target, fuse with, or infect host cells outside its normal range.
[0293] In some embodiments, fusosomes contain one or more fusogens on their outer surface (e.g., incorporated into the cell membrane) to target specific cell or tissue types. Fusogens include, but are not limited to, protein-based, lipid-based, and chemical-based fusogens. Fusogens may bind to partners on the surface of target cells. In some embodiments, fusogen-containing fusosomes will integrate their membranes into the lipid bilayer of target cells.
[0294] In some embodiments, the fusogen is a paramyxovirus fusogen. In some embodiments, the fusogen is Nipah virus protein F, measles virus F protein, Tupaia paramyxovirus F protein, paramyxovirus F protein, Hendra virus F protein, Henipavirus F protein, Morbillivirus F protein, Respirovirus F protein, Sendai virus F protein, Rubulavirus F protein, or Avulavirus F protein.
[0295] In some embodiments, the fusogen is a Poxviridae fusogen.
[0296] Additional exemplary fusogens are disclosed in U.S. Pat. No. 9,695,446, U.S. Pat. App. Pub. No. 2004 / 0028687, U.S. Pat. No. 6,416,997, U.S. Pat. No. 7,329,807, U.S. Pat. App. Pub. No. 2017 / 0112773, U.S. Pat. App. Pub. No. 2009 / 0202622, WO 2006 / 027202, and U.S. Pat. App. Pub. No. 2004 / 0009604, the contents of all of which are incorporated herein by reference.
[0297] In some embodiments, a fusogen described herein comprises an amino acid sequence of Table 1D, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion thereof, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over a length of 100, 200, 300, 400, 500, or 600 amino acids. For example, in some embodiments, a fusogen described herein comprises an amino acid sequence having at least 80% identity to any amino acid sequence of Table 1D. In some embodiments, the nucleic acid sequences described herein encode an amino acid sequence of Table 1D, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion thereof, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto over a length of 40, 50, 60, 80, 100, 200, 300, 400, 500, or 600 amino acids.
[0298] In some embodiments, a fusogen described herein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-56, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion of said sequence, for example, an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over a length of 100, 200, 300, 400, 500, or 600 amino acids. For example, in some embodiments, a fusogen described herein comprises an amino acid sequence having at least 80% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 1-56. In some embodiments, the nucleic acid sequences described herein encode an amino acid sequence set forth in any one of SEQ ID NOs: 1-56, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion thereof, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over a length of 40, 50, 60, 80, 100, 200, 300, 400, 500, or 600 amino acids.
[0299] [Table 1D-1] [Table 1D-2] [Table 1D-3] [Table 1D-4] [Table 1D-5] [Table 1D-6] [Table 1D-7] [Table 1D-8] [Table 1D-9] [Table 1D-10] [Table 1D-11] [Table 1D-12] [Table 1D-13] [Table 1D-14] [Table 1D-15]
[0300] In some embodiments, a fusogen described herein comprises an amino acid sequence in Table 2, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion of such a sequence, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over a length of 100, 200, 300, 400, 500, or 600 amino acids. For example, in some embodiments, a fusogen described herein comprises an amino acid sequence having at least 80% identity to any of the amino acid sequences in Table 2. In some embodiments, the nucleic acid sequences described herein encode an amino acid sequence in Table 2, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion thereof, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto over a length of 40, 50, 60, 80, 100, 200, 300, 400, 500, or 600 amino acids.
[0301] In some embodiments, a fusogen described herein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 57-132, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion of said sequence, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over a length of 100, 200, 300, 400, 500, or 600 amino acids. For example, in some embodiments, a fusogen described herein comprises an amino acid sequence having at least 80% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 57-132. In some embodiments, the nucleic acid sequences described herein encode an amino acid sequence set forth in any one of SEQ ID NOs: 57-132, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, or a portion thereof, e.g., an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over a length of 40, 50, 60, 80, 100, 200, 300, 400, 500, or 600 amino acids.
[0302] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13] [Table 2-14] [Table 2-15] [Table 2-16] [Table 2-17] [Table 2-18] [Table 2-19] [Table 2-20] [Table 2-21] [Table 2-22]
[0303] Other proteins In some embodiments, fusogens may include pH-dependent proteins, homologs thereof, fragments thereof, and protein fusions comprising one or more proteins or fragments thereof. Fusogens may mediate membrane fusion at the cell surface, within endosomes, or within another membrane-bound space.
[0304] In some embodiments, fusogens include EFF-1, AFF-1, gap junction proteins such as connexins (Cn43, GAP43, CX43, etc.) (DOI: 10.1021 / jacs.6b05191), other tumor-associated proteins, homologs thereof, fragments thereof, variants thereof, and protein fusions comprising one or more proteins or fragments thereof.
[0305] Lipid fusogens In some embodiments, fusosomes may contain one or more fusogenic lipids, such as saturated fatty acids. In some embodiments, the saturated fatty acids have 10-14 carbons. In some embodiments, the saturated fatty acids have longer chain carboxylic acids. In some embodiments, the saturated fatty acids are monoesters.
[0306] In some embodiments, the fusosomes can comprise one or more unsaturated fatty acids. In some embodiments, the unsaturated fatty acids have C16 to C18 unsaturated fatty acids. In some embodiments, the unsaturated fatty acids include oleic acid, glycerol monooleate, glycerides, diacylglycerols, modified unsaturated fatty acids, and any combination thereof.
[0307] Without wishing to be bound by theory, in some embodiments, negatively curved lipids promote membrane fusion. In some embodiments, fusosomes contain one or more negatively curved lipids, e.g., exogenous negatively curved lipids, within their membranes. In embodiments, negatively curved lipids or their precursors are added to source cells or to culture media containing fusosomes. In embodiments, source cells are engineered to express or overexpress one or more lipid synthesis genes. The negatively curved lipids can be, for example, diacylglycerol (DAG), cholesterol, phosphatidic acid (PA), phosphatidylethanolamine (PE), or fatty acids (FA).
[0308] Without wishing to be bound by theory, in some embodiments, positively curved lipids inhibit membrane fusion. In some embodiments, fusosomes contain reduced levels of one or more positively curved lipids, e.g., exogenous positively curved lipids, in the membrane. In embodiments, the levels are reduced by inhibiting lipid synthesis, e.g., by knocking out or knocking down lipid synthesis genes in the source cells. The positively curved lipid can be, for example, lysophosphatidylcholine (LPC), phosphatidylinositol (PtdIns), lysophosphatidic acid (LPA), lysophosphatidylethanolamine (LPE), or monoacylglycerol (MAG).
[0309] Chemical Fusogens In some embodiments, the fusosomes may be treated with a fusogenic chemical, hi some embodiments, the fusogenic chemical is polyethylene glycol (PEG) or a derivative thereof.
[0310] In some embodiments, the chemical fusogen induces local dehydration between the two membranes, which leads to unfavorable molecular packing of the bilayer. In some embodiments, the chemical fusogen induces dehydration in the nearby region of the lipid bilayer, causing displacement of aqueous molecules between the two membranes and allowing interaction between the two membranes.
[0311] In some embodiments, the chemical fusogen is a cation. Some non-limiting examples of cations include Ca, Mg, Mn, Zn, La, Sr, and H.
[0312] In some embodiments, chemical fusogens bind to target membranes by modifying surface polarity, which alters hydration-dependent intermembrane repulsion.
[0313] In some embodiments, the chemical fusogen is soluble and lipid soluble. Some non-limiting examples include oleoylglycerol, dioleoylglycerol, trioleoylglycerol, and variants and derivatives thereof.
[0314] In some embodiments, the chemical fusogen is a water-soluble chemical. Some non-limiting examples include polyethylene glycol, dimethyl sulfoxide, and variants and derivatives thereof.
[0315] In some embodiments, the chemical fusogen is a small organic molecule. A non-limiting example includes n-hexyl bromide.
[0316] In some embodiments, the chemical fusogen does not alter the composition, cell viability, or ion transport properties of the fusogen or target membrane.
[0317] In some embodiments, the chemical fusogen is a hormone or vitamin. Some non-limiting examples include abscisic acid, retinol (vitamin A1), tocopherol (vitamin E), and variants and derivatives thereof.
[0318] In some embodiments, fusosomes comprise an agent that stabilizes actin and polymerized actin. Without wishing to be bound by theory, stabilized actin within fusosomes can facilitate fusion with target cells. In embodiments, the agent that stabilizes polymerized actin is selected from actin, myosin, biotin-streptavidin, ATP, neural Wiskott-Aldrich syndrome protein (N-WASP), or formin. See, e.g., Langmuir. 2011 Aug 16;27(16):10061-71 and Wen et al., Nat Commun. 2016 Aug 31;7. In embodiments, fusosomes comprise exogenous actin, e.g., wild-type actin or actin containing a mutation that promotes polymerization. In embodiments, fusosomes comprise ATP or phosphocreatine, e.g., exogenous ATP or phosphocreatine.
[0319] Small molecule fusogens In some embodiments, fusosomes can be treated with fusogenic small molecules, some non-limiting examples of which include nonsteroidal anti-inflammatory drugs (NSAIDs) such as halothane, meloxicam, piroxicam, tenoxicam, and chlorpromazine.
[0320] In some embodiments, the small molecule fusogen may be present in micelle-like aggregates or may be aggregate-free.
[0321] Modification to protein fusogens Protein fusogens or viral envelope proteins can be retargeted by mutating amino acid residues in the fusogen protein or the targeting protein (e.g., hemagglutinin protein). In some embodiments, the fusogen is randomly mutated. In some embodiments, the fusogen is rationally mutated. In some embodiments, the fusogen is subjected to directed evolution. In some embodiments, the fusogen is truncated and only a subset of the peptides is used in the retroviral vector or VLP. For example, amino acid residues in the measles hemagglutinin protein can be mutated to change the protein's binding properties and redirect fusion (doi:10.1038 / nbt942, Molecular Therapy vol.16 no.8, 1427-1436 Aug.2008, doi:10.1038 / nbt1060, DOI:10.1128 / JVI.76.7.3558-3563.2002, DOI:10.1128 / JVI.75.17.8016-8020.2001, doi:10.1073pnas.0604993103).
[0322] Protein fusogens can be retargeted by covalently conjugating a targeting moiety to a fusion protein or targeting protein (e.g., hemagglutinin protein). In some embodiments, the fusion and targeting moiety are covalently linked by expression of a chimeric protein comprising the fusogen linked to the targeting moiety. Targets include any peptide (e.g., receptor) displayed on target cells. In some instances, the target is expressed at a higher level on target cells than on non-target cells. For example, single-chain variable fragments (scFVs) can be conjugated to fusogens to redirect fusion activity to cells displaying scFV-binding targets (doi:10.1038 / nbt1060, DOI 10.1182 / blood-2012-11-468579, doi:10.1038 / nmeth.1514, doi:10.1006 / mthe.2002.0550, HUMAN GENE THERAPY 11:817-826, doi:10.1038 / nbt942, doi:10.1371 / journal.pone.0026381, DOI 10.1186 / s12896-015-0142-z). For example, engineered ankyrin repeat proteins (DARPins) can be conjugated to fusogens to redirect fusion activity against cells expressing DARPin-binding targets (doi:10.1038 / mt.2013.16, doi:10.1038 / mt.2010.298, doi:10.4049 / jimmunol.1500956), as well as combinations of various DARPins (doi:10.1038 / mto.2016.3). For example, receptor ligands and antigens can be conjugated to fusogens to redirect fusion activity against cells expressing target receptors (DOI:10.1089 / hgtb.2012.054, DOI:10.1128 / JVI.76.7.3558-3563.2002).Targeting proteins also include, for example, antibodies or antigen-binding fragments thereof (e.g., Fab, Fab', F(ab')2, Fv fragments, scFv antibody fragments, disulfide-linked Fv (sdFv), Fd fragments consisting of VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (either VL or VH), nanobodies, or camelid VHH domains), antigen-binding fibronectin type III (Fn3) scaffolds such as fibronectin polypeptide minibodies, cytokines, chemokines, or T cell receptors (TCRs). Protein fusogens can be retargeted by non-covalently conjugating a targeting moiety to the fusion protein or targeting protein (e.g., hemagglutinin protein). For example, fusion proteins can be engineered to bind to the Fc region of an antibody that targets an antigen on a target cell, redirecting the fusion activity of the antibody to cells that display the target (DOI:10.1128 / JVI.75.17.8016-8020.2001, doi:10.1038 / nm1192). Modified and unmodified fusogens can be displayed on the same retroviral vector or VLP (doi:10.1016 / j.biomaterials.2014.01.051).
[0323] Targeting moieties can be, for example, humanized antibody molecules, intact IgA, IgG, IgE, or IgM antibodies; bispecific or multispecific antibodies (e.g., Zybodies®, etc.); antibody fragments such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd' fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); camelid antibodies; masked antibodies (e.g., Probodies®); small modular immunopharmaceuticals ("SMIPs™"); single chain or tandem domain antibodies. These may include iabodies (TandAb®); VHHs; Anticalins®; Nanobodies®; minibodies; BiTEs®; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; microproteins (MicroProteins); Fynomers®, Centyrins®; and KALBITOR®.
[0324] In embodiments, the retargeted fusogen binds to a cell surface marker on the target cell, such as a protein, glycoprotein, receptor, cell surface ligand, agonist, lipid, sugar, class I transmembrane protein, class II transmembrane protein, or class III transmembrane protein.
[0325] Fusosomes may display targeting moieties that are not conjugated to protein fusogens in order to redirect fusogenic activity to cells bound by the targeting moiety or to affect homing.
[0326] Targeting moieties attached to fusosomes can be tailored to have different binding strengths. For example, scFvs and antibodies with varying binding strengths can be used to alter the fusion activity of fusosomes toward cells displaying high or low amounts of target antigen (doi:10.1128 / JVI.01415-07, doi:10.1038 / cgt.2014.25, doi:10.1002 / jgm.1151). For example, DARPins with different affinities can be used to alter the fusion activity of retroviral vectors or VLPs toward cells displaying high or low amounts of target antigen (doi:10.1038 / mt.2010.298). Targeting moieties can also be tailored to target different regions on the target ligand, which affects the fusion rate with cells displaying the target (doi:10.1093 / protein / gzv005).
[0327] In some embodiments, protein fusogens can be modified to reduce immune reactivity, e.g., as described herein. For example, protein fusogens can be decorated with molecules that reduce immune interactions, such as PEG (DOI: 10.1128 / JVI.78.2.912-921.2004). Thus, in some embodiments, the fusogen comprises PEG, e.g., a PEGylated polypeptide. Amino acid residues of fusogens that are targeted by the immune system can be modified to prevent them from being recognized by the immune system (doi: 10.1016 / j.virol.2014.01.027, doi: 10.1371 / journal.pone.0046667). In some embodiments, the protein sequence of the fusogen is modified to resemble an amino acid sequence found in humans (humanization). In some embodiments, the protein sequence of the fusogen is modified to a protein sequence that binds less strongly to the MHC complex. In some embodiments, the protein fusogen is derived from a virus or organism that does not infect humans (and against which humans have not been vaccinated), increasing the likelihood that the patient's immune system is naive to the protein fusogen (e.g., there is a negligible humoral or cellular adaptive immune response to the fusogen) (doi:10.1006 / mthe.2002.0550, doi:10.1371 / journal.ppat.1005641, doi:10.1038 / gt.2011.209, DOI 10.1182 / blood-2014-02-558163). In some embodiments, the glycosylation of the fusogen can be altered to alter immune interactions or reduce immune reactivity. Without wishing to be bound by theory, in some embodiments, a protein fusogen derived from a virus or organism that does not infect humans has no natural fusion targets in the patient and therefore has high specificity.
[0328] Positive target cell-specific regulatory elements In some embodiments, the retroviral nucleic acids described herein comprise a positive target cell-specific regulatory element such as a tissue-specific promoter, a tissue-specific enhancer, a tissue-specific splice site, a tissue-specific site that extends the half-life of an RNA or protein, a tissue-specific mRNA export promoting site, a tissue-specific translation enhancing site, or a tissue-specific post-translational modification site.
[0329] The retroviral nucleic acids described herein can include regions, such as origins of replication, selection cassettes, promoters, enhancers, translation initiation signals (Shine-Dalgarno or Kozak sequences), introns, polyadenylation sequences, 5' and 3' untranslated regions that can interact with host cell proteins to carry out transcription and translation and direct, increase, regulate, or control the transcription or expression of an operably linked polynucleotide. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements can be used, including ubiquitous promoters and inducible promoters.
[0330] In certain embodiments, the control element is capable of directing, increasing, regulating, or controlling the transcription or expression of an operably linked polynucleotide in a cell-specific manner. In certain embodiments, the retroviral nucleic acid comprises one or more expression control sequences that are specific for a particular cell, cell type, or cell lineage, e.g., a target cell, i.e., expression of a polynucleotide operably linked to a particular cell, cell type, or cell lineage-specific expression control sequence is expressed in the target cell but not (or expressed at a lower level) in non-target cells.
[0331] In certain embodiments, the retroviral nucleic acid may include exogenous, endogenous, or heterologous regulatory sequences, such as promoters and / or enhancers.
[0332] In embodiments, a promoter contains a recognition site for binding of an RNA polymerase, which initiates and transcribes a polynucleotide operably linked to the promoter. In certain embodiments, promoters that operate in mammalian cells contain an AT-rich region located approximately 25-30 bases upstream from the site where transcription begins and / or another sequence, a CNCAAT region, found approximately 70-80 bases upstream from the start of transcription, where N can be any nucleotide.
[0333] In embodiments, an enhancer comprises a segment of DNA containing sequences that can provide enhanced transcription and, in some cases, can function independently of orientation relative to another regulatory sequence. Enhancers can function cooperatively or additively with promoters and / or other enhancer elements. In some embodiments, a promoter / enhancer segment of DNA comprises sequences that can provide both promoter and enhancer function.
[0334] Exemplary ubiquitous expression control sequences include the cytomegalovirus (CMV) immediate early promoter, the viral Simian Virus 40 (SV40) (e.g., early or late), Moloney murine leukemia virus (MoMLV) LTR promoter, Rous sarcoma virus (RSV) LTR, herpes simplex virus (HSV) (thymidine kinase) promoter, the H5, P7.5, and P11 promoters from vaccinia virus, elongation factor 1-alpha (E1) promoter, and the HIV-1 virus (HIV-2) promoter. F1a) promoter, early growth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock 70 kDa protein 5 (HSPA5), heat shock protein 90 kDa beta, member 1 (HSP90B1), heat shock protein 70 kDa (HSP70), β-kinesin (β-KIN), human ROSA These include 26 loci (Orions et al., Nature Biotechnology 25, 1477-1482 (2007)), ubiquitin C promoter (UBC), phosphoglycerate kinase-1 (PGK) promoter, cytomegalovirus enhancer / chicken β-actin (CAG) promoter, β-actin promoter and myeloproliferative sarcoma virus enhancer, negative control region deletion, and d1587rev primer binding site substitution (MND) promoter (Challita et al., J Virol. 69(2):748-55 (1995)).
[0335] In some embodiments, a promoter may be paired with a heterologous gene to confer the regulatory function of that promoter on the heterologous gene. In some embodiments, cis-regulatory elements from a promoter of a first gene may be linked to segments of a promoter of a different gene to create a chimeric promoter with properties of both promoters.
[0336] In some embodiments, the promoter is a tissue-specific promoter, e.g., a promoter that drives expression in liver cells, e.g., hepatocytes, liver sinusoidal endothelial cells, bile duct cells, stellate cells, antigen-presenting cells present in the liver (e.g., Kupffer cells), immune lymphocytes present in the liver (e.g., T cells, B cells, or NK cells), or portal tract fibroblasts. Various suitable liver-specific promoters (e.g., hepatocyte-specific promoters and liver sinusoidal endothelial cell promoters) are listed in Table 3 below. Table 3 also lists several ubiquitous promoters that are not specific to liver cells. In some embodiments, the fusosomes (e.g., viral vectors) described herein comprise in their nucleic acid a promoter having a sequence in Table 3, or a transcriptionally active fragment thereof, or a variant having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the fusosomes (e.g., viral vectors) described herein comprise in their nucleic acid a promoter having a transcription factor binding site derived from a region within 3 kb of the transcription start site of a gene listed in Table 3. In some embodiments, the fusosomes (e.g., viral vectors) described herein comprise in their nucleic acid a region within 2.5 kb, 2 kb, 1.5 kb, 1 kb, or 0.5 kb immediately upstream of the transcription start site of a gene listed in Table 3, or a transcriptionally active fragment thereof, or a variant having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto.
[0337] In some embodiments, the fusosomes (e.g., viral vectors) described herein comprise in their nucleic acid a promoter having a sequence set forth in any one of SEQ ID NOs: 133-142, or a transcriptionally active fragment thereof, or a variant having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto.
[0338] In some embodiments, the promoter is a promoter that drives expression in liver cells, such as hepatocytes, liver sinusoidal endothelial cells, bile duct cells, stellate cells, antigen-presenting cells present in the liver (e.g., Kupffer cells), immune lymphocytes present in the liver (e.g., T cells, B cells, or NK cells), or portal tract fibroblasts. In some embodiments, the fusosomes (e.g., viral vectors) described herein comprise in their nucleic acid a promoter having a sequence set forth in any one of SEQ ID NOs: 133-136 or 519-525, or a transcriptionally active fragment thereof, or a variant having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the promoter is a hepatocyte-specific human (ApoE.HCR-hAAT(hApoE) promoter. In some embodiments, the promoter has a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 133. In some embodiments, the promoter has the sequence set forth in SEQ ID NO: 133.
[0339] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] Various consensus sequences within liver-specific cis-regulatory modules (e.g., promoters) have been described. In some embodiments, the liver-specific cis-regulatory module comprises binding sites for one or more of HNF1α, C / EBP, LEF1, FOX, IRF, LEF1 / TCF, Tal1β / E47, and MyoD. In some embodiments, the liver-specific cis-regulatory module comprises a sequence set forth in Figure 1 or Table 1 of Chuah et al., "Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates," Mol Ther. 2014 Sep;22(9):1605-1613, the entire contents of which are incorporated herein by reference, including the sequences in Figure 1 and Table 1. In some embodiments, the liver-specific cis-regulatory module comprises the human sequence of HS-CRM1, HS-CRM2, HS-CRM3, HS-CRM4, HS-CRM5, HS-CRM6, HS-CRM7, HS-CRM8, HS-CRM9, HS-CRM10, HS-CRM11, HS-CRM12, HS-CRM13, or HS-CRM14, as described in Chuah et al., supra. Additional cell-specific promoters and cis-regulatory elements, such as liver-specific promoters or cis-regulatory elements, can be identified using the methods described in Chuah et al., supra.
[0340] An internal ribosome entry site (IRES) typically facilitates direct internal ribosome entry to the start codon (e.g., ATG) of a cistron (protein-encoding region), thereby resulting in cap-independent translation of the gene. See, e.g., Jackson et al. (1990) Trends Biochem Sci 15(12):477-83, and Jackson and Kaminski. (1995) RNA 1(10):985-1000. In certain embodiments, a vector contains one or more exogenous genes encoding one or more exogenous agents. In certain embodiments, to achieve efficient translation of each of multiple exogenous protein agents, polynucleotide sequences can be separated by one or more IRES sequences or polynucleotide sequences encoding self-cleaving polypeptides.
[0341] The retroviral nucleic acids herein may also contain one or more Kozak sequences, e.g., short nucleotide sequences that facilitate initial binding of mRNA to the small ribosomal subunit, increasing translation. The consensus Kozak sequence is (GCC)RCCATGG, where R is a purine (A or G) (Kozak, (1986) Cell. 44(2):283-92, and Kozak, (1987) Nucleic Acids Res. 15(20):8125-48).
[0342] Promoters Responsive to Heterologous Transcription Factors and Inducers In some embodiments, the retroviral nucleic acid comprises elements that allow for conditional expression of the exogenous agent, e.g., any type of conditional expression, including, but not limited to, inducible expression, repressible expression, cell type-specific expression, or tissue-specific expression. In some embodiments, to achieve conditional expression of the exogenous agent, expression is controlled by subjecting the cell, tissue, or organism to a treatment or condition that causes expression of the exogenous agent or that increases or decreases expression of the exogenous agent.
[0343] Examples of inducible promoters / systems include, but are not limited to, steroid-inducible promoters such as promoters of genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormones), metallothionine promoters (inducible by treatment with various heavy metals), MX-1 promoters (inducible by interferon), the "GeneSwitch" mifepristone-regulatable system (Sirin et al., 2003, Gene, 323:67), cumate-inducible gene switches (WO 2002 / 088346), tetracycline-dependent regulatory systems, and the like.
[0344] Expression of a transgene can be activated or repressed by the presence or absence of an inducer molecule. In some cases, the inducer molecule activates or represses gene expression in a stepwise manner, and in other cases, the inducer molecule activates or represses gene expression in an all-or-nothing manner.
[0345] A commonly used inducible promoter / system is the tetracycline (Tet)-regulated system. The Tet system is based on the coexpression of two elements in each target cell: (i) a tetracycline-responsive element containing repeats of the Tet operator sequence (TetO) fused to a minimal promoter and connected to a gene of interest (e.g., a gene encoding an exogenous agent) and (ii) a fusion protein of a transcriptional transactivator (tTA), a Tet repressor (TetR), and the transactivation domain of the VP16 protein from herpes simplex virus. In the first described version, transgene expression was active in the absence of tetracycline or its potent analog, doxycycline (Dox) (referred to as the Tet-OFF system), but modification of four amino acids within the transactivator protein resulted in a reverse tTA (rtTA) that binds to TetO only in the presence of Dox (the Tet-ON system). In some embodiments, the VP16 domain in the transactivator was replaced with a minimal activation domain, potential splice donor and acceptor sites were removed, and the protein was codon-optimized, resulting in an improved transactivator variant, rtTA2S-M2, that is sensitive to Dox and has reduced baseline activity. Furthermore, various Tet-responsive promoter elements have been generated, including modifying the TetO 36 nucleotide interval from the adjacent operator to enhance regulation. Additional modifications may help further reduce basal activity and increase the dynamic range of expression. For example, the pTet-T11 (abbreviated as T1I) variant exhibits a high dynamic range and low background activity.
[0346] Conditional expression can also be achieved by using site-specific DNA recombinases. According to certain embodiments, the retroviral nucleic acid contains at least one (typically two) site(s) for recombination mediated by a site-specific recombinase, e.g., one or more recombination sites (e.g., 2, 3, 4, 5, 7, 10, 12, 15, 20, 30, 50, etc.) which may be wild-type proteins (see Landy, Current Opinion in Biotechnology 3:699-707 (1993)), or excision or integration proteins, enzymes, cofactors, or related proteins involved in recombination reactions, including mutants, derivatives (e.g., fusion proteins comprising the recombination protein sequence or fragments thereof), fragments, and variants thereof. Examples of recombinases include, but are not limited to, Cre, Int, IHF, Xis, Flp, Fis, Hin, Gin, ΦC31, Cin, Tn3 resolvase, TndX, XerC, XerD, TnpX, Hjc, Gin, SpCCE1, and ParA.
[0347] Riboswitches that regulate the expression of exogenous agents Some of the compositions and methods provided herein include one or more riboswitches or polynucleotides containing one or more riboswitches. Riboswitches are a common feature in bacteria that regulate gene expression and provide a means for RNA control of biological functions. Riboswitches can reside in the 5' untranslated region of mRNA and can enable regulatory control of gene expression through the binding of small molecule ligands that induce or inhibit riboswitch activity. In some embodiments, riboswitches control gene products involved in the production of small molecule ligands. Riboswitches typically operate in cis, although riboswitches that operate in trans have been identified. Natural riboswitches are composed of two domains: an aptamer domain that binds to a ligand through a three-dimensional folded RNA structure, and a function switching domain that induces or inhibits riboswitch activity based on the presence or absence of a ligand. Thus, there are two ligand-sensitive conformations that can be achieved by a riboswitch, representing an on state and an off state (Garst et al., 2011). Function switching domains can affect polynucleotide expression by regulating internal ribosome entry sites, pre-mRNA splice donor accessibility in retroviral gene constructs, translation, transcription termination, transcript degradation, miRNA expression, or shRNA expression (Dambach and Winkler 2009). Aptamers and function switching domains can be used as modular components, enabling synthetic RNA devices to control gene expression as native aptamers, mutated / evolved native aptamers, or fully synthetic aptamers identified from screening random RNA libraries (McKeague et al. 2016).
[0348] The purine riboswitch family is one of the largest families, with over 500 sequences identified (Mandal et al., 2003; U.S. Patent Application Publication No. 20080269258; and WO2006055351). Purine riboswitches share a similar architecture consisting of three conserved helical / stem structures (PI, P2, P3) and intervening loop / junction elements (J1-2, L2, J2-3, L3, J3-1). The aptamer domain of the purine family of riboswitches spontaneously changes its affinity / regulation with various purine compounds, including adenine, guanine, adenosine, guanosine, deoxyadenosine, and deoxyguanosine, depending on the sequence (Kim et al., 2007).
[0349] In some embodiments, the retroviral nucleic acid described herein comprises a promoter and a polynucleotide encoding an exogenous agent operably linked to a riboswitch. The riboswitch comprises one or more, for example, all of the following: a.) an aptamer domain, e.g., an aptamer domain capable of binding to a nucleoside analog antiviral drug and exhibiting reduced binding to guanine or 2'-deoxyguanosine compared to the nucleoside analog antiviral drug; b.) a function switching domain, e.g., a function switching domain capable of regulating expression of an exogenous agent, wherein binding of the nucleoside analog by the aptamer domain induces or represses the expression-regulating activity of the function switching domain, thereby regulating expression of the exogenous agent. In some embodiments, the exogenous agent can be a polypeptide, miRNA, or shRNA. For example, in one embodiment, the riboswitch is operably linked to a nucleic acid encoding a chimeric antigen receptor (CAR). In a non-limiting example provided herein, the exogenous gene encodes one or more engineered signaling polypeptides. For example, the target polynucleotide encoding the riboswitch and one or more engineered signaling polynucleotides can be found in the genome of a source cell, a replication-incompetent recombinant retroviral particle, a T cell and / or a NK cell.
[0350] An aptamer domain, for example, can be used as a modular component and combined with any of the function switching domains to affect RNA transcripts. In any of the embodiments disclosed herein, the riboswitch can affect RNA transcripts by regulating any of the following activities: internal ribosome entry site (IRES), pre-mRNA splice donor accessibility, translation, transcription termination, transcript degradation, miRNA expression, or shRNA expression. In some embodiments, the function switching domain can control the binding of an anti-IRES to an IRES (see, e.g., Ogawa, RNA (2011), 17:478-488, the disclosure of which is incorporated herein by reference in its entirety). In any of the embodiments disclosed herein, the presence or absence of a small molecule ligand allows the riboswitch to affect RNA transcripts. In some embodiments, the riboswitch can include a ribozyme. A riboswitch with a ribozyme can inhibit or enhance transcript degradation of a target polynucleotide in the presence of a small molecule ligand. In some embodiments, the ribozyme can be of the pistol class of ribozymes, the hammerhead class of ribozymes, the twist class of ribozymes, the hatchet class of ribozymes, or HDV (hepatitis delta virus).
[0351] Non-target cell-specific regulatory elements In some embodiments, the non-target cell-specific regulatory element or negative TCSSE comprises a tissue-specific miRNA recognition sequence, a tissue-specific protease recognition site, a tissue-specific ubiquitin ligase site, a tissue-specific transcriptional repression site, or a tissue-specific epigenetic repression site.
[0352] In some embodiments, non-target cells contain endogenous miRNA. Retroviral nucleic acid (e.g., a gene encoding an exogenous agent) may contain a recognition sequence for the miRNA. Thus, when the retroviral nucleic acid enters non-target cells, the miRNA may downregulate the expression of the exogenous agent. This helps to increase the specificity between target cells and non-target cells.
[0353] In some embodiments, miRNAs are small, 20-22 nucleotide non-coding RNAs that are typically excised from approximately 70 nucleotide foldback RNA precursor structures known as pre-miRNAs. Generally, miRNAs negatively regulate targets in one of two ways, depending on the degree of complementarity between the miRNA and the target. First, miRNAs that bind to protein-coding mRNA sequences with perfect or near-perfect complementarity typically induce the RNA-mediated interference (RNAi) pathway. MiRNAs that exert their regulatory effects by binding to imperfectly complementary sites within the 3' untranslated region (UTR) of mRNA targets typically repress target gene expression post-transcriptionally, apparently at the translational level, via a RISC complex similar to, or perhaps the same as, that used in the RNAi pathway. Consistent with translational control, miRNAs using this mechanism reduce the protein levels of target genes, while the mRNA levels of these genes are minimally affected. MiRNAs (e.g., naturally occurring miRNAs or artificially designed miRNAs) can specifically target any mRNA sequence. For example, in one embodiment, one skilled in the art can design a short hairpin RNA construct that is expressed as a human miRNA (e.g., miR-30 or miR-21) primary transcript. This design adds a Drosha processing site to the hairpin structure and has been shown to significantly improve knockdown efficiency (Pusch et al., 2004). The hairpin stem consists of a 22-nt dsRNA (e.g., antisense, perfectly complementary to the target of interest) and a 15-19 nt loop derived from a human miR. Adding the miR loop and miR30 flanking sequences to one or both sides of the hairpin increases Drosha and Dicer processing of the expressed hairpin by more than 10-fold compared to traditional shRNA designs that do not use microRNAs. Increased Drosha and Dicer processing increases siRNA / miRNA production and enhances the efficacy of the expressed hairpin.
[0354] Hundreds of different miRNA genes are differentially expressed during development and between tissue types. Several studies have suggested important regulatory roles for miRNAs in a wide range of biological processes, including developmental timing, cell differentiation, proliferation, apoptosis, carcinogenesis, insulin secretion, and cholesterol biosynthesis. (See Bartel 2004 Cell 116:281-97; Ambros 2004 Nature 431:350-55; Du et al. 2005 Development 132:4645-52; Chen 2005 N. Engl. J. Med. 353:1768-71; Krutzfeldt et al. 2005 Nature 438:685-89.) Molecular analyses have shown that miRNAs have distinct expression profiles in different tissues. Computational methods were used to analyze the expression of approximately 7,000 predicted human miRNA targets. Data suggest that miRNA expression contributes broadly to the tissue specificity of mRNA expression in many human tissues. (See Sood et al. 2006 PNAS USA 103(8):2746-51)
[0355] Thus, miRNA-based approaches can be used to restrict the expression of exogenous agents to target cell populations by using endogenous microRNA species to silence expression of the exogenous agents in non-target cell types. MicroRNAs induce sequence-specific post-transcriptional gene silencing in many organisms by inhibiting messenger RNA (mRNA) translation or causing mRNA degradation. See, e.g., Brown et al. 2006 Nature Med. 12(5):585-91. and WO 2007 / 000668, each of which is incorporated herein by reference in its entirety. In some embodiments, the retroviral nucleic acid comprises one or more (e.g., multiple) tissue-specific miRNA recognition sequences. In some embodiments, the tissue-specific miRNA recognition sequences are approximately 20-25, 21-24, or 23 nucleotides in length. In embodiments, the tissue-specific miRNA recognition sequences have perfect complementarity to miRNAs present in non-target cells. In some embodiments, the exogenous agent does not include GFP, e.g., does not include a fluorescent protein, e.g., does not include a reporter protein. In some embodiments, the off-target cells are not hematopoietic cells and / or the miRNA is not present in hematopoietic cells.
[0356] In some embodiments, methods described herein include tissue-specific expression of an exogenous agent in a target cell, comprising contacting a plurality of retroviral vectors comprising nucleotides encoding the exogenous agent and at least one tissue-specific microRNA (miRNA) with a plurality of cells, including target cells and non-target cells, wherein the exogenous agent is preferentially, e.g., restricted to, expression in the target cell.
[0357] For example, the retroviral nucleic acid can contain at least one miRNA recognition sequence operably linked to a nucleotide sequence bearing a corresponding miRNA in non-target cells, e.g., hematopoietic progenitor cells (HSPCs) and hematopoietic stem cells (HSCs), which prevents or reduces expression of the nucleotide sequence in the non-target cells but does not prevent or reduce expression in target cells, e.g., differentiated cells. In some embodiments, the retroviral nucleic acid contains at least one miRNA sequence targeting an miRNA that is present in an effective amount in the non-target cells (e.g., the concentration of the endogenous miRNA is sufficient to reduce or prevent expression of the transgene) and also contains the transgene. In embodiments, the miRNA used in this system is strongly expressed in non-target cells, such as HSPCs and HSCs, but not in differentiated progeny, e.g., of the myeloid and lymphoid lineages, preventing or reducing expression of the transgene in susceptible stem cell populations while maintaining expression and therapeutic effect in target cells.
[0358] In some embodiments, the negative TSCRE or NTSCRE comprises an miRNA recognition site, e.g., an miRNA recognition site bound by an miRNA endogenous to hematopoietic cells. Exemplary miRNAs are provided in Table 4. In some embodiments, the nucleic acid (e.g., a fusomal nucleic acid or a retroviral nucleic acid) comprises a sequence complementary to or having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% complementarity to an miRNA in Table 4. In some embodiments, the nucleic acid (e.g., a fusomal nucleic acid or a retroviral nucleic acid) comprises a sequence that is fully complementary to a seed sequence within an endogenous miRNA, e.g., an miRNA in Table 4. In embodiments, the seed sequence is at least 6, 7, 8, 9, or 10 nucleotides in length.
[0359] In some embodiments, the nucleic acid (e.g., a fusomal or retroviral nucleic acid) comprises a sequence complementary to, or at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% complementary to, an miRNA set forth in any one of SEQ ID NOs: 143-160. In some embodiments, the nucleic acid (e.g., a fusomal or retroviral nucleic acid) comprises a sequence fully complementary to a seed sequence within an endogenous miRNA, e.g., an miRNA set forth in any one of SEQ ID NOs: 143-160. In embodiments, the seed sequence is at least 6, 7, 8, 9, or 10 nucleotides in length.
[0360] [Table 4]
[0361] In some embodiments, the negative TSCRE or NTSCRE comprises an miRNA recognition site for a miRNA described herein. Exemplary miRNAs include Griffiths-Jones et al.Nucleic Acids Res.2006 Jan 1,34;Chen and Lodish,Semin Immunol.2005 Apr;17(2):155-65;Chen et al.Science.2004 Jan 2;303(5654):83-6;Barad et al.Genome Res.2004 Dec;14(12):2486-2494;Krichevsky et al.,RNA.2003 Oct;9(10):1274-81;Kasashima et al.Biochem Biophys Res Commun.2004 Sep 17;322(2):403-10;Houbaviy et al.,Dev Cell.2003 Aug;5(2):351-8;Lagos-Quintana et al.,Curr Biol.2002 Apr 30;12(9):735-9; Calin et al., Proc Natl Acad Sci US A. 2004 Mar 2;101(9):2999-3004; Sempere et al. Genome Biol. 2004;5(3):R13; Metzler et al., Genes Chromosomes Cancer. 2004 Feb;39(2):167-9; Calin et al., Proc Natl Acad Sci US A. 2002 Nov 26;99(24):15524-9; Mansfield et al. Nat Genet. 2004 Oct;36(10):1079-83; Michael et al. Mol Cancer Res. 2003 Oct;1(12):882-91; and those found at www.miRNA.org.
[0362] In some embodiments, the negative TSCRE or NTSCRE comprises miRNA recognition sites for miRNAs selected from miR-1b, miR-189b, miR-93, miR-125b, miR-130, miR-32, miR-128, miR-22, miR124a, miR-296, miR-143, miR-15, miR-141, miR-143, miR-16, miR-127, miR99a, miR-183, miR-19b, miR-92, miR-9, miR-130b, miR-21, miR-30b, miR-16, miR-142-s, miR-99a, miR-212, miR-30c, miR-213, miR-20, miR-155, miR-152, miR-139, miR-30b, miR-7, miR-30c, miR-18, miR-137, miR-219, miR-1d, miR-178, miR-24, miR-122a, miR-215, miR-142-a, miR-223, miR-142, miR-124a, miR-190, miR-149, miR-193, miR-181, let-7a, miR-132, miR-27a, miR-9*, miR-200b, miR-266, miR-153, miR-135, miR-206, miR-24, miR-19a, miR-199, miR-26a, miR-194, miR-125a, miR-15a, miR-145, miR-133, miR-96, miR-131, miR-124b, miR-151, miR-7b, miR-103, and miR-208.
[0363] In some embodiments, the nucleic acid (e.g., a fusomal nucleic acid or a retroviral nucleic acid) comprises two or more miRNA recognition sites. In some embodiments, each of the two or more miRNA recognition sites is recognized by any miRNA described herein, such as any of those listed in Table 4. In some embodiments, each of the two or more miRNA recognition sites is recognized by an miRNA set forth in any one of SEQ ID NOS: 143-160. In some embodiments, the two or more miRNA recognition sites can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, or more miRNA recognition sites. Two or more miRNA recognition sites can be arranged in tandem within the nucleic acid to provide multiple tandem binding sites for miRNAs.
[0364] In some embodiments, the two or more miRNA recognition sites can comprise at least one first miRNA recognition site, such as 1, 2, 3, 4, 5, 6, or more first miRNA recognition sites, and at least one second miRNA recognition site, such as 1, 2, 3, 4, 5, 6, or more second miRNA recognition sites. In some embodiments, the nucleic acid comprises two or more first miRNA recognition sites, each of which is present in tandem within the nucleic acid to provide multiple tandem binding sites for the first miRNA, and / or the nucleic acid further comprises two second miRNA recognition sites, each of which is present in tandem within the nucleic acid to provide multiple tandem binding sites for the second miRNA. In some embodiments, the first miRNA recognition site and the second miRNA recognition site are recognized by the same miRNA, and in some embodiments, the first miRNA recognition site and the second miRNA recognition site are recognized by different miRNAs. In some embodiments, the first miRNA recognition site and the second miRNA recognition site are recognized by miRNAs present in the same non-target cell, and in some embodiments, the first miRNA recognition site and the second miRNA recognition site are recognized by miRNAs present in different non-target cells. In some embodiments, one or both of the first miRNA recognition site and the second miRNA recognition site are recognized by any of the miRNAs listed, such as any of the sets listed in Table 4. In some embodiments, one or both of the first miRNA recognition site and the second miRNA recognition site are recognized by the miRNA set forth in any one of SEQ ID NOs: 143-160.
[0365] In some embodiments, one or more miRNA recognition sites on a fusomal nucleic acid (e.g., a retroviral nucleic acid) are transcribed in cis with an exogenous agent. In some embodiments, one or more miRNA recognition sites on a fusomal nucleic acid (e.g., a retroviral nucleic acid) are located downstream of a polyA tail sequence, e.g., between the polyA tail sequence and a WPRE. In some embodiments, one or more miRNA recognition sites on a fusomal nucleic acid (e.g., a retroviral nucleic acid) are located downstream of a WPRE.
[0366] immunomodulation In some embodiments, the retroviral vectors or VLPs described herein comprise elevated CD47. See, e.g., U.S. Patent No. 9,050,269, incorporated herein by reference in its entirety. In some embodiments, the retroviral vectors or VLPs described herein comprise elevated complement regulatory proteins. See, e.g., Spanish Patent No. 2627445 T3 and U.S. Patent No. 6,790,641, each of which is incorporated herein by reference in its entirety. In some embodiments, the retroviral vectors or VLPs described herein lack or comprise reduced levels of an MHC protein, e.g., MHC-1 class 1 or class II. See, e.g., U.S. Patent Application Publication No. 20170165348, incorporated herein by reference in its entirety.
[0367] Retroviral vectors or VLPs may be recognized by the subject's immune system. In the case of enveloped viral vector particles (e.g., retroviral vector particles), membrane-associated proteins displayed on the surface of the viral envelope may be recognized, and the viral particles themselves may be neutralized. Furthermore, upon infection of target cells, the viral envelope may be integrated with the cell membrane, resulting in viral envelope proteins being displayed on the surface of the cell or remaining closely associated with the surface of the cell. Therefore, the immune system may also target cells infected with viral vector particles. Both effects may lead to a decrease in the effectiveness of exogenous agent delivery by viral vectors.
[0368] The viral particle envelope is usually derived from the membrane of the source cell, and therefore membrane proteins expressed in the cell membrane from which the viral particle buds can be incorporated into the viral envelope.
[0369] immunoregulatory protein CD47 The internalization of extracellular material into cells is generally carried out by a process called endocytosis (Rabinovitch, 1995, Trends Cell Biol. 5(3):85-7; Silverstein, 1995, Trends Cell Biol. 5(3):141-2; Swanson et al., 1995, Trends Cell Biol. 5(3):89-93; Allen et al., 1996, J. Exp. Med. 184(2):627-37). Endocytosis is divided into two general categories: phagocytosis, which involves the uptake of particles, and pinocytosis, which involves the uptake of fluids and solutes.
[0370] Based on studies using knockout mice lacking the membrane receptor CD47, professional phagocytes have been shown to distinguish between self and non-self (Oldenborg et al., 2000, Science 288(5473):2051-4). CD47 is a ubiquitous member of the Ig superfamily that interacts with the immunosuppressive receptor SIRP alpha (signal-regulatory receptor protein alpha) found on macrophages (Fujioka et al., 1996, Mol. Cell. Biol. 16(12):6887-99; Veillette et al., 1998, J. Biol. Chem. 273(35):22719-28; Jiang et al., 1999, J. Biol. Chem. 274(2):559-62). Although CD47-SIRPα interactions appear to inactivate autologous macrophages in mice, a severe reduction in CD47 (perhaps 90%) is seen on human blood cells derived from several Rh genotypes that show little or no evidence of anemia (Mouro-Chanteloup et al., 2003, Blood 101(1):338-344) and little or no evidence of enhanced cellular interactions with phagocytic monocytes (Arndt et al., 2004, Br. J. Haematol. 125(3):412-4).
[0371] In some embodiments, the retroviral vector or VLP (e.g., a viral particle having a radius of less than about 1 μm, less than about 400 nm, or less than about 150 nm) comprises at least a biologically active portion of CD47, e.g., on an exposed surface of the retroviral vector or VLP. In some embodiments, the retroviral vector (e.g., a lentivirus) or VLP comprises a lipid coat. In embodiments, the amount of biologically active CD47 in the retroviral vector or VLP is about 20-250, 20-50, 50-100, 100-150, 150-200, or 200-250 molecules / μm 2 In some embodiments, the CD47 is human CD47.
[0372] The methods described herein can include avoiding phagocytosis of particles by phagocytes. The methods can include expressing at least one peptide comprising at least a biologically active portion of CD47 in a retroviral vector or VLP such that the retroviral vector or VLP comprising CD47 is exposed to a phagocyte and the viral particle avoids phagocytosis by the phagocyte or exhibits reduced phagocytosis compared to an otherwise similar, unmodified retroviral vector or VLP. In some embodiments, the half-life of the retroviral vector or VLP in a subject is extended compared to an unmodified retroviral vector or VLP.
[0373] MHC deletion Major histocompatibility complex class I (MHC-I) is a host cell membrane protein that can be incorporated into the viral envelope. Because it is highly polymorphic in nature, it is a major target of the body's immune response (McDevitt HO (2000) Annu. Rev. Immunol. 18:1-17). MHC-I molecules exposed on the plasma membrane of source cells may be incorporated into viral particle envelopes during vector budding. These MHC-I molecules, derived from source cells and incorporated into viral particles, can then be transferred to the plasma membrane of target cells. Alternatively, MHC-I molecules may remain closely associated with the target cell membrane as a result of the tendency of viral particles to absorb and remain bound to the target cell membrane.
[0374] The presence of exogenous MHC-I molecules on or near the plasma membrane of transduced cells can elicit an alloreactive immune response in a subject. This can lead to immune-mediated killing or phagocytosis of the transduced cells, either through ex vivo gene transfer followed by administration of the transduced cells to a subject, or through direct in vivo administration of viral particles. Furthermore, when MHC-I bearing viral particles are administered in vivo into the bloodstream, the viral particles can be neutralized by pre-existing MHC-I-specific antibodies before reaching their target cells.
[0375] Thus, in some embodiments, the source cells are modified (e.g., genetically engineered) to reduce MHC-I expression on the cell surface. In embodiments, the source comprises a genetically engineered disruption of the gene encoding β2-microglobulin (β2M). In embodiments, the source cells comprise a genetically engineered disruption of one or more genes encoding the MHC-I α chain. The cells may comprise a genetically engineered disruption of all copies of the gene encoding β2-microglobulin. The cells may comprise a genetically engineered disruption of all copies of the gene encoding the MHC-I α chain. The cells may comprise both a genetically engineered disruption of the gene encoding β2-microglobulin and a genetically engineered disruption of the gene encoding the MHC-I α chain. In some embodiments, the retroviral vector or VLP comprises a reduced number of surface-exposed MHC-I molecules. The number of surface-exposed MHC-I molecules can be reduced so that the immune response to MHC-I is reduced to a therapeutically relevant extent. In some embodiments, the enveloped viral vector particles are substantially devoid of surface-exposed MHC-I molecules.
[0376] HLA-G / E overexpression In some embodiments, the retroviral vector or VLP displays on its envelope a tolerogenic protein, e.g., an ILT-2 or ILT-4 agonist, e.g., HLA-E or HLA-G, or any other ILT-2 or ILT-4 agonist. In some embodiments, the retroviral vector or VLP has increased expression of HLA-E, HLA-G, ILT-2, or ILT-4 compared to a reference retrovirus, e.g., an unmodified retrovirus that is otherwise similar to the retrovirus.
[0377] In some embodiments, the retroviral composition has reduced MHC class I compared to unmodified retrovirus and increased HLA-G compared to unmodified retrovirus.
[0378] In some embodiments, the retroviral vector or VLP results in increased expression of HLA-G or HLA-E, e.g., an increase in HLA-G or HLA-E expression of 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to a reference cellular retrovirus, e.g., an unmodified retrovirus that is otherwise similar to the retrovirus, wherein HLA-G or HLA-E expression is assayed in vitro using flow cytometry, e.g., FACS.
[0379] In some embodiments, retroviruses with increased HLA-G expression exhibit reduced immunogenicity, as measured by reduced immune cell infiltration, for example, in a teratoma formation assay.
[0380] Complement regulatory proteins Complement activity is normally controlled by several complement regulatory proteins (CRPs). These proteins prevent pseudoinflammation and host tissue damage. One group of proteins, including CD55 / decay-accelerating factor (DAF) and CD46 / membrane cofactor protein (MCP), inhibits the C3 / C5 convertases of the classical and alternative pathways. Another set of proteins, including CD59, regulates MAC assembly. CRPs have been used to prevent rejection of xenotransplant tissues and have also been shown to protect viruses and viral vectors from complement inactivation.
[0381] Membrane-located complement regulators include, for example, decay-accelerating factor (DAF) or CD55, factor H (FH)-like protein-1 (FHL-1), C4b-binding protein (C4BP), complement receptor 1 (CD35), membrane cofactor protein (MCP) or CD46, and CD59 (protectin) (e.g., to prevent formation of the membrane attack complex (MAC) and protect cells from lysis).
[0382] Albumin-binding proteins In some embodiments, the lentivirus binds to albumin. In some embodiments, the lentivirus comprises a protein on its surface that binds to albumin. In some embodiments, the lentivirus comprises an albumin binding protein on its surface. In some embodiments, the albumin binding protein is a streptococcal albumin binding protein. In some embodiments, the albumin binding protein is a streptococcal albumin binding domain.
[0383] Expression of non-fusogenic proteins in lentiviral envelopes In some embodiments, the lentivirus is engineered to include one or more proteins on its surface. In some embodiments, the protein affects immune interactions with a subject. In some embodiments, the protein affects the pharmacology of the lentivirus in a subject. In some embodiments, the protein is a receptor. In some embodiments, the protein is an agonist. In some embodiments, the protein is a signaling molecule. In some embodiments, the protein on the lentivirus surface includes an anti-CD3 antibody, e.g., OKT3, or IL7.
[0384] In some embodiments, the mitogenic transmembrane protein and / or cytokine-based transmembrane protein is present in the source cell and can be incorporated into the retrovirus as it buds from the source cell membrane. The mitogenic transmembrane protein and / or cytokine-based transmembrane protein can be expressed as a separate cell surface molecule on the source cell, rather than as part of the viral envelope glycoprotein.
[0385] In some embodiments of any of the aspects described herein, the retroviral vector, VLP, or pharmaceutical composition is substantially non-immunogenic. Immunogenicity can be quantified, for example, as described herein.
[0386] In some embodiments, the retroviral vector or VLP fuses with a target cell to produce a recipient cell. In some embodiments, recipient cells fused to one or more retroviral vectors or VLPs are assessed for immunogenicity. In embodiments, recipient cells are analyzed for the presence of antibodies on the cell surface, for example, by staining with an anti-IgM antibody. In other embodiments, immunogenicity is assessed by a PBMC cytolytic assay. In embodiments, recipient cells are incubated with peripheral blood mononuclear cells (PBMCs) and then assessed for lysis of the cells by the PBMCs. In other embodiments, immunogenicity is assessed by a natural killer (NK) cytolytic assay. In embodiments, recipient cells are incubated with NK cells and then assessed for lysis of the cells by the NK cells. In other embodiments, immunogenicity is assessed by a CD8+ T cell lytic assay. In embodiments, recipient cells are incubated with CD8+ T cells and then assessed for lysis of the cells by the CD8+ T cells.
[0387] In some embodiments, the retroviral vector or VLP comprises an elevated level of an immunosuppressant (e.g., an immunosuppressant protein) compared to that produced from a reference retroviral vector or VLP, e.g., an unmodified source cell otherwise similar to the source cell, or HEK293 cells. In some embodiments, the elevated level is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold. In some embodiments, the retroviral vector or VLP comprises an immunosuppressant that is not present in the reference cell. In some embodiments, the retroviral vector or VLP comprises a decreased level of an immunostimulatory substance (e.g., an immunostimulatory protein) compared to that produced from a reference retroviral vector or VLP, e.g., an unmodified source cell otherwise similar to the source cell, or HEK293 cells. In some embodiments, the reduced level is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% compared to a reference retroviral vector or VLP, hi some embodiments, the immunostimulatory agent is substantially absent from the retroviral vector or VLP.
[0388] In some embodiments, the retroviral vector or VLP, or the source cell from which the retroviral vector or VLP is derived, has one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or more of the following characteristics: a. less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less expression of MHC class I or MHC class II compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from an otherwise similar source cell, HeLa cell, or HEK293 cell; b. expression of one or more costimulatory proteins, including but not limited to, LAG3, ICOS-L, ICOS, Ox40L, OX40, CD28, B7, CD30, CD30L4-1BB, 4-1BBL, SLAM, CD27, CD70, HVEM, LIGHT, B7-H3, or B7-H4, less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less, compared to a reference retroviral vector or VLP, such as an unmodified retroviral vector, or a VLP derived from a cell that is otherwise similar to the source cell, or a HEK cell, or a reference cell described herein; c. expression of a surface protein, e.g., CD47, that inhibits macrophage phagocytosis, e.g., expression detectable by a method described herein, e.g., expression of a surface protein, e.g., CD47, that inhibits macrophage phagocytosis by more than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more, compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from an otherwise similar cell to the source cell, such as a Jurkat cell or HEK293 cell; d. expression of a soluble immunosuppressive cytokine, e.g., IL-10, e.g., expression detectable by a method described herein, e.g., greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more, expression of a soluble immunosuppressive cytokine, e.g., IL-10, compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from an otherwise similar source cell or HEK293 cell; e. expression of a soluble immunosuppressive protein, e.g., PD-L1, e.g., expression detectable by a method described herein, e.g., greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more, expression of a soluble immunosuppressive protein, e.g., PD-L1, compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from an otherwise similar source cell or HEK293 cell; f. expression of soluble immunostimulatory cytokines, e.g., IFN-gamma or TNF-α, of less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, or HEK293 cells, or U-266 cells; g. expression of endogenous immunostimulatory antigens, such as Zg16 or Hormad1, of less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less compared to a reference retroviral vector or VLP, such as an unmodified retroviral vector or a VLP derived from cells otherwise similar to the source cells, or HEK293 cells, or A549 cells, or SK-BR-3 cells; h. HLA-E or HLA-G expression, as compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, or HEK293 cells, or Jurkat cells, as detectable, e.g., by methods described herein; i. a surface glycosylation profile, including, for example, sialic acid, which acts to suppress NK cell activation; j. TCR α / β expression is less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or Jurkat cells; k. less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% expression of ABO blood groups compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, such as HEK293 cells or HeLa cells; l. expression of minor histocompatibility antigens (MHAs) of less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or Jurkat cells; or m. Has less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less, or no detectable mitochondrial MHA compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or Jurkat cells.
[0389] In embodiments, the costimulatory protein is 4-1BB, B7, SLAM, LAG3, HVEM, or LIGHT, and the reference cells are HDLM-2. In some embodiments, the costimulatory protein is BY-H3, and the reference cells are HeLa. In some embodiments, the costimulatory protein is ICOSL or B7-H4, and the reference cells are SK-BR-3. In some embodiments, the costimulatory protein is ICOS or OX40, and the reference cells are MOLT-4. In some embodiments, the costimulatory protein is CD28, and the reference cells are U-266. In some embodiments, the costimulatory protein is CD30L or CD27, and the reference cells are Daudi.
[0390] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition does not substantially elicit an immunogenic response by the immune system, e.g., the innate immune system. In embodiments, the immunogenic response can be quantified, e.g., as described herein. In some embodiments, the immunogenic response by the innate immune system includes a response by innate immune cells, including, but not limited to, NK cells, macrophages, neutrophils, basophils, eosinophils, dendritic cells, mast cells, or gamma / delta T cells. In some embodiments, the immunogenic response by the innate immune system includes a response by the complement system, including soluble blood components and membrane-bound components.
[0391] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition does not substantially elicit an immunogenic response by the immune system, e.g., the adaptive immune system. In some embodiments, an immunogenic response by the adaptive immune system includes an immunogenic response by adaptive immune cells, including, but not limited to, a change, e.g., an increase, in the number or activity of T lymphocytes (e.g., CD4 T cells, CD8 T cells, and / or gamma delta T cells) or B lymphocytes. In some embodiments, an immunogenic response by the adaptive immune system includes, but is not limited to, an increase in the level of a soluble blood component, including, but not limited to, a change, e.g., an increase, in the number or activity of cytokines or antibodies (e.g., IgG, IgM, IgE, IgA, or IgD).
[0392] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition is modified to reduce its immunogenicity, ie, the retroviral vector, VLP, or pharmaceutical composition has an immunogenicity that is less than 5%, 10%, 20%, 30%, 40%, or 50% less than that of a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, HEK293 cells, or Jurkat cells.
[0393] In some embodiments of any of the aspects described herein, the retroviral vector, VLP, or pharmaceutical composition is derived from a source cell, a mammalian cell, having an altered genome, e.g., modified to reduce immunogenicity, e.g., using the methods described herein. Immunogenicity can be quantified, e.g., as described herein.
[0394] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition is derived from depleted mammalian cells with, for example, one, two, three, four, five, six, seven, or more knockouts of the following: a. MHC class I, MHC class II or MHA; b. one or more costimulatory proteins, including but not limited to LAG3, ICOS-L, ICOS, Ox40L, OX40, CD28, B7, CD30, CD30L 4-1BB, 4-1BBL, SLAM, CD27, CD70, HVEM, LIGHT, B7-H3, or B7-H4; c. a soluble immune stimulating cytokine, e.g., IFN-γ or TNF-α; d. endogenous immune stimulatory antigens, such as Zg16 or Hormad1; e. T cell receptor (TCR); f. ABO blood group coding genes, e.g., ABO genes; g. Transcription factors that promote immune activation, such as NFkB; h. Transcription factors that regulate MHC expression, such as class II transactivator (CIITA), regulator of Xbox 5 (RFX5), RFX-associated protein (RFXAP), or RFX ankyrin repeat (RFXANK; also known as RFXB); or i. TAP proteins (TAP2, TAP1, TAPBP, etc.) that reduce MHC class I expression.
[0395] In some embodiments, the retroviral vector or VLP is derived from a source cell with a genetic modification that results in increased expression of an immunosuppressive agent, e.g., one, two, three, or more of the following (e.g., prior to the genetic modification, the cell did not express the agent): a. a surface protein that inhibits macrophage phagocytosis, e.g., CD47; increased expression of CD47 compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, such as HEK293 cells or Jurkat cells; b. increased expression of a soluble immunosuppressive cytokine, e.g., IL-10, compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, such as HEK293 cells or Jurkat cells; c. a soluble immunosuppressive protein, e.g., PD-1, PD-L1, CTLA4, or BTLA; increased expression of the immunosuppressive protein compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or Jurkat cells; d. increased expression of a tolerogenic protein, e.g., an ILT-2 or ILT-4 agonist, e.g., HLA-E or HLA-G or other endogenous ILT-2 or ILT-4 agonist, e.g., HLA-E, HLA-G, ILT-2 or ILT-4, compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or Jurkat cells; or e. Surface proteins that inhibit complement activity, e.g., complement regulatory proteins, e.g., proteins that bind decay accelerating factor (DAF, CD55), e.g., factor H (FH)-like protein-1 (FHL-1), e.g., C4b binding protein (C4BP), e.g., complement receptor 1 (CD35), e.g., membrane complement proteins (MCP, CD46), e.g., profectin (CD59), e.g., proteins that inhibit classical and alternative complement pathway CD / C5 convertase enzymes, e.g., proteins that regulate MAC assembly; e.g., increased expression of a complement regulatory protein compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, e.g., HEK293 cells or Jurkat cells.
[0396] In some embodiments, the increase in expression level is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold or more compared to a reference retroviral vector or VLP.
[0397] In some embodiments, the retroviral vector or VLP is derived from a source cell that has been modified to reduce expression of an immunostimulatory substance, for example, one, two, three, four, five, six, seven, eight, or more of the following: a. less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less expression of MHC class I or MHC class II compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or HeLa cells; b. expression of one or more costimulatory proteins, including but not limited to, LAG3, ICOS-L, ICOS, Ox40L, OX40, CD28, B7, CD30, CD30L 4-1BB, 4-1BBL, SLAM, CD27, CD70, HVEM, LIGHT, B7-H3, or B7-H4, less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less, compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell otherwise similar to the source cell, HEK293 cell, or a reference cell described herein; c. expression of soluble immunostimulatory cytokines, such as IFN-gamma or TNF-α, of less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% compared to a reference retroviral vector or VLP, such as an unmodified retroviral vector or a VLP derived from cells otherwise similar to the source cells, HEK293 cells, or U-266 cells; d. expression of an endogenous immunostimulatory antigen, e.g., Zg16 or Hormad1, of less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% or less compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from cells otherwise similar to the source cells, HEK293 cells, or A549 cells or SK-BR-3 cells; e. T cell receptor (TCR) expression is less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from cells otherwise similar to the source cell, HEK293 cells, or Jurkat cells; f. less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% expression of ABO blood groups compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, such as HEK293 cells or HeLa cells; g. expression of a transcription factor that drives immune activation, e.g., NFkB, of less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, e.g., HEK293 cells or Jurkat cells; h. expression of transcription factors regulating MHC expression, e.g., class II transactivator of myocardium (CIITA), regulator of Xbox 5 (RFX5), RFX-related protein (RFXAP), or RFX ankyrin repeats (RFXANK; also known as RFXB), is less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cell, such as HEK293 cells or Jurkat cells; i. expression of a TAP protein, e.g., TAP2, TAP1, or TAPBP, that reduces MHC class I expression by less than 50%, 40%, 30%, 20%, 15%, 10%, or 5% compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector, or a VLP derived from cells otherwise similar to the source cells, such as HEK293 cells or HeLa cells; In some embodiments, a retroviral vector, VLP, or pharmaceutical composition derived from a mammalian cell, e.g., HEK293, that has been modified using an shRNA-expressing lentivirus to reduce MHC class I expression, expresses less MHC class I than an unmodified retroviral vector or VLP, e.g., a retroviral vector or VLP derived from an unmodified cell (e.g., a mesenchymal stem cell). In some embodiments, a retroviral vector or VLP derived from a mammalian cell, e.g., HEK293, that has been modified using an HLA-G-expressing lentivirus to increase HLA-G expression, e.g., has increased HLA-G expression compared to an unmodified retroviral vector or VLP derived from an unmodified cell (e.g., HEK293).
[0398] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition is derived from a source cell, e.g., a mammalian cell, that is substantially non-immunogenic, and the source cell stimulates, e.g., induces, T cell IFN-gamma secretion at levels of 0 pg / mL to greater than 0 pg / mL when assayed in vitro by an IFN-gamma ELISPOT assay.
[0399] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition is derived from a source cell, e.g., a mammalian cell, derived from a cell culture treated with an immunosuppressant, e.g., a glucocorticoid (e.g., dexamethasone), a cytostatic (e.g., methotrexate), an antibody (e.g., muromonab-CD3), or an immunophilin modulator (e.g., cyclosporine or rapamycin).
[0400] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition is derived from a source cell, eg, a mammalian cell, and the mammalian cell comprises an exogenous agent, eg, a therapeutic agent.
[0401] In some embodiments, the retroviral vector, VLP, or pharmaceutical composition is derived from a source cell, eg, a mammalian cell, and the mammalian cell is a recombinant cell.
[0402] In some embodiments, the retroviral vector, VLP, or medicament is derived from mammalian cells genetically modified to express a viral immunoevasin, such as hCMV US2 or US11.
[0403] In some embodiments, the surface of the retroviral vector or VLP, or the surface of the source cell, is covalently or non-covalently modified with a polymer, e.g., a biocompatible polymer that reduces immunogenicity and immune-mediated clearance, such as PEG.
[0404] In some embodiments, the surface of the retroviral vector or VLP, or the surface of the source cell, is covalently or non-covalently modified with sialic acid, for example, a sialic acid containing sugar polymer that includes an NK inhibitory glycan epitope.
[0405] In some embodiments, the surface of the retroviral vector or VLP, or the surface of the source cell, is enzymatically treated, for example with a glycosidase enzyme, such as α-N-acetylgalactosaminidase, to remove ABO blood groups.
[0406] In some embodiments, the surface of the retroviral vector or VLP, or the surface of the source cell, is enzymatically treated to cause, eg, induce, expression of an ABO blood type that matches the blood type of the recipient.
[0407] Parameters for assessing immunogenicity In some embodiments, the retroviral vector or VLP is derived from a source cell, e.g., a mammalian cell, that has been modified, e.g., modified using the methods described herein, to be substantially non-immunogenic or have reduced immunogenicity. The immunogenicity of the source cell and retroviral vector or VLP can be determined by any of the assays described herein.
[0408] In some embodiments, the retroviral vector or VLP has an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more increase, in in vivo graft survival compared to a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from cells that are otherwise similar to the source cell.
[0409] In some embodiments, the retroviral vectors or VLPs have reduced immunogenicity as measured by a reduced humoral response following one or more implantations of the retroviral vector or VLP into a suitable animal model, e.g., an animal model described herein, compared to the humoral response following one or more implantations of a reference retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell otherwise similar to the source cell, into a suitable animal model, e.g., an animal model described herein. In some embodiments, the reduced humoral response is measured by anti-cellular antibody titers, e.g., anti-retroviral or anti-VLP antibody titers, e.g., by ELISA, in serum samples. In some embodiments, serum samples from animals administered the retroviral vector or VLP have a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater reduction in anti-viral or anti-VLP antibody titers compared to serum samples from animals administered the native retroviral vector or VLP. In some embodiments, serum samples from animals administered retroviral vectors or VLPs have anti-retroviral or anti-VLP antibody titers that are increased, e.g., by 1%, 2%, 5%, 10%, 20%, 30%, or 40% from baseline, e.g., baseline refers to a serum sample from the same animal prior to administration of the retroviral vector or VLP.
[0410] In some embodiments, the retroviral vector or VLP has a phagocytic index of 0, 1, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90% or more, as determined by assaying an in vitro phagocytic index as described in Example 8, when incubated with macrophages in an in vitro assay of macrophage phagocytosis, e.g., as measured by the assay of Example 8. In some embodiments, the retroviral vector or VLP has a phagocytic index of 0, 1, 10, 100, or more, as determined by the assay of Example 8, as determined by the assay of Example 8, as determined by the assay of Example 8, when incubated with macrophages in an in vitro assay of macrophage phagocytosis.
[0411] In some embodiments, the source cells or recipient cells have reduced cytotoxicity-mediated cytolysis by PBMCs, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in cytotoxicity-mediated cytolysis compared to reference cells, e.g., unmodified cells otherwise similar to the source cells, or recipient cells that have received an unmodified retroviral vector or VLP, or mesenchymal stem cells, using the assay of Example 17. In embodiments, the source cells express exogenous HLA-G.
[0412] In some embodiments, the source cells or recipient cells have reduced NK-mediated cytolysis, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in NK-mediated cytolysis compared to a reference cell, e.g., an unmodified cell otherwise similar to the source cell, or a recipient cell that has received an unmodified retroviral vector or VLP, wherein the NK-mediated cytolysis is assayed in vitro by a chromium release assay or a europium release assay, e.g., using the assay of Example 18.
[0413] In some embodiments, the source cells or recipient cells have a reduction in CD8+ T cell-mediated cytolysis, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in CD8 T cell-mediated cytolysis compared to a reference cell, e.g., an unmodified cell otherwise similar to the source cell, or a recipient cell that has received an unmodified retroviral vector or VLP, wherein CD8 T cell-mediated cytolysis is assayed in vitro using Example 19.
[0414] In some embodiments, the source cells or recipient cells have reduced CD4+ T cell proliferation and / or activation, e.g., by 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to reference cells, e.g., unmodified cells otherwise similar to the source cells, or recipient cells that have received an unmodified retroviral vector or VLP, where CD4 T cell proliferation is assayed in vitro (e.g., a co-culture assay of modified or native mammalian source cells and CD4+ T cells with CD3 / CD28 Dynabeads).
[0415] In some embodiments, the retroviral vector or VLP causes a decrease in T cell IFN-gamma secretion, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more decrease in T cell IFN-gamma secretion, compared to a reference cell retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell that is otherwise similar to the source cell, where T cell IFN-gamma secretion is assayed in vitro, e.g., by IFN-gamma ELISPOT.
[0416] In some embodiments, the retroviral vector or VLP causes a reduction in immunogenic cytokine secretion, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in immunogenic cytokine secretion, compared to a reference cellular retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell that is otherwise similar to the source cell, where immunogenic cytokine secretion is assayed in vitro using ELISA or ELISPOT.
[0417] In some embodiments, the retroviral vector or VLP results in an increase in immunosuppressive cytokine secretion, e.g., an increase of 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to a reference cellular retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell that is otherwise similar to the source cell, where immunosuppressive cytokine secretion is assayed in vitro using ELISA or ELISPOT.
[0418] In some embodiments, the retroviral vector or VLP results in increased expression of HLA-G or HLA-E, e.g., an increase in HLA-G or HLA-E expression of 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to a reference cellular retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell that is otherwise similar to the source cell, wherein HLA-G or HLA-E expression is assayed in vitro using flow cytometry, e.g., FACS. In some embodiments, the retroviral vectors or VLPs are derived from source cells that have been modified to increase HLA-G or HLA-E expression, e.g., to increase HLA-G or HLA-E expression by 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, and HLA-G or HLA-E expression is assayed in vitro using flow cytometry, e.g., FACS. In some embodiments, retroviral vectors or VLPs derived from modified cells with increased HLA-G expression exhibit reduced immunogenicity.
[0419] In some embodiments, the retroviral vector or VLP has or results in increased expression of a T cell inhibitory ligand (e.g., CTLA4, PD1, PD-L1), e.g., an increase in expression of a T cell inhibitory ligand of, for example, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to a reference cellular retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from an otherwise similar cell to the source cell, wherein expression of the T cell inhibitory ligand is assayed in vitro using flow cytometry, e.g., FACS.
[0420] In some embodiments, the retroviral vector or VLP has reduced expression of a costimulatory ligand, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in costimulatory ligand expression compared to a reference cellular retroviral vector or VLP, e.g., an unmodified retroviral vector or a VLP derived from a cell that is otherwise similar to the source cell, where costimulatory ligand expression is assayed in vitro using flow cytometry, e.g., FACS.
[0421] In some embodiments, the retroviral vector or VLP has reduced expression of MHC class I or MHC class II, e.g., reduced MHC class I or MHC class II expression by, for example, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, compared to a reference cellular retroviral vector or VLP, e.g., an unmodified retroviral vector or a cell otherwise similar to the source cell, or a VLP derived from a HeLa cell, wherein MHC class I or II expression is assayed in vitro using flow cytometry, e.g., FACS.
[0422] In some embodiments, the retroviral vector or VLP is derived from a substantially non-immunogenic cell source, e.g., a mammalian cell source. In some embodiments, immunogenicity can be quantified, e.g., as described herein. In some embodiments, the mammalian cell source comprises any one, all, or a combination of the following characteristics: a. The source cells are obtained from an autologous cell source, e.g., cells obtained from the recipient receiving, e.g., administered, the retroviral vector or VLP; b. the source cells are obtained from an allogeneic cell source matched, e.g., of similar gender, to the recipient, e.g., the recipient described herein, to receive, e.g., administer, the retroviral vector or VLP; c. the source cells are obtained from an allogeneic cell source that is HLA-matched to the recipient's HLA, e.g., in one or more alleles; d. The source cells are obtained from an allogeneic cell source that is HLA homozygous; e. The source cells are obtained from an allogeneic cell source that lacks MHC class I and II (or has reduced levels compared to reference cells); or f. The source cells are obtained from a cell source known to be substantially non-immunogenic, including, but not limited to, stem cells, mesenchymal stem cells, induced pluripotent stem cells, embryonic stem cells, Sertoli cells, or retinal pigment epithelial cells.
[0423] In some embodiments, the subject receiving the retroviral vector or VLP has, is known to have, or is tested for pre-existing antibodies (e.g., IgG or IgM) that react with the retroviral vector or VLP. In some embodiments, the subject receiving the retroviral vector or VLP does not have detectable levels of pre-existing antibodies that react with the retroviral vector or VLP. Antibody testing is described, for example, in Example 13.
[0424] In some embodiments, subjects who receive a retroviral vector or VLP have, are known to have, or are tested for antibodies (e.g., IgG or IgM) that react with the retroviral vector or VLP. In some embodiments, subjects who receive a retroviral vector or VLP (e.g., at least one, two, three, four, five, or more times) do not have detectable levels of antibodies that react with the retroviral vector or VLP. In embodiments, the level of the antibodies does not increase by more than 1%, 2%, 5%, 10%, 20%, or 50% between two time points, the first time point being before the first administration of the retroviral vector or VLP and the second time point being after one or more administrations of the retroviral vector or VLP. Antibody testing is described, for example, in Example 14.
[0425] Exogenous agents In some embodiments, the retroviral vectors, VLPs, or pharmaceutical compositions described herein encode an exogenous agent.
[0426] Exogenous protein agents In some embodiments, the exogenous agent comprises a cytosolic protein, e.g., a protein produced in the recipient cell and localized in the cytoplasm of the recipient cell. In some embodiments, the exogenous agent comprises a secreted protein, e.g., a protein produced and secreted by the recipient cell. In some embodiments, the exogenous agent comprises a nuclear protein, e.g., a protein produced in the recipient cell and imported into the nucleus of the recipient cell. In some embodiments, the exogenous agent comprises an organelle protein (e.g., a mitochondrial protein), e.g., a protein produced in the recipient cell and imported into an organelle (e.g., mitochondria) of the recipient cell. In some embodiments, the protein is a wild-type protein or a mutant protein. In some embodiments, the protein is a fusion protein or a chimeric protein.
[0427] In some embodiments, the exogenous agent is OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, PAL, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LNBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, BTD, HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL,GRHPR、HOGA1、LDLR、ACAD8、ACADSB、ACAT1、ACSF3、ASPA、AUH、DNAJC19、ETHE1、FBP1、FTCD、GSS、HIBCH、IDH2、L2HGDH、MLYCD、OPA3、OPLAH、OXCT1、POLG、PPM1K、SERAC1、SLC25A1、SUCLA2、SUCLG1、TAZ、AGK、CLPB、TMEM70、ALDH18A1、OAT、CA5A、GLUD1、GLUL、UMPS、S LC22A5、CPT1A、HADHA、HADH、SLC52A1、SLC52A2、SLC52A3、HADHB 、GYS2、PYGL、SLC2A2、ALG1、ALG2、ALG3、ALG6、ALG8、ALG9、ALG11、 ALG12、ALG13、ATP6V0A2、B3GLCT、CHST14、COG1、COG2、COG4、COG5 、COG6、COG7、COG8、DOLK、DHDDS、DPAGT1、DPM1、DPM2、DPM3、G6PC3 、GFPT1、GMPPA、GMPPB、MAGT1、MAN1B1、MGAT2、MOGS、MPDU1、MPI、NGLY1、PGM1、PGM3、RFT1、SEC23B、SLC35A1、SLC35A2、SLC35C1、SSR4、SRD5A3、TMEM165、TRIP11、TUSC3、ALG14、B4GALT1、DDOST、NUS1、RPN2、SEC23A、SLC35A3、ST3GAL3、STT3A、STT3B、AGA、ARSA、ARS B、ASAH1、ATP13A2、CLN3、CLN5、CLN6、CLN8、CTNS、CTSA、CTSD、CT SF、CTSK、DNAJC5、FUCA1、GAA、GALC、GALNS、GLA、GLB1、GM2A、GNPT AB, NPC1, NPC2, SGSH, PPT1, PSAP, SLC17A5, SMPD1, SUMF1, TPP1, AHCY, GNMT, MAT1A, GCH1, PCBD1, PTS, QDPR, SPR, DNAJC12, ALDH4A1, PRODH, HPD, GBA, HGD, AMN, CD320, CUBN, GIF, TCN1, TCN2, PREPL, PHGDH, PSAT1, PSPH, AMT, GCSH, GLDC, LIAS, NFU1, SLC6A9, SLC2A1, ATP7A, AP1S1, CP, SLC33A1, PEX7, Encoded by a gene in PHYH, AGPS, GNPAT, ABCD1, ACOX1, PEX1, PEX2, PEX3, PEX5, PEX6, PEX10, PEX12, PEXl3, PEX14, PEX16, PEX19, PEX26, AMACR, ADA, ADSL, AMPD1, GPHN, MOCOS, MOCS1, PNP, XDH, SUOX, OGDH, SLC25A19, DHTKD1, SLC13A5, FH, DLAT, MPC1, PDHA1, PDHB, PDHX, PDP1, ABCC2, SLCO1B1, SLCO1B3, HFE2, ADAMTS13, PYGM, COL1A2, TNFRSF11B, TSC1, TSC2, DHCR7, PGK1, VLDLR, KYNU, F5, C3, COL4A1, CFH, SLC12A2, GK, SFTPC, CRTAP, P3H1, COL7A1, PKLR, TALDO1, TF, EPCAM, VHL, GC, SERPINA1, ABCC6, F8, F9, ApoB, PCSK9, LDLRAP1, ABCG5, ABCG8, LCAT, SPINK5, or GNE.
[0428] In some embodiments, the exogenous agent is selected from the group consisting of OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAL, PAH, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LMBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, The exogenous agent is encoded by a gene selected from the group consisting of BTD, HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, and LDLR. In some embodiments, the exogenous agent is the enzyme phenylalanine ammonia-lyase (PAL).
[0429] In some embodiments, the exogenous agent comprises a protein in Table 5, below. In some embodiments, the exogenous agent comprises the wild-type human sequence of any of the proteins in Table 5, a functional fragment thereof (e.g., an enzymatically active fragment thereof), or a functional variant thereof. In some embodiments, the exogenous agent comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence in Table 5, e.g., a Uniprot Protein Accession Number sequence in column 4 of Table 5 or an amino acid sequence in column 5 of Table 5. In some embodiments, the payload gene encoding the exogenous agent encodes an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence in Table 5. In some embodiments, the payload gene encoding the exogenous agent has a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to a nucleic acid sequence in Table 5, e.g., the Ensemble Gene accession numbers in column 3 of Table 5.
[0430] In some embodiments, the exogenous agent comprises the amino acid sequence set forth in any one of SEQ ID NOs: 161-518. In some embodiments, the exogenous agent comprises the wild-type human sequence set forth in any one of SEQ ID NOs: 161-518, a functional fragment thereof (e.g., an enzymatically active fragment thereof), or a functional variant thereof. In some embodiments, the exogenous agent comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 161-518. In some embodiments, the payload gene encoding the exogenous agent encodes an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 161-518. In some embodiments, the payload gene encoding the exogenous agent encodes an amino acid sequence set forth in any one of SEQ ID NOs: 161-518.
[0431] [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7] [Table 5-8] [Table 5-9]
Table 5-10
Table 5-11
Table 5-12
Table 5-13
Table 5-14
Table 5-15
Table 5-16
Table 5-17
Table 5-18
Table 5-19
Table 5-20
Table 5-21
Table 5-22
Table 5-23
Table 5-24
Table 5-25
Table 5-26
Table 5-27
Table 5-28
Table 5-29
Table 5-30
Table 5-31
Table 5-32
Table 5-33
Table 5-34
Table 5-35
Table 5-36
Table 5-37
Table 5-38
Table 5-39
Table 5-40
Table 5-41
Table 5-42
Table 5-43
Table 5-44
Table 5-45
Table 5-46
Table 5-47
Table 5-48
Table 5-49
Table 5-50
Table 5-51
Table 5-52
Table 5-53
Table 5-54
Table 5-55
Table 5-56
Table 5-57
Table 5-58
Table 5-59
Table 5-60
Table 5-61
Table 5-62
Table 5-63
Table 5-64
Table 5-65
Table 5-66
Table 5-67
Table 5-68
Table 5-69
Table 5-70
Table 5-71
Table 5-72
Table 5-73
Table 5-74
Table 5-75
Table 5-76
Table 5-77
Table 5-78
Table 5-79
Table 5-80
Table 5-81
Table 5-82
Table 5-83
Table 5-84
Table 5-85
Table 5-86
Table 5-87
Table 5-88
Table 5-89
Table 5-90
Table 5-91
Table 5-92
Table 5-93
Table 5-94
Table 5-95
Table 5-96
Table 5-97
Table 5-98
Table 5-99
Table 5-100
Table 5-101
Table 5-102
Table 5-103
Table 5-104
Table 5-105
Table 5-106
Table 5-107
Table 5-108
Table 5-109
Table 5-110
Table 5-111
Table 5-112
Table 5-113
Table 5-114
Table 5-115
Table 5-116
Table 5-117
Table 5-118
Table 5-119
Table 5-120
Table 5-121
Table 5-122
Table 5-123
Table 5-124
Table 5-125
Table 5-126
Table 5-127
Table 5-128
Table 5-129
Table 5-131
Table 5-133
Table 5-135
Table 5-136
Table 5-137
Table 5-138
Table 5-139
Table 5-141
[0432] Insulator array In some embodiments, the fusosome, retroviral, or lentiviral vector, or VLP further comprises one or more insulator sequences, e.g., insulator sequences described herein. Insulator sequences may contribute to protecting the lentiviral expression sequence, e.g., a therapeutic polypeptide, from integration site effects, which may be mediated by cis-acting elements present in genomic DNA and lead to deregulated expression of the transferred sequence (e.g., position effects; see, e.g., Burgess-Beusse et al., 2002, Proc. Natl. Acad. Sci., USA, 99:16433, and Zhan et al., 2001, Hum. Genet., 109:471) or deregulated expression of endogenous sequences adjacent to the transferred sequence. In some embodiments, the transfer vector comprises one or more insulator sequences in the 3' LTR, and upon integration of the provirus into the host genome, the provirus comprises one or more insulators in the 5' LTR and / or 3' LTR by replicating the 3' LTR. Suitable insulators include, but are not limited to, the chicken β-globin insulator (Chung et al., 1993. Cell 74:505; Chung et al., 1997. N4S 94:575; and Bell et al., 1999. Cell 98:387, incorporated herein by reference), or an insulator from the human β-globin locus, such as chicken HS4. In some embodiments, the insulator binds to CCCTC-binding factor (CTCF). In some embodiments, the insulator is a barrier insulator. In some embodiments, the insulator is an enhancer-blocking insulator. See, e.g., Emery et al., Human Gene Therapy, 2011, and Browning and Trobridge, Biomedicines, 2016, both of which are incorporated by reference in their entireties.
[0433] In some embodiments, the insulator in the retroviral nucleic acid reduces genotoxicity in recipient cells, which can be measured, for example, as described in Cesana et al., "Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo," Mol Ther. 2014 Apr;22(4):774-85. doi:10.1038 / mt.2014.3. Epub 2014 Jan 20.
[0434] Cell-derived fusosomes The present disclosure provides, in some aspects, a fusosome comprising: (a) lipid bilayer, (b) a lumen surrounded by a lipid bilayer (e.g., containing the cytosol); (c) exogenous or overexpressed fusogens, e.g., fusogens that are located within a lipid bilayer; wherein the fusosomes are derived from a source cell; and Here, the fusosomes have partial or complete nuclear inactivation (eg, nucleoli).
[0435] The present disclosure provides, in some aspects, a fusosome composition comprising a plurality of fusosomes derived from a source cell, wherein the plurality of fusosomes comprises: (a) lipid bilayer, (b) a lumen containing the cytosol and surrounded by a lipid bilayer; (c) exogenous or overexpressed fusogens placed in the lipid bilayer; (d) a nucleic acid, e.g., a nucleic acid comprising a payload gene; and Here, fusosomes do not contain a nucleus; wherein the amount of viral capsid protein in the fusosome composition is less than 1% of the total protein; where: (i) when a plurality of fusosomes contact a cell population comprising target cells and non-target cells, the cargo is present in at least 10-fold greater abundance in target cells than in non-target cells or reference cells; or (ii) multiple fusosomes fuse with target cells at a rate at least 50% higher than with non-target or reference cells; Here, the target cells are selected from liver sinusoidal endothelial cells, bile duct cells, stellate cells, antigen-presenting cells present in the liver (e.g., Kupffer cells), immune lymphocytes present in the liver (e.g., T cells, B cells, or NK cells), or portal tract fibroblasts.
[0436] The present disclosure provides, in some aspects, a fusosome composition comprising a plurality of fusosomes derived from a source cell, wherein the plurality of fusosomes comprises: (a) lipid bilayer, (b) a lumen containing the cytosol and surrounded by a lipid bilayer; (c) exogenous or overexpressed fusogens placed in the lipid bilayer; (d) a nucleic acid comprising a payload gene encoding an exogenous agent of Table 5; wherein the fusosome does not contain a nucleus; and Here, the amount of viral capsid protein in the fusosome composition is less than 1% of the total protein.
[0437] The present disclosure provides, in some aspects, a fusosome composition comprising a plurality of fusosomes derived from a source cell, wherein the plurality of fusosomes comprises: (a) lipid bilayer, (b) a lumen containing the cytosol and surrounded by a lipid bilayer; (c) exogenous or overexpressed fusogens placed in the lipid bilayer; (d) a nucleic acid comprising a payload gene, wherein the nucleic acid comprises an NTCSRE operably linked to the payload gene, and the NTCSRE comprises a non-liver cell-specific miRNA recognition sequence, e.g., a non-liver cell-specific miRNA recognition sequence bound by an miRNA present in hematopoietic cells or plasmacytoid dendritic cells (pDCs), e.g., a miRNA present in hematopoietic cells or plasmacytoid dendritic cells (pDCs) at higher levels than in liver cells, e.g., a non-liver cell-specific miRNA recognition sequence bound by an miRNA in Table 4; and wherein the fusosome does not contain a nucleus; and Here, the amount of viral capsid protein in the fusosome composition is less than 1% of the total protein.
[0438] In some embodiments, the miRNA is present in non-target cells (e.g., hematopoietic cells or pDCs) at levels at least 10, 100, 1,000, or 10,000 times greater than the level of the miRNA present in target cells (e.g., liver cells, e.g., liver cells described herein). In some embodiments, the miRNA is not detectably present in target cells (e.g., liver cells). In some embodiments, the miRNA is not present in target cells (e.g., liver cells).
[0439] The present disclosure provides, in some aspects, a fusosome composition comprising a plurality of fusosomes derived from a source cell, wherein the plurality of fusosomes comprises: (a) lipid bilayer, (b) a lumen containing the cytosol and surrounded by a lipid bilayer; (c) exogenous or overexpressed fusogens placed in the lipid bilayer; (d) a nucleic acid comprising a payload gene, the nucleic acid comprising a promoter operably linked to the payload gene, wherein the promoter is a liver-specific promoter, e.g., a promoter specific to liver sinusoidal endothelial cells, bile duct cells, stellate cells, antigen-presenting cells present in the liver (e.g., Kupffer cells), immune lymphocytes present in the liver (e.g., T cells, B cells, or NK cells), or portal tract fibroblasts; wherein the fusosome does not contain a nucleus; and Here, the amount of viral capsid protein in the fusosome composition is less than 1% of the total protein.
[0440] The present disclosure provides, in some aspects, a fusosome composition comprising a plurality of fusosomes derived from a source cell, wherein the plurality of fusosomes comprises: (a) lipid bilayer, (b) a lumen containing the cytosol and surrounded by a lipid bilayer; (c) exogenous or overexpressed fusogens placed in the lipid bilayer; (d) a nucleic acid comprising a payload gene, the nucleic acid comprising a promoter having a sequence in Table 3, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto; wherein the fusosome does not contain a nucleus; and wherein the amount of viral capsid protein in the fusosome composition is less than 1% of the total protein;
[0441] The present disclosure provides, in some aspects, a fusosome composition comprising a plurality of fusosomes derived from a source cell, wherein the plurality of fusosomes comprises: (a) lipid bilayer, (b) a lumen containing the cytosol and surrounded by a lipid bilayer; (c) exogenous or overexpressed fusogens placed in the lipid bilayer; (d) a nucleic acid comprising: (i) payload genes; (ii) an NTCSRE operably linked to the payload gene, e.g., the NTCSRE comprises a non-liver cell-specific miRNA recognition sequence, e.g., a non-liver cell-specific miRNA recognition sequence bound by an miRNA in Table 4; and (iii) optionally, a positive target cell-specific regulatory element, e.g., a positive liver cell-specific regulatory element (e.g., a liver cell-specific promoter) operably linked to the payload gene, wherein the positive liver cell-specific regulatory element increases expression of the payload gene in the target cell relative to an otherwise similar fusosome lacking the positive target cell-specific regulatory element; wherein the fusosome does not contain a nucleus; and Here, the amount of viral capsid protein in the fusosome composition is less than 1% of the total protein.
[0442] In some embodiments, one or more of the following are present: i) the fusosomes contain or are contained in cell biological material; ii) fusosomes contain enucleated cells; iii) fusosomes contain inactivated nuclei; iv) fusosomes fuse with target cells at a higher rate, e.g., at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, than with non-target cells, e.g., in the assay of Example 43; v) the fusosomes fuse with target cells at a higher rate, e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, than other fusosomes, e.g., in the assay of Example 43; vi) the fusosomes fuse with the target cells at a rate such that the agent within the fusosomes is delivered to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the target cells after 24, 48, or 72 hours, e.g., in the assay of Example 43; vii) The fusogen is present in at least 10, 50, 100, 500, 1,000, 2,000, 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000, 100,000,000, 500,000,000, or 1,000,000,000 copies or less, as measured, for example, by the assay of Example 27. viii) The fusosomes comprise the therapeutic agent in a copy number of at least 10, 50, 100, 500, 1,000, 2,000, 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000, 100,000,000, 500,000,000, or 1,000,000,000 copies or less, e.g., as measured by the assay of Example 89. ix) The ratio of the copy number of the fusogen to the copy number of the therapeutic drug is 1,000,000:1 to 100,000:1, 100,000:1 to 10,000:1, 10,000:1 to 1,000:1, 1,000:1 to 100:1, 100:1 to 50:1, 50:1 to 20:1, 20:1 to 10:1, 10:1 to 5:1, 5:1 to 2:1 , 2:1 to 1:1, 1:1 to 1:2, 1:2 to 1:5, 1:5 to 1:10, 1:10 to 1:20, 1:20 to 1:50, 1:50 to 1:100, 1:100 to 1:1,000, 1:1,000 to 1:10,000, 1:10,000 to 1:100,000, or 1:100,000 to 1:1,000,000; x) the fusosomes comprise a lipid composition substantially similar to that of the source cells, or one or more of CL, Cer, DAG, HexCer, LPA, LPC, LPE, LPG, LPI, LPS, PA, PC, PE, PG, PI, PS, CE, SM, and TAG are within 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% of the corresponding lipid levels in the source cells; xi) the fusosomes contain a proteomic composition similar to that of the source cells, e.g., using the assay of Example 88; xii) the fusosomes comprise a lipid to protein ratio that is within 10%, 20%, 30%, 40%, or 50% of the corresponding ratio in the source cells, as measured, for example, using the assay of Example 41; xiii) the fusosomes comprise a ratio of protein to nucleic acid (e.g., DNA) that is within 10%, 20%, 30%, 40%, or 50% of the corresponding ratio in the source cells, e.g., as measured using the assay of Example 42; xiv) the fusosomes comprise a lipid to nucleic acid (e.g., DNA) ratio that is within 10%, 20%, 30%, 40%, or 50% of the corresponding ratio in the source cells, e.g., as measured using the assay of Example 92; xv) the fusosomes have a half-life in a subject, e.g., a mouse, that is within 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% of the half-life of a reference cell, e.g., a source cell, e.g., by the assay of Example 61; xvi) the fusosomes transport at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% more (e.g., about 11.6% more) glucose (e.g., labeled glucose, e.g., 2-NBDG) across the membrane in the absence of glucose than a negative control, e.g., an otherwise similar fusosome, as measured, e.g., using the assay of Example 51; xvii) the fusosomes comprise esterase activity in their lumen that is within 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% of the esterase activity in a reference cell, e.g., a source cell or a mouse embryonic fibroblast, e.g., using the assay of Example 52; xviii) the fusosomes comprise a metabolic activity level within 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the citrate synthase activity in a reference cell, e.g., a source cell, e.g., as described in Example 54; xix) The fusosomes comprise a respiration level (e.g., oxygen consumption rate) within 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the respiration level in a reference cell, e.g., a source cell, e.g., as described in Example 55. xx) the fusosomes comprise an annexin V staining level of at most 18,000, 17,000, 16,000, 15,000, 14,000, 13,000, 12,000, 11,000, or 10,000 MFI, e.g., using the assay of Example 56; or the fusosomes comprise an annexin V staining level that is at least 5%, 10%, 20%, 30%, 40%, or 50% less than the annexin V staining level of otherwise similar fusosomes treated with menadione in the assay of Example 56; or the fusosomes comprise an annexin V staining level that is at least 5%, 10%, 20%, 30%, 40%, or 50% less than the annexin V staining level of macrophages treated with menadione in the assay of Example 56. xxi) the fusosomes have an miRNA content level that is at least at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more than that of the source cells, e.g., by the assay of Example 34; xxii) the fusosomes have a soluble:insoluble protein ratio within or greater than 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of that of the source cells, e.g., by the assay of Example 39, or within or greater than 1%-2%, 2%-3%, 3%-4%, 4%-5%, 5%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, or 80%-90% of that of the source cells; xxiii) the fusosomes have an LPS level that is less than or equal to 5%, 1%, 0.5%, 0.01%, 0.005%, 0.0001%, 0.00001% of the LPS content of the source cells, e.g., as measured by mass spectrometry, e.g., in the assay of Example 40; xxiv) the fusosomes are capable of signaling, e.g., delivery of an extracellular signal in response to insulin, e.g., AKT phosphorylation, or glucose (e.g., labeled glucose, e.g., 2-NBDG) uptake in response to insulin, at 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% more than a negative control, e.g., otherwise similar fusosomes, in the absence of insulin using, e.g., the assay of Example 50; xxv) the fusosomes are targeted to a tissue, such as the liver, lung, heart, spleen, pancreas, gastrointestinal tract, kidney, testis, ovary, brain, reproductive organs, central nervous system, peripheral nervous system, skeletal muscle, endothelium, inner ear, or eye, and when administered to a subject, e.g., a mouse, after 24, 48, or 72 hours, e.g., by the assay of Example 65, at least 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the fusosomes in the administered population are present in the target tissue; xxvi) the fusosomes have a level of juxtacrine signaling that is at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% greater than the juxtacrine signaling induced by a reference cell, e.g., a source cell or a bone marrow stromal cell (BMSC), e.g., by the assay of Example 57; xxvii) the fusosomes have a level of paracrine signaling that is at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% greater than the level of paracrine signaling induced by a reference cell, e.g., a source cell or a macrophage, e.g., by the assay of Example 58; xxviii) the fusosomes polymerize actin at a level that is within 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the actin level polymerized in a reference cell, e.g., a source cell or a C2C12 cell, e.g., by the assay of Example 59; xxix) the fusosomes have a membrane potential within about 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% of the membrane potential of a reference cell, e.g., a source cell or a C2C12 cell, e.g., by the assay of Example 60, or the fusosomes have a membrane potential of about -20 to -150 mV, -20 to -50 mV, -50 to -100 mV, or -100 to -150 mV; xxx) the fusosomes are capable of extravasation from blood vessels of the source cells or a proportion of cells of the same type as the source cells, e.g., at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, using, e.g., the assay of Example 45, wherein the source cells are neutrophils, lymphocytes, B cells, macrophages, or NK cells; xxxi) fusosomes are capable of crossing cell membranes, such as endothelial cell membranes or the blood-brain barrier; xxxii) the fusosomes are capable of secreting protein at a rate, e.g., at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% greater than a reference cell, e.g., a mouse embryonic fibroblast, using, e.g., the assay of Example 49; xxxiii) the fusosomes meet pharmaceutical or Good Manufacturing Practice (GMP) standards; xxxiv) fusosomes were manufactured according to good manufacturing practices (GMP); xxxv) the fusosomes have pathogen levels below a predetermined threshold, e.g., are substantially free of pathogens; xxxvi) the fusosomes have contaminant levels below a predetermined standard, e.g., are substantially free of contaminants; xxxvii) fusosomes are poorly immunogenic, e.g., as described herein; xxxviii) the source cells are selected from neutrophils, granulocytes, mesenchymal stem cells, bone marrow stem cells, induced pluripotent stem cells, embryonic stem cells, myeloblasts, myoblasts, hepatocytes, or neurons, such as retinal neurons; or xxxix) The source cells are other than 293 cells, HEK cells, human endothelial cells, or human epithelial cells, monocytes, macrophages, dendritic cells, or stem cells.
[0443] The present disclosure also provides, in some aspects, fusosomes comprising: a) a lipid bilayer and a lumen that is miscible with aqueous solution, e.g., water, wherein the fusosomes are derived from a source cell; b) exogenous or overexpressed fusogens placed in the lipid bilayer; and c) Organelles located within the lumen, e.g., a therapeutically effective number of organelles.
[0444] In some embodiments, one or more of the following are present: i) the source cells are selected from endothelial cells, macrophages, neutrophils, granulocytes, leukocytes, stem cells (e.g., mesenchymal stem cells, bone marrow stem cells, induced pluripotent stem cells, embryonic stem cells), m...
Claims
1. below: a) a lipid bilayer comprising a retargeted paramyxovirus fusogen, said fusogen being linked to a targeting moiety that binds to a cell surface marker on liver cells for retargeted delivery to liver cells; and b) Below: (i) a payload gene encoding an exogenous agent; and (ii) a positive liver cell-specific regulatory element operably linked to the payload gene, wherein the positive liver cell-specific regulatory element increases expression of the payload gene in liver cells relative to an otherwise similar fusosome lacking the positive liver cell-specific regulatory element, wherein the positive liver cell-specific regulatory element comprises a liver cell-specific promoter; (iii) a non-target cell-specific regulatory element (NTCSRE) operably linked to said payload gene, wherein said NTCSRE reduces expression of said payload gene in non-liver cells relative to otherwise similar fusosomes lacking the NTCSRE, wherein said NTCSRE comprises a non-liver cell-specific miRNA recognition sequence. A nucleic acid comprising containing, fusosomes.
2. below: a) a lipid bilayer comprising a retargeted paramyxovirus fusogen, said fusogen being linked to a targeting moiety that binds to a cell surface marker on liver cells for retargeted delivery to liver cells; and b) Below: (i) a payload gene encoding an exogenous agent; and (ii) a promoter selected from the group consisting of Apoa2, Cyp3a4, LP1B, MIR122, hemopexin, SERPINA1, or HLP promoter; (iii) a non-target cell-specific regulatory element (NTCSRE) operably linked to said payload gene, wherein said NTCSRE reduces expression of said payload gene in non-liver cells relative to otherwise similar fusosomes lacking the NTCSRE, wherein said NTCSRE comprises a non-liver cell-specific miRNA recognition sequence. A nucleic acid comprising Fusosomes containing
3. below: (i) a first exogenous or overexpressed immunosuppressive protein on a lipid bilayer; or The fusosomes of claim 1 or 2, further comprising either or both of (ii) a first immunostimulatory protein that is absent or present at a reduced level compared to fusosomes produced from an otherwise similar unmodified source cell.
4. The fusosome according to any one of claims 1 to 3, wherein the payload gene is a gene that treats a genetic defect.
5. The fusosome of claim 3 or 4, comprising (i) and (ii).
6. A fusosome according to any one of claims 3 to 5, comprising (i) and further comprising a second exogenous or overexpressed immunosuppressive protein on the lipid bilayer.
7. The fusosome according to any one of claims 3 to 6, wherein the immunosuppressive protein is a complement regulatory protein or CD47.
8. The fusosome according to any one of claims 3 to 7, wherein the immunostimulatory protein is an MHC I or MHC II protein.
9. The payload gene is OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMA, MMA, MMA, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, PAL, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETF, ETF, ETFDH, ASL, D2HG, HMGL, MCC, MCC, ABCD4, HCFC1, LNBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, BTD, HLCS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, LDLR, ACAD8, ACADSB, ACAT1, ACSF3, ASPA, AUH, DNAJC19, ETHE1, FBP1, FTC, GSS, HIBCH, IDH2, L2HG, MLYCD, OPA3, OPLAH, OXCT1, POLG, PPM1K, SERAC1, SLC25A1, SUCLA2, SUCLG1, TAZ, AGK, CLPB, TMEM70, ALDH18A1, OAT, CA5A, GLUD1, GLUL, UMPS, SLC22A5, CPT1A, HADHA, HADH, SLC52A1, SLC52A2, SLC52A3, HADHB, GYS2, PYGL, SLC2A2, ALG1, ALG2, ALG3, ALG6, ALG8, ALG9, ALG11, ALG12, ALG13, ATP6V0A2, B3GLCT, CHST14, COG1, COG2, COG4, COG5, COG6, COG7, COG8, DOLK, DHDD, DPM, DPM, DPM, G6PC3, GFPT1, GM, GM, MAGT1, MAN1B1, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PGM3, RFT1, SEC23B, SLC35A1,<h2 style=";text-align:left;direction:ltr">SLC35A2、SLC35C1、SSR4、SRD5A3、TME M165、TRIP11、TUSC3、ALG14、B4GALT1 I'm sorry, I'm sorry, I'm sorry, I'm sorry RSB、ASAH1、ATP13A2、CLN3、CLN5、CLN 6、CLN8、CTNS、CTSA、CTSD、CTSF、CTSK 、DNAJC5、FUCA1、GAA、GALC、GALNS、GLA、GLB1、GM2A、GNPTAB、GNPTG、GNS、GR N、GUSB、HEXA、HEXB、HGSNAT、HYAL1、I DS、IDUA、KCTD7、LAMP2、MAN2B1、MANB A、MCOLN1、MFSD8、NAGA、NAGLU、NEU1、 NPC1、NPC2、SGSH、PPT1、PSAP、SLC17A 5、SMPD1、SUMF1、TPP1、AHCY、GNMT、MA T1A、GCH1、PCBD1、PTS、QDPR、SPR、DNA JC12、ALDH4A1、PRODH、HPD、GBA、HGD、 AMN、CD320、CUBN、GIF、TCN1、TCN2、PRE PL、PHGDH、PSAT1、PSPH、AMT,GCSH、GL DC、LIAS、NFU1、SLC6A9、SLC2A1、ATP7 A、AP1S1、CP、SLC33A1、PEX7、PHYH、AG PS、GNPAT、ABCD1、ACOX1、PEX1、PEX2、 PEX3、PEX5、PEX6、PEX10、PEX12、PEX1 3、PEX14、PEX16、PEX19、PEX26、AMACR 、ADA、ADSL、AMPD1、GPHN、MOCOS、MOCS1、PNP、XDH、SUOX、OGDH、SLC25A19、DH TKD1、SLC13A5、FH、DLAT、MPC1、PDHA1 、PDHB、PDHX、PDP1、ABCC2、SLCO1B1、S LCO1B3、HFE2、ADAMTS13、PYGM、COL1A 2、TNFRSF11B、TSC1、TSC2、DHCR7、PGK 1、VLDLR、KYNU、F5、C3、COL4A1、CFH、S LC12A2、GK、SFTPC、CRTAP、P3H1、COL7 A1、PKLR、TALDO1、TF、EPCAM、VHL、GC、 SERPINA1、ABCC6、F8、F9、ApoB、PCSK9、The fusosome according to any one of claims 1 to 8, which is selected from LDLRAP1, ABCG5, ABCG8, LCAT, SPINK5 and GNE.
10. The fusosome of any one of claims 1 to 9, wherein the payload gene encodes an exogenous agent comprising a sequence set forth in any one of SEQ ID NOs: 161 to 518, or a functional fragment thereof, or a functional variant thereof comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 161 to 518.
11. The payload gene encoding the exogenous agent is selected from the group consisting of OTC, CPS1, NAGS, BCKDHA, BCKDHB, DBT, DLD, MUT, MMAA, MMAB, MMACHC, MMADHC, MCEE, PCCA, PCCB, UGT1A1, ASS1, PAH, ATP8B1, ABCB11, ABCB4, TJP2, IVD, GCDH, ETFA, ETFB, ETFDH, ASL, D2HGDH, HMGCL, MCCC1, MCCC2, ABCD4, HCFC1, LMBRD1, ARG1, SLC25A15, SLC25A13, ALAD, CPOX, HMBS, PPOX, BTD, HL The fusosome according to any one of claims 1 to 10, which is selected from CS, PC, SLC7A7, CPT2, ACADM, ACADS, ACADVL, AGL, G6PC, GBE1, PHKA1, PHKA2, PHKB, PHKG2, SLC37A4, PMM2, CBS, FAH, TAT, GALT, GALK1, GALE, G6PD, SLC3A1, SLC7A9, MTHFR, MTR, MTRR, ATP7B, HPRT1, HJV, HAMP, JAG1, TTR, AGXT, LIPA, SERPING1, HSD17B4, UROD, HFE, LPL, GRHPR, HOGA1, or LDLR.
12. The fusosome of any one of claims 1 to 11, wherein the retargeted paramyxovirus fusogen comprises paramyxovirus F and G proteins, or F and H proteins, or F and HN proteins, or derivatives thereof, or any combination thereof.
13. 13. The fusosome of any of claims 1 to 12, wherein the retargeted paramyxovirus fusogen comprises sequences selected from Nipah virus F and G proteins, Measles virus F and H proteins, Tupaia paramyxovirus F and H proteins, Hendra virus F and G proteins, Henipavirus F and G proteins, Morbillivirus F and H proteins, Respirovirus F and HN proteins, Sendai virus F and HN proteins, Rubulavirus F and HN proteins, Canine distemper virus F and H proteins, or Abulavirus F and HN proteins, or derivatives thereof, or any combination thereof.
14. The fusosome of any of claims 1 to 13, wherein the retargeted paramyxovirus fusogen comprises a domain of at least 100 amino acids in length having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a wild-type paramyxovirus fusogen, and optionally the wild-type paramyxovirus fusogen is set forth in any one of SEQ ID NOs: 1 to 132.
15. The fusosome of claim 14, wherein the wild-type paramyxovirus is a Nipah virus, and optionally, the Nipah virus is a Henipa virus.
16. The fusosome of claim 15, wherein the retargeted paramyxovirus fusogen comprises a sequence selected from Nipah virus F and G proteins or derivatives thereof.
17. The fusosome of any one of claims 1 to 16, wherein the targeting moiety is covalently attached to the retargeted paramyxovirus fusogen.
18. 18. The fusosome of any of claims 1 to 17, wherein the targeting moiety is or comprises an antibody or antigen-binding fragment thereof (e.g., a Fab, Fab', F(ab')2, Fv fragment, scFv antibody fragment, disulfide-linked Fv (sdFv), an Fd fragment consisting of a VH and CH1 domain, a linear antibody, a single domain antibody such as a sdAb (either VL or VH), a nanobody, or a camelid VHH domain), an antigen-binding fibronectin type III (Fn3) scaffold such as a fibronectin polypeptide minibody.
19. The fusosome according to any one of claims 1 to 18, wherein the liver cell-specific promoter comprises a liver cell-specific promoter.
20. 20. The fusosome of any one of claims 1 or 3 to 19, wherein the promoter is selected from enhanced transthyretin (ET), Alb, Apoa2, Cyp3a4, LP1B, MIR122, hemopexin, SERPINA1, or HLP promoters.
21. The fusosome of any one of claims 2 to 20, wherein the promoter has a sequence set forth in any one of SEQ ID NOs: 133 to 136, or 519 to 525, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto.
22. The fusosome according to any one of claims 1 or 3 to 20, wherein the promoter is an ApoE.HCR-hAAT promoter.
23. The fusosome of any one of claims 1 to 22, wherein the non-liver cell-specific miRNA recognition sequence can be bound by one or more of miR-142, mir-181a-2, mir-181b-1, mir-181c, mir-181a-1, mir-181b-2, mir-181d, miR-223, or miR-126.
24. The fusosome of claim 14, wherein the promoter comprises a sequence set forth in SEQ ID NO: 133 or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO:
133.
25. The fusosome of any one of claims 1 to 24, wherein the nucleic acid comprises one or more insulator sequences.
26. The fusosome of claim 25, wherein the nucleic acid comprises two insulator sequences, the two insulator sequences comprising a first insulator sequence upstream of the payload gene and a second insulator sequence downstream of the payload gene.
27. The fusosome of claim 26, wherein the first and second insulator sequences comprise the same or different sequences.
28. The fusosome according to any one of claims 1 to 27, wherein the fusosome is a retroviral vector particle.
29. The fusosome of any one of claims 1 to 28, wherein the nucleic acid is capable of being integrated into the genome of a liver cell.
30. The fusosome according to any one of claims 1 to 27, wherein the fusosome is a lentiviral vector.
31. The fusosome according to any one of claims 1 to 30, wherein the liver cell is selected from a hepatocyte, a liver sinusoidal endothelial cell, a bile duct cell, a stellate cell, an antigen presenting cell present in the liver, an immune lymphocyte present in the liver, or a portal tract fibroblast.
32. A pharmaceutical composition comprising the fusosome of any one of claims 1 to 31 and a pharma- ceutically acceptable carrier, diluent, or excipient.
33. A composition comprising a fusosome according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32 for use in delivering an exogenous agent to a subject.
34. A composition comprising a fusosome according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32 for use in regulating liver or liver cell function in a subject.
35. 35. The composition of claim 33 or 34, wherein the liver or liver cells are present in the subject.
36. The composition according to any one of claims 33 to 35, characterized in that the composition is administered to the subject.
37. A composition comprising a fusosome according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32 for use in treating a subject having a genetic defect.
38. The composition of claim 37 , wherein the fusosomes contain a payload gene encoding an exogenous agent for treating a genetic defect.
39. 39. The composition of claim 37 or 38, wherein the genetic defect is a genetic defect that can be treated by a payload gene encoding the exogenous agent.
40. The composition of any of claims 36 to 39, wherein the subject is a human subject.
41. below: a) providing a cell comprising said nucleic acid and said fusogen; b) culturing said cells under conditions allowing the production of fusosomes; and A method for producing fusosomes according to any one of claims 1 to 31, comprising: c) isolating, enriching or purifying fusosomes from the cells, thereby producing fusosomes.
42. 33. Use of a fusosome according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32 for the manufacture of a medicament for use in delivering an exogenous agent to a subject.
43. 33. Use of a fusosome according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32 for the manufacture of a medicament for use in regulating liver or liver cell function in a subject.
44. Use of a fusosome according to any of claims 1 to 31 or a pharmaceutical composition according to claim 32 for the manufacture of a medicament for use in treating a subject having a genetic defect.
Citation Information
Patent Citations
Retroviral particles protected from complement-mediated destruction
JP2002526085A
Chimeric promoter controlling smooth muscle expression
JP2004502426A
Reovirus-derived membrane fusion protein
JP2004520019A
Lentiviral vectors comprising micrornas
WO2008071959A1
AUF1 encoding compositions for muscle cell uptake, satellite cell populations, and satellite cell mediated muscle generation
WO2016196350A1
